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Immunotherapy is an advanced technology for treatment of oncoviruses leading cancers. 
However, lack of effective and safe vaccines against the oncoviruses has limited the 
development. This thesis aims to apply Hepatitis B core (HBc) virus like particle (VLP) 
as a platform for innovation of chimeric adjuvant-free VLP vaccines targeting 
oncoviruses. Two chimeric HBc VLP-based vaccines presenting Epstein–Barr virus 
nuclear antigen 1 (EBNA1) epitope (short and non-structural epitope) and Hepatitis C 
virus (HCV) core epitope (long and structural epitope) were successfully expressed and 
purified in the Escherichia coli (E. coli) expression system with high production yields, 
62.1 mg/g and 40.3 mg/g of wet cell weight, respectively.  
To further understand and evaluate the influence of insertion of different epitopes to 
HBc VLP, the stability of chimeric HBc VLP vaccines under different stresses were 
analysed in comparison with non-chimeric HBc VLP. Computational protein modelling 
was employed to assist the understanding of the possible cause for the differences. 
Results indicate that the stability of chimeric HBc VLP vaccines was related to the 
hydrophobicity of chimeric HBc monomers. The stability of chimeric HBc VLP 
decreased with the decrease of hydrophobicity of its monomer. This finding would help 
and improve the efficiency in the development and design of chimeric HBc VLP-based 
vaccines. 
In the immunogenicity evaluation, both adjuvant-free EBNA1-HBc VLP and HCV 




with other reported vaccine candidates of EBV and HCV. The achieved immune 
responses of adjuvant-free EBNA1-HBc VLP and HCV core-HBc VLP groups were 
comparable to the groups with aluminium adjuvant. No side effect and death of mice 
were detected during the examination. This confirms that adjuvant-free HBc VLP can 
present either short non-structured epitope or long structured epitope and can induce 
strong epitope-specific immune response with low safety risks. Chimeric EBNA1-HBc 
VLP tended to elicit predominated humoral immune response, while chimeric HCV 
core-HBc VLP induced predominated cellular immune response. This indicates that the 
nature of antigens presented by HBc VLP has an impact on the immune response 
performance, which should be considered in the design of chimeric HBc VLP vaccines 
in the future. The thesis also found that the addition of aluminium adjuvant would 
improve the humoral immune response while supressing the cellular immune response 
of chimeric HBc VLP vaccines. EBNA1-HBc VLP was less affected by the adjuvant 
on the immune response tendency compared with HCV core-HBc VLP. At last, long-
term immunogenicity of two chimeric HBc VLPs were examined by evaluated the 
epitope specific memory T cells. Both HCV core-HBc VLP and EBAN1-HBc VLP 
showed good potential for long-term protection. 
With all above findings, chimeric adjuvant-free HBc VLP-based vaccine is promising 
to present different types of oncoviruses epitopes with high epitope-specific immune 
response and low risks. More epitopes targeting different oncoviruses could be 
presented by chimeric adjuvant-free HBc VLP platform for cancer treatment, and 
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Chapter 1 Introduction  
1.1 Background 
Cancers have caused the death of millions of people globally and remain a severe issue 
in modern society [8]. Cancer, also known as “Pathology of the Century”, has also been 
defined as the “the modern disease par excellence” or even the “the quintessential 
product of modernity” [9-11]. From the eighteenth century to now, cancers have 
become the second major cause of death worldwide [12]. In this case, different 
treatments against cancers have been developed. Traditional approaches include 
surgery, chemotherapy and radiation therapy [13]. However, these traditional treatment 
methods have several drawbacks such as pain and infection to the patient, damages to 
patients’ body and side effects. 
Recently, researchers have proven that a kind of viruses, oncovirus, is related to around 
16 % of 38 different types of cancers [14]. These oncoviruses are studied as targets for 
the treatment and prevention of cancers in the development of immunotherapy. 
Immunotherapy, is a kind of novel approach to treat cancers by using patients’ own 
immune system for cancer prevention or to fight against cancer cells [15]. Researchers 
have employed different platforms to develop cancer vaccines, such as virus-like 
particles (VLPs) [16], ferritin [17] and nanoparticles [18] to prevent and treat the 
infections which potentially lead to cancers [19]. 
Among these platforms, Hepatitis B core virus-like particle (HBc VLP) platform is one 




foreign epitopes in the last decade [20-22]. HBc VLP platform has drawn the interest 
of researchers due to its unique structure and merits [23, 24]. HBc VLP has a repetitive 
antigenic structure that could present the foreign epitope in a high density and trigger 
strong epitope specific immune response due to its self-adjuvant property [16, 25-27]. 
In addition, HBc VLP has no viral genome, which makes it a safer vaccine candidate 
compared with the traditional viral vaccines [28, 29]. Moreover, HBc VLP-based 
vaccines can be produced in multiple expression systems [30, 31]. 
To produce effective VLP-based vaccines presenting foreign epitopes from oncoviruses, 
the development of recent technology and challenges of VLP-based vaccines were 
reviewed. Several challenges have been identified including 1) to design and present 
different types of foreign antigens on the surface of chimeric VLP, 2) to perform 
effective soluble expression and purification of designed chimeric VLP proteins to 
achieve high production yield using suitable expression system, 3) to maintain 
assembled VLP structure of produced chimeric VLP proteins with good stability to 
ensure its immunogenicity and 4) to achieve strong and long-term antigen specific 
immunogenicity of produced chimeric VLP vaccine in vivo. 
1.2 Aim and Objectives 
The aim of this project is to develop effective adjuvant free chimeric HBc VLP derived 
vaccines by applying HBc VLP platform to present foreign epitopes targeting 
oncoviruses. To achieve this aim, this project focuses on objectives as follows: 




VLPs presenting different foreign epitopes targeting Hepatitis C virus (HCV) and 
Epstein–Barr virus (EBV) using E. coli expression system in high production yields, 
2. To study and understand the possible mechanism that can influence on the 
stability and the assembly of produced chimeric HBc VLPs, 
3. To evaluate the in vivo immunogenicity of two produced chimeric HBc VLP 
to confirm their performance of effective and long-term antigen specific immune 
response. 
The process of this project is illustrated in Figure 1.1. EBV and HCV epitope, Epstein-
Barr nuclear antigens 1 (EBNA1), and Hepatitis C virus core (HCV core), were fused 
to HBc VLP protein to form chimeric EBNA1-HBc and HCV core-HBc VLPs. The 
designed recombinant chimeric HBc VLPs were expressed and purified using E.coli 
expression system. The characterizations and properties of expressed chimeric HBc 
VLPs were investigated systematically. Then the immunogenicity performance and 
stability of produced chimeric HBc VLPs were evaluated, and computational protein 
modelling and molecular dynamic (MD) simulation were employed for the evaluation 










1.3 Thesis outline 
In Chapter 1, the background, the aim and objectives, structure and thesis outline are 
introduced. 
In Chapter 2, recent development and challenges of VLP-based platform as cancer 
vaccines were reviewed. 
In Chapter 3, chimeric HBc VLPs targeting the EBV and HCV were designed by 
presenting two foreign epitopes, EBNA1 and HCV core, on the N-terminus of HBc 
VLP, respectively. Optimizations for the conditions of expression and downstream 
purification were performed aiming to produce the designed chimeric HBc VLPs with 
high production yields in soluble form. 
In Chapter 4, characterization and the abilities of chimeric EBNA1-HBc VLP and 
HCV core-HBc VLP to maintain the assembled VLP structure were evaluated under 
different physical and chemical stresses compared with wild type (wt) HBc VLP to 
examine the impact of insertion of foreign epitopes on the stability of chimeric HBc 
VLPs after insertion of different types of epitopes. Protein computational modelling 
and MD simulation were applied to assist the understanding of the change of the 
physical property of chimeric VLPs which causes the differences between the stability 
of wt HBc VLP and chimeric HBc VLPs. 
In Chapter 5, chimeric HBc VLP presenting short and non-structural epitope, EBNA1, 
was constructed and produced using optimized production conditions. In vivo humoral 
and cellular immune response induced by adjuvant free EBNA1-HBc VLP was 




Long-term protection ability of adjuvant free EBNA1-HBc VLP was evaluated by 
detection of EBNA1 specific memory T cells produced in the immunized mice. 
In Chapter 6, chimeric HBc VLP presenting long and structural epitope, HCV core, 
was constructed and produced using optimized production conditions. In vivo HCV 
core specific humoral and cellular immune response induced by adjuvant free chimeric 
HCV core-HBc VLP was examined and compared with chimeric EBNA1-HBc. Then 
the difference in immunogenicity and the impact on the immune response type caused 
by insertion of different types of foreign epitopes were evaluated. Long-term 
immunogenicity of adjuvant free HCV core-HBc VLP was evaluated by detection of 
HCV core specific memory T cells produced in the immunized mice. 






[1] A.S. Clem, Fundamentals of vaccine immunology, J. Glob. Infect. Dis. 3(1) (2011) 73-78. 
[2] K.L. Hartshorn, M.R. White, E.C. Crouch, Contributions of the N-and C-terminal domains 
of surfactant protein d to the binding, aggregation, and phagocytic uptake of bacteria, 
Infection and immunity 70(11) (2002) 6129-6139. 
[3] J.B. Margolick, R.B. Markham, A.L. Scott, The immune system and host defense against 
infections, Infectious disease epidemiology: theory and practice (2014) 317-43. 
[4] D. Baxter, Active and passive immunity, vaccine types, excipients and licensing, Occup. 
Med. 57(8) (2007) 552-556. 
[5] Centers for Disease Control and Prevention (CDC). https://www.cdc.gov/vaccines/vac-
gen/immunity-types.htm. (Accessed April 20 2020). 
[6] World Health Organization. https://www.who.int/csr/disease/smallpox/en/. 
[7] P. National Research Council Division of Health, P. Disease, Vaccine Supply and 
Innovation, National Academies Press (US) 
Copyright (c) National Academy of Sciences., Washington (DC), 1985. 
[8] L. Falzone, S. Salomone, M. Libra, Evolution of Cancer Pharmacological Treatments at the 
Turn of the Third Millennium, Front. Pharmacol. 9(1300) (2018). 
[9] W.F. Bynum, W.F. Bynum, W.F. Bynum, R. Porter, Medicine and the five senses, 
Cambridge University Press1993. 
[10] S. Mukherjee, The emperor of all maladies: a biography of cancer, Simon and 
Schuster2010. 
[11] A. Arnold-Forster, A pathology of progress? Locating the historiography of cancer, BJHS 
49(4) (2016) 627-634. 
[12] J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. 
Forman, F. Bray, Cancer incidence and mortality worldwide: sources, methods and major 
patterns in GLOBOCAN 2012, International journal of cancer 136(5) (2015) E359-E386. 
[13] National Cancer Institute (NIH). https://www.cancer.gov/about-cancer/treatment/types. 
(Accessed March 24 2020). 
[14] M. Zapatka, I. Borozan, D.S. Brewer, M. Iskar, A. Grundhoff, M. Alawi, N. Desai, H. 
Sültmann, H. Moch, M. Alawi, C.S. Cooper, R. Eils, V. Ferretti, P. Lichter, I. Borozan, 
D.S. Brewer, C.S. Cooper, N. Desai, R. Eils, V. Ferretti, A. Grundhoff, M. Iskar, K. 
Kleinheinz, P. Lichter, H. Nakagawa, A.I. Ojesina, C.S. Pedamallu, M. Schlesner, X. Su, 
M. Zapatka, P. Pathogens, P. Consortium, The landscape of viral associations in human 
cancers, Nat. Genet. 52(3) (2020) 320-330. 
[15] S. Kruger, M. Ilmer, S. Kobold, B.L. Cadilha, S. Endres, S. Ormanns, G. Schuebbe, B.W. 
Renz, J.G. D’Haese, H. Schloesser, V. Heinemann, M. Subklewe, S. Boeck, J. Werner, M. 
von Bergwelt-Baildon, Advances in cancer immunotherapy 2019 – latest trends, J. Exp. 
Clin. Cancer Res. 38(1) (2019) 268. 
[16] N.K.C. Linda H.L. Lua, Frank Sainsbury, Yap P. Chuan,Nani Wibowo, Anton P.J. 
Middelberg, Bioengineering Virus-Like Particles as Vaccines, Biotechnology and 
Bioengineering 111 (2014) 425-440. 
[17] Z. Wang, H. Gao, Y. Zhang, G. Liu, G. Niu, X. Chen, Functional ferritin nanoparticles for 





[18] J. Liu, L. Miao, J. Sui, Y. Hao, G. Huang, Nanoparticle cancer vaccines: Design 
considerations and recent advances, Asian Journal of Pharmaceutical Sciences (2019). 
[19] P.-L. Lollini, F. Cavallo, P. Nanni, G. Forni, Vaccines for tumour prevention, Nature 
Reviews Cancer 6(3) (2006) 204-216. 
[20] M.O. Mohsen, D.E. Speiser, A. Knuth, M.F. Bachmann, Virus-like particles for 
vaccination against cancer, Wiley Interdisciplinary Reviews: Nanomedicine and 
Nanobiotechnology n/a(n/a) e1579. 
[21] D. Yan, Y.-Q. Wei, H.-C. Guo, S. Sun, The application of virus-like particles as vaccines 
and biological vehicles, Applied microbiology and biotechnology 99 (2015). 
[22] H.K. Ong, W.S. Tan, K.L. Ho, Virus like particles as a platform for cancer vaccine 
development, PeerJ 5 (2017) 4053-4053. 
[23] C. Lemke, A. Salem, A. Krieg, G. Weiner, Abstract 1417: Combination cancer 
immunotherapy using checkpoint blockade and intratumoral virus-like particles 
containing CpG ODN, Cancer Res. 76(14 Supplement) (2016) 1417. 
[24] L. Klimek, T. Kündig, M.F. Kramer, S. Guethoff, E. Jensen-Jarolim, C.B. Schmidt-Weber, 
O. Palomares, M.O. Mohsen, T. Jakob, M. Bachmann, Virus-like particles (VLP) in 
prophylaxis and immunotherapy of allergic diseases, Allergo Journal International 27(8) 
(2018) 245-255. 
[25] S.A. Keller, M. Bauer, V. Manolova, S. Muntwiler, P. Saudan, M.F. Bachmann, Cutting 
Edge: Limited Specialization of Dendritic Cell Subsets for MHC Class II-Associated 
Presentation of Viral Particles, The Journal of Immunology 184(1) (2010) 26. 
[26] A.F. Sander, P.-L. Lollini, Virus-like antigen display for cancer vaccine development, 
what is the potential?, Expert Review of Vaccines 17(4) (2018) 285-288. 
[27] J.d.S. Apostólico, V.A.S. Lunardelli, F.C. Coirada, S.B. Boscardin, D.S. Rosa, Adjuvants: 
Classification,<i> Modus Operandi</i>, and Licensing, Journal of Immunology Research 
2016 (2016) 1459394. 
[28] J. Chroboczek, I. Szurgot, E. Szolajska, Virus-like particles as vaccine, Acta Biochim Pol 
61(3) (2014) 531-9. 
[29] R. Noad, P. Roy, Virus-like particles as immunogens, Trends Microbiol. 11(9) (2003) 438-
44. 
[30] A.P. Middelberg, T. Rivera-Hernandez, N. Wibowo, L.H. Lua, Y. Fan, G. Magor, C. 
Chang, Y.P. Chuan, M.F. Good, M.R. Batzloff, A microbial platform for rapid and low-
cost virus-like particle and capsomere vaccines, Vaccine 29(41) (2011) 7154-62. 
[31] M.W. Liew, A. Rajendran, A.P. Middelberg, Microbial production of virus-like particle 




Chapter 2: Literature Review: Recent 
technology and challenges of virus like 
particle (VLP)-based platform applied in 
cancer vaccines development 
2.1 Introduction 
Recent researchers have proven that viruses are associated with various types of cancers 
globally [1]. These viruses are called oncoviruses which mainly include human 
papillomavirus (HPV), hepatitis B virus (HBV) and hepatitis C virus (HCV), Epstein–
Barr virus (EBV), Merkel cell polyomavirus, Kaposi's sarcoma-associated herpesvirus 
(KSHV) and human T-lymphotropic virus [2]. To develop the treatments against these 
oncoviruses, immunotherapy, a novel approach to treat cancers by using patients’ own 
immune system [3], has been investigated and developed. It is believed that 
immunotherapy is an efficient approach to treat diseases of hematological cancers and 
virus leading cancers. There are several types of immunotherapy that have been 
developed against cancers including immune checkpoint inhibitors, T-cell transfer 
therapy, monoclonal antibodies, immune system modulators and cancer vaccines [4]. 
Among them, cancer vaccines are regarded as one of the best candidates [5] because of 
their exquisite specificity, low toxicity, and the potential for a durable treatment effect 




In the investigation of effective cancer vaccines, one of the subunit vaccines, virus-like 
particle (VLP), has attracted researchers’ attention because of its unique structure and 
its merits. VLPs are molecules with structures similar to natural viruses and are mainly 
constructed with capsid proteins of viruses [7]. However, VLPs have no viral genes, 
which means that they are non-infective and non-replicative. These properties make 
VLPs promising candidates for the development of effective and safe cancer vaccines. 
However, only a few VLP-based cancer vaccines are available in the market at present 
such as HBV, HPV and Influenza vaccines [8-11]. 
To produce VLP-based cancer vaccines, challenges could be much more than the 
production for traditional vaccines for the following reasons: 1) cost-effective 
bioprocess development to produce designer VLP vaccines, 2) complexity to maintain 
the biomolecular structure of VLP vaccines, 3) in vivo immunogenicity related directly 
to the molecular structure of VLP vaccines [12].  
To better understand the development and overcome the challenges in the production 
of VLPs as cancer vaccines for immunotherapy, related literatures are reviewed in this 
chapter. In this chapter, seven parts are included. 1) vaccine types are described to 
understand the properties and features of different vaccines, 2) different types of cancer 
vaccines are reviewed to understand the development of recent cancer vaccines, 3) 
oncovirus is reviewed to understand the application of immunotherapy in cancer 
treatment, 4) studies on chimeric VLPs targeting oncoviruses are reviewed to 




modelling of VLPs is reviewed to assist the study on the biomolecule’s design and 
stability. 6) production process of chimeric VLP-based vaccines is reviewed to fully 
understand the bottlenecks of expression and purification of chimeric VLP vaccines, 
and 7) characterization methods for VLPs are reviewed to understand the recent 
technology for analysis of the structure and properties of VLPs. 
2.2 Vaccine types 
Immunity can be acquired through two ways which are the passive or the active means 
[13]. Active immunity is acquired when the immune system is exposed to an antigen. 
The immune system takes some time to response but normally the acquired immunity 
can last longer time [14]. In comparison, passive immunity is acquired by giving the 
specific antibody against the infection. The response to passive immunity is normally 
immediate but the immune efficiency lasts shorter time compared with active immunity 
[14]. Both passive and active immunization can be acquired from natural or artificial 
sources. 
In the modern immunotherapy for diseases, patients are exposed with a pathogenic 
antigen which can trigger the immune response of patients by active immunization to 
develop immunity to specific antigens [15]. In this way, patients after vaccination can 
obtain long-term immunity against the pathogenic antigen because of the activation of 
immune system. Excellent examples of immunotherapy through active immunization 
are the influenza vaccination and smallpox vaccination [16]. 




made from 1) live attenuated viruses through different methods to weaken its infectious 
and 2) inactivated viruses which are killed to destroy producing capacity of viruses [17]. 
However, the safety issues for inactivated vaccines and live attenuated vaccines limit 
their development and applications. To reduce the risk during the vaccination, advanced 
vaccines such as mRNA vaccines and subunit vaccines are then developed. Table 2.1 
summarizes the different types of vaccines and their commercial vaccines. 
Table 2.1 Vaccine types and their available vaccines (modified from [18]) 
Vaccine type Available vaccines 
Traditional vaccines 
Live attenuated virus 
Measles, mumps, rubella (MMR 
combined vaccine); Varicella 
(chickenpox); Influenza (nasal spray); 
Rotavirus; Zoster (shingles); Yellow fever 
Inactivated virus 
Polio (IPV); Seasonal influenza; Hepatitis 
A virus (HAV); Rabies 
Advanced vaccines 
mRNA vaccines COVID-19, HIV-1 
Subunit vaccines 
Influenza (injection); Haemophilus 
influenza type b (Hib); Pertussis (part of 
DTaP combined immunization); 
Pneumococcal; Meningococcal, Human 
papillomavirus (HPV); Hepatitis B virus 
(HBV) 
2.2.1 Traditional vaccines 
2.2.1.1 Live attenuated vaccines  




classified as traditional vaccines. Various techniques have been applied to produce 
traditional vaccines. One traditional approach to produce live attenuated vaccines is 
passing target virus through a series of cell cultures or animal embryos (typically chick 
embryos) to weaken its infection and adaptation of the virus to the growth in the 
cultured cells. This process is accompanied by a gradual loss of virulence of target virus 
for the natural host [19, 20]. For example, in the chicken embryos culture process, the 
virus is grown in a series of embryos to increase its ability to replicate in chicken cells 
and to reduce its ability to replicate in human cells. In theory, through hundreds of 
passes, the attenuated virus gradually loses its replicability in human cells, and its 
infectivity against human becomes significantly weaken to render it safe for human 
vaccination. Therefore, attenuated virus retains the ability to trigger the immune 
response against the virus and protect human from future infection [21]. However, in 
practical application, this method remains the risk that the virus can recover its 
replication ability after entering human and may cause the disease. In addition, 
mutations of virus could happen when the attenuated virus replicates in the human body, 
and it could turn to be a more deadly form. Oral polio vaccine (OPV) is one example. 
OPV is a kind of live attenuated vaccines when it was developed for the treatment of 
poliomyelitis. It is reported that the attenuated polio virus could turn to a virulent form 
and cause some rare cases of paralytic polio[22]. Therefore, OPV is banned for use in 




2.2.1.2 Inactivated vaccines 
Inactivated vaccine is another popular traditional vaccine. The viruses are replicated by 
approaches such as cell cultivation or chicken embryos cultivation. The produced 
viruses are then inactivated by heat or chemicals such as formaldehyde or formalin [23]. 
The process destroys the replication ability of the pathogen, while keeps its antigenicity 
to be recognized by human body and trigger the immune response against the target 
pathogen [24]. 
Activated vaccines show much lower risks of reverting the pathogen to a more virulent 
form since inactivated pathogens lose its replication ability completely [23]. However, 
the protection period of inactivated is normally shorter compared with live attenuated 
vaccines. To obtain the similar long-term immunogenicity, several boosters need to be 
used. Inactivated polio vaccine and the seasonal influenza vaccine are two common 
inactivated vaccine in the market at present as shown in Table 2.1 [18]. 
2.2.2 Advanced vaccines 
2.2.2.1 Messenger RNA (mRNA) vaccines 
mRNA has been investigated as an advanced therapeutic tool in the fields of vaccine 
development. mRNA vaccines can be produced through in vitro transcription of a 
complementary DNA (cDNA) template using a bacteriophage RNA polymerase [25]. 
The application of mRNA vaccine has several merits over traditional vaccine 
candidates as well as DNA-based vaccines [26]. Firstly, mRNA is a non-infectious 




of infection or insertional mutagenesis. Secondly, several approaches for the 
modifications of mRNA have been developed to increase its stability and translatability 
[27, 28]. mRNA carriers such as polymers and nanoparticles have been developed to 
enable the rapid uptake and expression of mRNA vaccines in the cytoplasm [29]. 
Finally, rapid, inexpensive and scalable production of mRNA vaccines have been 
developed thanks to the high yields of in vitro transcription reactions. However, mRNA 
can be degraded during normal cellular processes. This could affect in vivo half-life of 
mRNA vaccine which influences on its immunogenicity efficacy. To overcome this 
issue, various modifications and delivery methods including covalent conjugates, 
protamine complexes, nanoparticles based on lipids or polymers, and hybrid 
formulations have been investigated [29, 30]. One recent application of mRNA vaccine 
is the novel COVID-19 vaccine manufactured by Pfizer-BioNTech and Morderna. 
Moderna reported that vaccine candidate mRNA-1273 achieved an efficacy of 94.1% 
during the phase 3 clinical trial, enrolled 30,420 volunteers who were randomly 
assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each 
group) [31]. Another Pfizer-BioNTech vaccine candidate, BNT162b2, was 95% 
effective in preventing COVID-19 (95% credible interval, 90.3 to 97.6) during the 
phase 3 clinical trial, which enrolled 43,548 participants [32]. 
2.2.2.2 Subunit vaccines 
As shown in Table 2.1, subunit vaccine contains only part or parts of the pathogens 




in the last few decades [33-35]. Since subunit vaccines use parts of the pathogens to 
retain the ability to trigger a response from the immune system, it is much safer in the 
application compared with traditional vaccines. One specific part from the pathogen 
which is suitable for presenting as the antigen is isolated to form subunit vaccine. The 
subunit vaccine technique is now commonly applied in the development of acellular 
pertussis and influenza vaccines [21]. As is listed in Table 2.2, four different types of 
subunit vaccines including protein subunit, peptide subunit, polysaccharide subunit and 
virus like particle (VLP) based vaccines have been developed. 
Subunit vaccines can be generated by using genetic engineering such as recombinant 
protein technique [36] or conjugating polysaccharide to carrier proteins [37]. 
Recombinant vaccines containing specific antigens targeting different diseases were 
developed. By fusing the gene sequence of the antigen with other protein carrier 
sequence, the recombinant vaccines can be recognized by human body and can trigger 
antigen specific immune response in the body for further protection against the 
pathogens [35, 38, 39]. Subunit vaccines obtain several advantages over traditional 
vaccines in terms of safety, short production and specific immune target [40]. However, 
in the development of subunit vaccines, the major challenges are the low 
immunogenicity efficiency and the stability of the vaccine candidates [33]. Further 






Table 2.2 List of different types of subunit vaccines. 
Type Target disease or virus 
Protein subunit SARS-CoV-2 
Peptide subunit 
Malaria Parasite, Alzheimer’s Disease, 
Pneumococcal Disease, HCV, Influenza 
Virus and HIV-1 
Polysaccharide subunit Pneumococcal Disease 
Virus like particle HBV, HPV, HEV, HAV and Influenza A 
2.2.2.2.1 Protein-based subunit vaccines 
Figure 2.1 illustrates the structure of classical vaccine with whole pathogen, protein-
based subunit vaccine and peptide-based subunit vaccine. Protein-based subunit 
vaccine (Figure 2.1B) is formed by assembly of a single protein molecule with other 
protein molecules to form a complex [41]. Protein-based subunit vaccine can be 
produced by isolation of a specific protein from a virus or expressed as a recombinant 
protein subunit using different expression system such as bacteria and yeast. However, 
protein-based vaccines have challenges including the vaccine efficacy, the cost of 
recombinant protein production, stability and purity problems. The use of a whole 
foreign protein may cause autoimmune responses. For example, M protein from group 
A streptococcal (GAS) is the major virulence factor of GAS and a target for vaccine 
development [42]. However, the conserved C-terminal regions of M protein could elicit 
autoimmunity, therefore the whole protein cannot be used as an antigen without 
substantial risk of toxic side-effects [43]. Recently, Spike protein of SARS-CoV-2 has 




COVID-19. S-Trimer COVID-19 vaccine (SCB-2019) has been developed using 
Trimer-Tag to allow for trimerization of SARS-CoV-2 spike (S)-protein [44]. In a phase 
1 clinical trial, SCB-2019 was confirmed to induce high level of antibodies against 
SARS-CoV-2. In addition, strong Th1-biased cell-mediated immune responses were 
observed. Further phase 2 and 3 clinical trial is needed to confirm the vaccine efficacy 
and stability of this novel protein-based subunit vaccine against SARS-CoV-2. 
 
Figure 2.1 Schematic evolution of vaccines: (A) classical vaccine incorporating whole 
pathogen, (B) protein-based subunit vaccine, and (C) peptide-based subunit vaccine [45]. 
2.2.2.2.2 Peptide-based subunit vaccines 
This autoimmune response can be reduced or eliminated by using short peptide as 
epitope rather than large pathogen components as is shown in Figure 2.1C. Peptide-
based vaccines can be produced with high purity and well-defined composition using 
low-cost expression system such as bacteria and yeast [45]. The produced peptide-
based subunit vaccines are more stable, water-soluble than protein-based subunit 
vaccines. In addition, several peptide epitopes including different subtypes of a 
pathogen, different stages in the life cycle of a pathogen or even epitopes from multiple 




subunit vaccine candidates are expected to induce strong immune response mediated 
by lymphocytes such as cytotoxic T-lymphocytes (CTL, CD8+ T-cells) and B-cells [46]. 
However, peptide epitopes are very susceptible to enzymatic degradation in the body, 
which is significantly influence on the vaccine efficacy of peptide-based subunit 
vaccines. To enhance the metabolic stability of a peptide epitope, various approaches 
have been developed including modification the C- or N-terminal of the peptide subunit, 
synthesis in a retro-inverted form and conjugate with carriers [47-49]. Peptide-based 
subunit vaccines have been adapted in the development of vaccines against viruses such 
as HCV, Influenza Virus and HIV-1 and diseases such as Malaria Parasite, Alzheimer’s 
Disease, Pneumococcal Disease [45]. However, the major challenge for peptide 
vaccines is the weaker overall immune response in comparison to traditional vaccines 
While this issue is of particular relevance in infectious diseases, it may also pertain to 
other disease areas as well, because stronger immune responses can often be associated 
with greater protection and durability. 
2.2.2.2.3 Polysaccharide-based subunit vaccines 
Capsular polysaccharides (CPS) from bacteria have been investigated and employed 
for the production of polysaccharide-based subunit vaccines. Pneumococcal disease is 
one target disease for the development of polysaccharide-based subunit vaccines. The 
latest pneumococcal conjugate vaccine contains 13-valent pneumococcal serotypes 
(PCV13). This vaccine's efficacy of PCV13 against pneumococcal infections was 45.6% 




observed in the development of pneumococcal polysaccharide-based subunit vaccines. 
One issue is that the pneumococcal polysaccharide-based subunit vaccines are not 
effective in infants and young children (under 18–24 months) [51]. In theory, the 
repeating subunits of pneumococcal polysaccharide-based subunit vaccines can 
stimulate immune response in B cells independent of T-cell. However, the ability to 
mount a T-cell–independent immune response of infants and young children is weak 
[52]. Another issue is that the immune response induced by polysaccharide-based 
subunit vaccine is short term immunity and revaccination is needed [51]. In this case, 
modification and redesign of polysaccharide-based subunit vaccines are required for its 
application as promising vaccine candidates. 
2.2.2.2.4 Virus like particle (VLP)-based vaccines 
VLP is a special form of protein-based subunit vaccine and is composed of the capsid 
proteins of virus and it obtains the molecular structure similar to the virus while has no 
viral gene sequence. VLPs have the morphology of a highly repetitive immunogenic 
surface structure which enables VLP to induce strong immune response in body. Since 
VLPs have no viral genomes, they are unable to infect or replicate in the body. This 
non-infectious feature of VLP proteins greatly improves their safety compared with 
other subunit vaccine candidates [53, 54] . 
Briefly, VLPs can be mainly categorized as non-enveloped and enveloped structures. 
Non-enveloped VLPs were assembled from single viral subunit expressed by different 




the assembly process of enveloped VLPs needs the assistance of lipid membranes from 
expression cells [55]. Non-enveloped VLPs are generally easier in the production and 
purification compared with enveloped VLPs, while enveloped VLPs are more flexible 
and can be integrated with different pathogens [56]. In this case, enveloped VLPs are 
more suitable to present full-length monomeric or multimeric conformational antigens 
from target viruses and non-enveloped VLPs are more suitable for presenting short 
epitope from target viruses [57]. 
Due to the unique structure of VLPs, they have been broadly investigated and 
developed as preventive cancer vaccines for the treatment of different cancers such as 
cervical cancers and Hepatocellular carcinoma. In addition, VLPs are also applied as 
preventive vaccines in the treatment of other infectious diseases such as influenza and 
foot-mouth disease. VLPs are in the structure of highly repeated order, and such 
assembled structure normally are considered as effectively crosslinked B-cell receptors 
[58]. It is reported that VLPs can trigger the strong immune response with the assistance 
of the antigen presenting cells due to their unique structure. Due to the characteristic of 
VLPs, VLPs show good self-adjuvating property and different VLP-based vaccines 
constructed with the structure proteins from the virus have been developed after the 
first recombinant Hepatitis B surface antigen (HBsAg) VLP was successfully 
commercialized in 1982 [12]. In addition to the approach to use the structure proteins 
from cancer related virus to form the VLPs as vaccine candidates, VLPs were also 




or conjugation. A successful vaccination depends largely on its immunogenicity and 
presentation efficiency of the tumour antigens, and VLPs obtain many advantages over 
other candidates including the safety as well as the efficiency [53, 54]. However, up to 
date, few VLP-based vaccines against viruses including human papilloma virus (HPV), 
hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis E virus (HEV), and 
influenza A have been commercialized (as listed in Table 2.3). Among them, HPV 
VLP and HBV VLP are reviewed in the following session. 
Table 2.3 Current commercial VLP-based vaccines [59] 
Virus Species Antigen/s Adjuvant Commercial Name (Company) 
HPV Capsid protein L1 AS04 Cervarix (GSK) 
HPV Capsid protein L1 Aluminium Gardasil (Merck) 
HBV HBsAg Aluminium Engerix-B (GSK) 
HBV HBsAg Aluminium Recombivax HB (Merck) 
HBV HBsAg Aluminium GenHevac B (Pasteur) 
HBV HBsAg AS04 Fendrix (GSK) 
HEV Capsid protein CP Aluminium Hecolin (Xiamen Innovax Biotech) 
Influenza A HA and NA glycoproteins Liposome Inflexal V (Crucell) 
HAV Inactivated HAV Virosome Epaxal (Crucell) 
2.2.2.2.4.1 Human papillomavirus (HPV) vaccines 
Cervical cancer is reported to be a server cancer and its survival rate varies depending 
on the stage [60]. HPV is regarded as the main agent to cause the cervical cancer, and 




types of HPV (HPV-16 and HPV-18) [60]. At present, the most promising way to 
reduce the risk of cervical cancer is the early vaccination of HPV vaccines as preventive 
protection. Multivalent Gardasil, Cervarix, and Gardasil 9 are the commercial HPV 
vaccines available in the market. L1 protein of HPV which is the major capsid protein 
of HPV can self-assembly into VLPs and is used to generate preventive vaccines. The 
commercial Gardasil 9 vaccine provides fully vaccinated people with protection against 
nine types of HPV including: 1) types 16 and 18, the two types that cause the majority 
of HPV-related cancers, 2) the five next most common HPV types associated with 
cervical cancer (types 31, 33, 45, 52 and 58) and 3) two non-cancer-causing HPV types 
(types 6 and 11), which cause 90% of genital warts [61]. Research studies have shown 
early signs of the vaccine's success including: 1) a 77% reduction in HPV types 
responsible for almost 75% of cervical cancer, 2) almost 50% reduction in the incidence 
of high-grade cervical abnormalities in Victorian girls under 18 years of age and 3) a 
90% reduction in genital warts in heterosexual men and women under 21 years of age 
[62]. 
Researchers have found that in addition to L1 major capsid protein of HPV, L2 minor 
capsid protein of HPV with a highly conserved structure could be another option for 
the development of novel HPV VLP-based vaccines [63]. It is reported that vaccination 
with L2 peptide can induce cross-neutralizing antibodies and conferred cross-protection 
in vivo. However, the induced antibody titer was much lower compared with the 




VLP-based vaccine was generated by fusing L2 sequence to the C-terminal of L1 
protein to improve its immunogenicity and induced the high antibody titer [66]. 
Nicotiana benthamiana was used as the host cell to express the novel recombinant 
L1/L2 VLP. The molecular characterization indicated that L2 was exposed on the 
surface of expressed chimeric VLP. The immunogenicity evaluation confirmed the 
improved humoral immune response against both L1 and L2 antigen and the novel 
chimeric VLP vaccine were demonstrated to protect the mice from HPV-16 and HPV-
52 [66]. Similarly, Huber et al. (2015) constructed the HPV VLP vaccine by fusing the 
L2 protein from HPV-45 to the L1 protein from HPV-18. The in vivo immunization 
results indicated that the chimeric L1/L2 HPV vaccine can cross-protect against four 
different types of HPVs after mice were injected with antisera from the L1/L2 HPV 
VLP vaccine immunized rabbits [67]. Also, there is no available therapeutic HPV 
vaccines to treat pre-existing cervical cancers. To fill the gap, researchers have made 
attempts to produce a chimeric therapeutic vaccine by inserting the non-structural E7 
protein of HPV into infectious bursal disease virus to form VLP-based vaccine (E7 VLP 
vaccine). E7 protein is proven to be a tumour-specific antigen, and is over expressed in 
the patients with HPV-associated cervical cancers [68]. The preliminary results from 
the tumour challenge experiment indicated that tumour of mice vaccinated with E7 VLP 
vaccine was completely inhibited [69]. Further research on this approach needs to be 
explored before clinical trial and marketing. The lessons and experience gained from 




based vaccines for treatments of other cancers. 
2.2.2.2.4.2 Hepatitis B virus (HBV) vaccines 
HBV related liver cancers are diagnosed in large number every year and its death rate 
is high among all cancers [70] and the survival rate of liver cancer patients is only about 
25-45% [71]. Around 30 % of the world population are infected with HBV, and among 
them, around 350 million people developed chronic infection [72]. It is reported that 
around 50% of liver cancers are related with the infection of Hepatitis B virus or 
Hepatitis C virus [73]. To date, commercial HBV preventive vaccines is available in 
the market. It has been proven that preventive vaccination is the most effective way to 
reduce the risk of liver cancers [74]. However, the limitation to access these vaccines 
and lack of therapeutic HBV vaccines have inhibited the step to eradicate HBV 
infection rate and reduce the risk of liver cancer. 
After the first recombinant hepatitis B vaccine was licensed in the United States in July 
1986, many optimized HBV vaccines were produced [75]. There are several HBV VLP 
vaccines on the market currently including Engerix-B, Enivac HB, Gene Vac-B, 
Hepavax-Gene, and Recombivax HB as shown in Table 2.3 [7]. 
 




Figure 2.2 shows the structure of Hepatitis B core (HBc) VLPs. HBc VLP is composed 
of the core capsid protein from HBV and the HBc VLP has two major isomorphs with 
triangulation numbers T = 4 and 3 that consist of 240 and 180 HBc monomers [77]. 
The sizes of wild type (wt) HBc VLP in two isomorphs are 35 and 32 nm in diameter, 
respectively. HBc VLPs have been reported to be successfully applied in the 
presentation of different foreign antigens. For example, Ye et al. (2014) successfully 
constructed the chimeric SP55-HBc and SP70-HBc VLP proteins to present the SP55 
and SP70 peptides from Enterovirus 71 (EV71) using Escherichia coli (E. coli) 
expression system and the produced chimeric VLP vaccine induced epitope-specific 
and HBc specific antibody responses in mice [78]. However, as claimed in the report, 
the chimeric SP55-HBc and SP70-HBc VLP proteins were expressed highly in the 
inclusion bodies, which potentially increased the complexity in production process such 
as protein refolding and assembly process. More applications of HBc VLP in the 
production of chimeric VLP-based vaccines are described in section 2.5. 
2.3 Cancer vaccines 
Cancer vaccines play an important role in treating infections which lead to cancers and 
other diseases by inducing strong and long term self-immune response [5]. As shown 
in Figure 2.3, after immunization, cancer vaccines stimulate dendritic cell (DC) and 
trigger Class I major histocompatibility complex (MHC) pathway for cellular immune 
response and Class II MHC pathway for humoral immune response. Cancer vaccines 




[79]. Preventive cancer vaccine aims to induce the immune response of the body to 
defend the viral infection which can consequently cause cancers; while therapeutic 
cancer vaccine aims to stimulate the immune system of the patients to kill or inhibit the 
growth of tumour cells [79].  
 
Figure 2.3 Mechanism of cancer vaccines [80]. DC: dendritic cell, MHC: major 
histocompatibility complex 
2.3.1 Therapeutic cancer vaccines 
Therapeutic cancer vaccines are designed to induce strong immune response of the host 
against the tumour cells leading to reduce or control the growth of the tumour. However, 
during the development of efficient therapeutic cancer vaccines several barriers remain. 
Among them, tumour-induced immunosuppression in tumour microenvironment (TME) 
is regarded as the major factor limiting the development of therapeutic cancer vaccines 




leukocytes, including regulatory T cells (Tregs) and myeloid derived suppressor cells 
(MDSCs) were found in TME. These leukocytes generate cytokines, such as TGF-β 
and IL-10, that enhance the tumour growth, metastasis, and angiogenesis [82]. In 
addition, tumour-associated macrophage (TAMs) also influences the activation of T-
cells and sometimes causes the death of activated T-cells [83, 84]. In this way, the 
efficiency of the immunotherapy to the tumour is largely reduced. Tegerstedt et al. 
(2005) have developed a VLP-based breast cancer vaccine by fusing the antigen, TAA 
HER-2/neu (Her2), to murine polyomavirus VLPs to produce a chimeric therapeutic 
cancer vaccine [85]. Her2 was selected as the antigen because it is recognized as the 
primary biomarker for the breast cancer which are overexpressed during the breast 
tumour’s growth [86]. They found that the chimeric Her2-Py VLP was able to induce 
strong Her2 specific T-cell immune response in vivo. This also leads to the tumour 
reduction and longer surviving time when examined by in vivo tumour challenge 
experiment. However, humoral immunity was barely detected. This could result from 
the position for the insertion of the antigen as Her2 antigen was buried internally in the 
vaccine. Another issue in the development of these breast cancer therapeutic vaccines 
is that the vaccine efficacy depends on the immunization timing, probably due to the 
existence of TME. In Tegerstedt’s study, delayed immunization only postponed tumour 
outgrowth but had a minor effect on the protection of breast cancer. Therefore, a 
successful therapeutic cancer vaccine should be able to trigger immune response against 




2.3.2 Preventive cancer vaccines  
Preventive cancer vaccines are designed to induce the immune response of the host 
against the origins that lead to the cancers. The origin which has been broadly studied 
is the oncovirus. Several oncoviruses including HBV, HCV, HPV, EBV, Kaposi's 
sarcoma-associated herpesvirus, human T-cell lymphotropic virus, and merkel cell 
polyomavirus have been recognized as the triggers for different cancers, and the 
preventive cancer vaccines against these viruses have been broadly investigated [87]. 
Preventive vaccines against these viruses have been developed and investigated. One 
of the most successful samples is the HPV vaccine which prevents the cervical cancer. 
Huber et al. (2015) developed a preventive vaccine, 18L1-45RG1, by fusing the L2 
protein of HPV-45 to the L1 protein of HPV-18. In the study, 18L1-45RG1 showed 
effective protection of mice against the infection of different types of HPVs after the 
mice were injected with serum from immunized rabbits with preventive 18L1-45RG1 
vaccine [67]. With the proven results of HPV vaccine against a broad range of HPVs, 
it is now commercially available world-widely. However, for the immunotherapy 
treatment of cervical cancer, only preventive HPV vaccine was commercially available 
and there is no therapeutic vaccine for cervical cancer yet.  
2.4 Oncovirus 
In Table 2.4, the information regarding the viruses and their related cancers are 
summarized. HBV, HCV, HPV, EBV and Human T-cell leukaemia virus type 1 




and direct carcinogens act. Comparing with traditional approaches for cancer treatment 
including invasive surgeries, chemotherapy, and radiotherapy, cancer vaccine treatment 
does less harm to the patients’ body and cause less side effects which are the two major 
issues in traditional cancer treatment approaches [88]. Among all investigated 
oncoviruses, HBV and HPV are two widely studied viruses and some commercial 
vaccines against these two viruses have been developed (listed in section 2.2.2.2.4). 
However, there is no commercial vaccines against the other two major oncoviruses, 
EBV and HCV, which are also related to severe cancers, even though HCV has been 
identified as the cause of severe liver disease and liver cancers by Harvey J. Alter, 
Charles M. Rice and Michael Houghton who awarded the 2020’s Nobel Prize in 
Physiology or Medicine. 
Table 2.4 Oncoviruses and related cancers (modified from [7]) 
Virus Oncoviruses associated cancers Mechanism of Carcinogenesis 
HBV Hepatocellular carcinoma Chronic inflammation 
HCV Hepatocellular carcinoma Chronic inflammation 
HPV 
Cervical, vulva, vagina, penis, anus and oropharynx 
cancers. 
Direct carcinogens act via expression 
of viral oncoproteins 
EBV 
Burkitt's lymphoma, Hodgkin lymphoma, B cell 
lymphoma, nasopharyngeal carcinoma, gastric and 
sporadic carcinoma. 
Direct carcinogens act via expression 
of viral oncoproteins 
HTLV-1 Adult T-cell leukemia 
Direct carcinogens act via expression 
of viral 
oncoproteins 
2.4.1 Epstein-Barr virus (EBV)  




in human populations [89]. Figure 2.4 illustrates the structure of EBV. EBV is a 
double-stranded DNA virus with enveloped structure. It is composed of envelop protein, 
envelope layer, viral tegument nucleocapsid layer and viral genome and the size of EBV 
is about 122–180 nm in diameter [90]. EBV is associated with Burkitt lymphoma [91]. 
Infection by EBV is often asymptomatic, however, EBV infection can turn pathologies 
from infectious mononucleosis (IM) to severe cancers. It is found that a preventive 
vaccine against EBV is able to prevent IM, and thus, potentially decrease risk of cancers 
[92]. In addition to IM, researchers have found that EBV is involved in the development 
of several autoimmune diseases such as multiple sclerosis [93]. The main infection 
pathway for EBV is saliva. EBV virions mainly target epithelial cells and B cells after 
entering the hosts [94]. Preventive and therapeutic vaccines against EBV are needed to 
prevent the EBV infection and controlling EBV-associated diseases such as cancers. 
 
Figure 2.4 TEM image and schematic representations of EBV [95] 
It is reported that Burkitt's lymphoma, Hodgkin lymphoma, B cell lymphoma, 
nasopharyngeal carcinoma, gastric and sporadic carcinoma are related to the infection 
of EBV [96, 97]. EBV-VLP composed of capsid protein of EBV is a promising 




remove all potential viral oncogenes while maintain the sequence for the assembly of 
viral capsid to form the EBV VLP. The engineered EBV VLP protein was expressed 
using 293-VII+ cell lines. Produced EBV-VLPs can both induce both humoral and 
cellular immune response [98]. EBV-specific CD8+ T cells activation was detected in 
the mice immunized with EBV VLPs. Recently, one novel chimeric Newcastle disease 
virus (NDV) VLPs were constructed to present the heterologous antigenic glycoprotein 
gp350/220 from EBV (EBVgp350/220 VLP) [99]. The constructed vaccine was 
examined in vivo, and the results indicated that the mice immunized with 
EBVgp350/220 VLP induced epitope specific immune response and the antibody 
produced in mice was able to neutralize the EBV in vitro. In addition, the antibody type 
from the immunized mice was predominantly IgG1 subclass, which indicates that the 
EBVgp350/220 VLP is a potentially promising preventive vaccine and has the tendency 
to elicit T helper type 2 (Th2) cell’s humoral immune response [99]. Another antigen 
for EBV, EBNA1 was considered to be the primary antigen of the EBV-specific T-cell 
response [100, 101]. One antigen-antibody complex was constructed by chemically 
conjugating EBNA1 with aDEC-205 dendritic cells (aDEC-205/EBNA1). EBNA1-
specific CD4+ and CD8+ T cells were detected in EBV positive patients. Also, 
humanized mice injected with aDEC-205/EBNA1 complex successfully developed 
EBNA1-specific IgM and T-cell responses [102]. These findings suggest that 
glycoprotein gp350/220 and EBNA1 could be used as the potential target epitopes for 




vaccines still need to be proved and then improved. In addition, there is no licensed 
EBV vaccine available yet. 
2.4.2 Hepatitis C virus (HCV) 
It is reported that approximately 170 million people have been infected with HCV 
globally. Normally the early stage of the HCV infection has no obvious symptom, 
however, it often leads to liver disease after long term infection [103]. Around 60-80 % 
of the people develop a long-term liver disease. 11% of these patients have the risk to 
deteriorate to liver cancers [104-106]. In addition, the reinfection of HCV is another 
major challenge for long-term protection [107]. The transit pathway for HCV is mainly 
by blood transmission [108]. Figure 2.5 illustrated the structure of HCV. HCV is a 
small enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae 
with the size of 55–65 nm in size [109]. It is composed of E1 and E2 glycoproteins, 
lipid envelope layer, capsid layer (core protein), and viral genome [110]. 
 
Figure 2.5 TEM image and schematic representations of HCV [111] 
For the development of vaccines against HCV, HCV-VLPs are reported to be a 




normally constructed using viral glycoproteins E1 and/or E2 (as shown in Figure 2.5). 
Various animal models including mouse and baboon have been tested for the 
immunogenicity efficiency of HCV-VLPs and satisfied results were obtained [112-115]. 
Recently, the protective efficacy of HCV VLPs was evaluated against chimpanzees, the 
only HCV susceptible animal model. E1- and E2-specific humoral and cell-mediated 
immune responses were successfully elicited, and protection ability of the vaccinated 
animals was achieved in the HCV challenge experiment [116]. However, the immune 
response level and long-term protection ability still need to be improved compared with 
other commercial vaccines. In addition, VLPs such as Hepatitis B surface antigen 
(HBsAg) VLP have been developed to present the epitope of hypervariable region 1 
(HVR1) of HCV to form HVR1-HBsAg VLP [117]. In the immunization experiment, 
chimeric HVR1-HBsAg VLP successfully induced HVR1 specific humoral immune 
response in the mice after vaccination. Also, in vitro studies confirmed that after 
vaccination, it showed effective protection against HCV [117]. In the meantime, 
HBsAg specific immune response in mice was also detected. This finding potentially 
explores the development of multivalent hepatitis vaccines. However, long-term 
protection was not conducted in this research. Another epitope, HCV core, is reported 
to be potentially employed for the development of HCV vaccines, since this is the most 
highly conserved region of the translated HCV genome both within, and between, 
different HCV genotypes [118]. Recently, a peptide derived from HCV core region 




60 % patients were detected to have peptide specific CD8+ activity and greater than 30% 
patients had increase in alanine transaminase which proves the improvement of 
vaccination efficacy. With these findings, HCV core epitope and glycoproteins E1 and 
E2 can potentially be applied as the target epitopes in the development of vaccines 
against HCV infection and related diseases. HCV vaccines with effective and long-term 
immune response should be further explored. 
2.5 Chimeric VLP vaccines 
In the development of VLP vaccines for the oncoviruses, researchers found that not all 
viral capsid proteins are suitable to form VLP vaccines. In this case, chimeric VLPs 
have been developed by adding foreign antigens through genetic modification or 
chemical coupling to the selected VLP. Chimeric VLPs can present multiple antigens 
and potentially target to multiple viruses. Several VLPs including HBc, HPV, Porcine 
Circovirus (PCV) and Murine polyomavirus VP1 (MuPyV) have been employed as the 
carrier of different antigens to form the chimeric VLP vaccines. Therefore, rational 
design and production of chimeric VLPs are crucial for future development and 
applications in clinical practice for cancer treatment. Table 2.5 lists some recent 
research in chimeric VLP vaccines development. The VLP carrier, presented antigen, 
host cell, target virus of disease and purification process have been summarized in the 
table and challenges of production of these VLP vaccines are briefly provided. Firstly, 
some chimeric VLP proteins were expressed in inclusion bodies in bacteria expression 




assembly process. For example, low recovery yield of chimeric VLP protein is reported 
[122]. Secondly, to improve the purification efficiency, affinity His-tag was normally 
fused to the chimeric VLP proteins. However, His-tag need to be removed when 
preparing the chimeric VLPs as vaccine candidates in clinical trial due to its possibility 
to impact on the vaccine immunogenicity [123]. Further tag-free purification process 
must be developed. The molecular complexity of chimeric VLPs and the maintenance 
of the structure of chimeric VLPs during purification process are the main challenges. 
Different purification strategies need to be designed regarding different chimeric VLP 
proteins. Finally, when applying genetic fusion strategy for insertion of foreign epitopes, 
insertion position needs to be considered according to different VLP carriers. Ideally, 
the inserted antigens are preferred to be exposed on the surface of chimeric VLPs to 
maximize their immunogenic potential. A buried antigen could influence the 
immunogenicity performance [124]. Details of production process of chimeric VLP 




Table 2.5 Recent productions of chimeric VLP-based vaccines. 
VLP Carried antigen Host cell Target virus or 
disease 
Purification process Challenges in production Year Ref. 
Truncated HBc NadA (MIR) 
FHbp (C-terminal) 
BL21 ClearColi 





1. Yield of chimeric VLP was around 8mg per litre 
of cultured cells. 
2. Melting point (Tm) of chimeric VLPs reduced due 
to the insertion of foreign antigen. 
3. Foreign antigens had to be inserted in specific 
position to avoid compromising VLP expression and 
assembly. 
4. Fusion tag was used. 
2020 [122] 
Truncated HBc CD8+ cell epitope 
(HF10 or ROP7) and 
a B cell epitope 
(SAG182−102 or 
SAG1301−320) of T. 
gondii (MIR) 




Inclusion body renaturation and 
Ni2
+ iminodiacetic acid (IDA) 
affinity chromatography 
1. Target chimeric VLP proteins were expressed in 
the inclusion bodies in E. coli. 
2. Fusion tag was used. 
2019 [121] 
Truncated HBc B cell epitopes on the 
VP1 of FMDV and a 
T cell epitope on non-
structural protein 3A 
（MIR） 
BL21 E. coli 
(DE3) (bacteria) 
Type A and O 
foot‐and‐mouth 
disease virus 
Inclusion body renaturation, Ni 
SepharoseTM chromatography 
and in vitro assembly of VLPs 
1. Chimeric VLP proteins were expressed in the 
inclusion bodies in E. coli. 
2. Affinity tag was used. 
2019 [120] 




Polyethylene glycol (PEG) 
precipitation and sucrose gradient 






ultracentrifugation 2. Low temperature induction was applied for 
soluble expression of recombinant chimeric VLP 
proteins. 




DEAE-Sepharose fast flow ion 
exchange chromatography and 
cesium chloride (CsCl) cushion 
and gradient centrifugation 
N/A 2018 [126] 
Truncated HBc Influenza H3N2 virus 




Influenza virus Polyethylene glycol (PEG) 
precipitation, Sepharose 4 FF size 
exclusion chromatography and 
Fractogel EMD TMAE (M) anion 
exchange chromatography 
1. Aggregation of chimeric VLP proteins in PEG 
precipitation was found and they used urea to avoid 
the aggregations. 
2. Hetero-tandem core technique was applied to 
avoid the insoluble expression of chimeric HBc VLP 
proteins. 
2017 [127] 
Truncated HBc  EV71-VP1, EV71-
VP2, and VZV-gE 
(MIR) 








precipitation, TSK-GEL SW3000 
gel filtration chromatography and 
DEAE-5PW anion exchange 
chromatography 
1. Some impurity proteins from host cells remain 
after purification process. 
2017 [128] 
Full length HBc SP55 or SP70 
peptides from EV71 
(MIR) 




Inclusion body renaturation and 
Ni-NTA His-Bind affinity 
chromatography 
1. Recombinant proteins were highly expressed as 
inclusion bodies. 




Truncated HBc pre-S1 (MIR) 
HCV core (C-





precipitation, Sepharose CL-4B 
1. The expression level of chimeric proteins was 





terminal) and hepatitis C 
virus (HCV) 





hepatitis B virus “a” 
determinant (aD) (C-
terminal) 
Sf9 (insect cell) Hepatitis B 
virus 
His-Trap HP affinity 
chromatography 
1. The sizes of expressed VLPs are not uniformed 
and are not the same compared with the one 
expressed in E. coli. 
2. Affinity tag was used. 
2020 [129] 







Cesium chloride (CsCl) 
ultracentrifugation 
1. Secondary structure of 31RG-1 peptide in the DE 
loop was different from that in the h4 coil regions of 
HPV16 VLPs. 
2018 [130] 
HPV16 L1 VLP β-amyloid 11–28 






HiTrap Capto S ImpAct ion 
exchange chromatography and 
Superdex 75 size exclusion 
chromatography 
1. Conformation of chimeric VLP is not clear. 
2. Expression level is low. 
2018 [131] 
Porcine Circovirus 
Type 2 VLP 
Middle portion of 
Loop CD (MP-Lcd) 





HisTrapTM HP chromatography 1. Substitution of MP-Lcd with a foreign peptide 
caused surface pattern changes around two-fold axes 
of PCV2 VLPs based on 3D structure simulation. 




capsid protein of 







Affinity chromatography 1. Large aggregation formed in the isolation process. 






2.6 Computational protein modelling for study of novel 
chimeric VLPs 
The design and production of novel chimeric VLP-based vaccines are normally 
believed to be complicated due to the consumption of time and money [134]. In addition, 
the structure stability and interaction between the subunits of chimeric VLPs play a 
crucial rule in the development of successful chimeric VLP-based vaccines [12]. To 
reduce the time consumption and improve the efficiency in vaccine development 
process, computational protein modelling was applied to improve the VLP sequence 
design and understand the process of assembly of chimeric VLPs. As shown in Figure 
2.6, the process of computational protein modelling includes 1) VLP structure 
construction using structure determination methods such as X-ray crystallography, cryo 
electron microscopy (cryoEM) and Nuclear Magnetic Resonance (NMR), 2) novel 
structure construction model using computational tools such as bioinformatics, 
homology modelling and fold recognition, 3) study of the interaction between subunits 
of novel VLP proteins using computational tools such as docking and molecular 
dynamic (MD) simulation, and 4) comparison of the results obtained from 
computational protein modelling with the results achieved in experiments. As reported, 
computational protein modelling has been extensively applied to biological research 
and drug discovery [135, 136], however, their application in VLP-based vaccines is still 





Figure 2.6 Application of computational tools for modular VLP design. [12] 
2.6.1 Structure determination of chimeric VLP 
To perform the computational protein modelling for the guidance of design and stability 




VLP proteins [137]. Several structure determination methods including X-ray 
crystallography, cryoEM and NMR could be applied to form the structure files of target 
VLP samples for computational modelling. For example, truncated HBc VLP structure 
was determined using X-ray crystallography to 3.3Å resolution in 1999 [138]. The 
structure of full length of HBc VLP was determined using cryoEM to 3.5Å resolution 
[139]. In addition, other VLPs such as Coxsackievirus A6 (CVA6) VLPs [140] and 
porcine circovirus type 2 (PCV2) VLPs [141] were determined using cryoEM and HPV 
VLPs [142] were determined by X-ray crystallography. These determined VLP protein 
structures can be download from RCSB Protein Data Bank website. Figure 2.7 
illustrates the 3D structure of monomer of HBc and assembled HBc VLP (PDB ID: 
3J2V). These VLP structures are the basis for the construction of chimeric VLPs by 
addition of foreign antigen structures. However, when adding foreign antigens to the 
determined VLP structures, the chimeric VLP structure could be different from the real 
structure and got incorrect results in the simulation later. 
 




2.6.2 Molecular dynamic (MD) simulation for the interaction between 
subunits of chimeric VLPs 
After getting the structure file of chimeric VLP protein, further MD simulation is 
needed to analyse the design of the VLPs [143]. Molecular simulation technique was 
developed following the rapid evolution of modern computer science [144]. To date, it 
has become a flexible tool to deliver clear microscopic bioinformation which was 
applied in the study of protein conformation transition to assist the experimental and 
theoretical studies [145]. It is reported that important information related to the 
assembly process of VLPs including nucleus size, average nucleation rate, and average 
free energy of association could be calculated through simulation process now [143]. 
With this calculated information, the process of assembly of VLPs as well as the factors 
that impact on their stability can be understood, which present essential clues to control 
and manage the self-assembly process of VLPs. Theoretical calculation or numerical 
simulation is usually related to mathematical models to explore the macroscopic 
thermodynamic or dynamic parameters for evaluating the self-assembly process. 
Thermodynamic of VLPs during the assembly process have been investigated using 
molecular simulation technique. A minimal model was employed to investigate the 
thermodynamic information of VLPs [146]. The energy change during the assembly 
process of VLPs was successfully simulated using ‘the piece model’ consisting of 
pentagonal and hexagonal pyramids [147]. In addition to the energy, the molecular 
interactions during the assembly progress were also revealed in the repulsive sites in 




parameters were evaluated using MD simulation. However, in the process of the 
simulation, whole VLP model is thought to be too large. The simulation was then 
successfully proceeded with a reduced model consisting of simplified trapezoidal 
capsomere structure of chimeric VLP and this structure was examined by MD 
simulation [148, 149]. Another similar model was composed of triangle pieces from 
VLPs was constructed and the kinetic trapping effects in self-assembly processes was 
successfully calculated [150]. However, it is still tough to reveal and control the self-
assembly process of VLPs using computational approach. Several issues such as the 
computational accuracy, the impact of the actual environment and large calculation due 
to the massive atom numbers of VLPs are remained [143, 151]. Improvement and 
development of computer hardware as well as the calculation algorithm and processing 
capacity are essential to make the application of computational protein modelling 
possible for the design and understand of VLP-based vaccine in the future. However, 
with current hardware and calculation algorithm, the interaction and assembly process 





2.7 Production and challenges of chimeric VLP vaccines 
 
Figure 2.8 Production process of chimeric VLP vaccine 
In general, as shown in Figure 2.8, a successful production process of chimeric VLP 
vaccine includes: 1) construction of recombinant VLP sequence with gene engineering 
techniques, 2) transfection or transduction to the selected host cell, 3) expression in the 
selected host cells, 4) purification and assembly of expressed capsomeres of chimeric 
VLP and 5) polishing and formulation of assembled chimeric VLP to form the final 
vaccine product [12]. 
Chimeric VLPs are constructed by inserting foreign epitopes to well-studied VLPs that 
have been developed. Figure 2.9 illustrates the process of production for different types 
of chimeric VLPs including non-enveloped and enveloped VLPs. In Figure 2.9a, 
construction of non-enveloped chimeric VLPs by genetic fusion is displayed. Briefly, 
target antigen sequence was genetically fused with VLP sequence and expressed in the 
host cells such as mammalian cells, insect cells, yeasts, bacteria. In Figure 2.9b, non-
enveloped chimeric VLPs were produced via chemical conjugation. Non-enveloped 




using various approaches such as disulphide bond formation, covalent conjugation and 
chemical cross-linking [152-154]. In Figure 2.9c, more complicated enveloped 
chimeric VLPs were produced via the protein transfer approach. Enveloped VLPs were 
expressed by host cells, and then mixed with the glycosylphosphatidylinositol (GPI)-
anchored proteins. Then, target antigens were added to the lipid bilayer of the VLPs to 
form the chimeric enveloped VLPs [7]. The licensed HBV and HPV VLP-based 
vaccines are all non-enveloped vaccines [10], while enveloped VLPs have been applied 
in study for Influenza vaccines [155, 156]. Compared with traditional egg-based 
production process of inactivated flu vaccine, production process of chimeric VLP 
vaccine is safer and with rapid production time. However, even though chimeric VLP 
vaccines were successfully produced, there are still a lot of challenges in the production 
of chimeric VLPs such as 1) soluble expression of VLP samples to avoid complicated 
renaturation process, 2) conformation and structure stability of diversity of chimeric 





Figure 2.9 Methods to produce different types of chimeric VLPs. [7] 
2.7.1 Design and construction of recombinant sequence 
The first step to produce chimeric VLP vaccines is to construct the recombinant DNA 




VLP conformation and specific immunogenicity [53]. To maximize the immunogenic 
potential of chimeric VLP vaccines, target antigens are desired to be presented on the 
surface of chimeric VLPs. Genetic fusion and chemical conjugation of target antigens 
are two popular approaches to engineer VLPs for the antigen presentation [157]. To 
perform the genetic fusion, foreign antigens are fused to the insertion positions or 
conjugation sites within the selected viral structural protein. These insertion positions 
or sites need to be able to present the foreign antigens on the surface of VLP. However, 
genetic fusion can affect the ability of chimeric proteins to assemble into VLPs [158, 
159]. In this case, the selection of insertion position in VLP proteins needs extra 
attention. In addition, the stability of VLPs after insertion of foreign epitopes is another 
concern in the design and construction [160]. To avoid these issues, foreign antigens 
can be conjugated to the selected VLP candidate through various conjugation 
techniques. Amino groups that are exposed on the surface can be suitable targets for 
the conjugation, or VLPs can be engineered to obtain some functional groups on the 
surface by post-production modifications.  
2.7.2 Transfection and transduction 
Before the host cells could express the target VLP proteins, plasmid containing antigen 
and VLP coding sequence needs to be transferred to the host cells. For different host 
cells, different approaches have been developed. Heat shock and electroporation are 
two popular methods to transduce the plasmid to bacteria host cells [161]. Virus 
infection method are often used to deliver the plasmid to insect and mammalian cells 




to the host cell is essential for the whole production. Standard procedures for heat shock 
and electroporation have been made and optimized for decades. 
2.7.3 Expression of chimeric VLPs 
Table 2.6 Statistics percentage for different expression system employed in VLP production 
[163] 
Expression system Percentage (%) 
Bacteria 28 
Yeast 20 
Insect cells 28 






Table 2.7 Comparison of different host cells for expression of chimeric VLPs [164]. 
Host cells Advantages Disadvantages 
E. coli • Ease of expression 
• Ability to scale-up 
• Low production cost 
• Does not allow for glycosylation. 
• Endotoxins 
• Inclusion body 
Yeast • Ease of expression 
• Ability to scale-up 
• Low production cost 
• Non-appropriate protein glycosylation (i.e., high 
mannose glycoprotein modification). 
• Risk of incorrect folding & assembly. 
Baculovirus/insect 
cell (B/IC) 
• Can produce large amounts of correctly folded VLP in high 
density cell culture conditions 
• Ability to scale-up 
• The risk of culturing opportunistic pathogens is minimized 
compared to mammalian cell culture 
• Host-derived insect cell/baculovirus components may act 
as vaccine adjuvants, help trigger a more effective immune 
response 
• Limited to high mannose glycoprotein modification. 
• Baculovirus contaminants may be difficult to 
remove 
• Host-derived insect cell/baculovirus components 
may also mask the immune response against the 
desired epitope 
Mammalian cells • Producer cells more closely related to the natural host 
• Appropriate post-translational modification (PTMs) and 
authentic assembly of VLPs 
• Higher production cost 
• Lower productivities 
Plants • Ease of expression 
• Ability to scale-up 
• No human-derived virus contamination 
• Cannot undergo PTMs and VLP assembly 
• Low expression levels 




VLP-based vaccines can be expressed both by prokaryotic and eukaryotic systems 
including bacteria, yeasts, insect cells, mammalian cells and plants. The percentage of 
the application of different expression system is revealed in Table 2.6 [163]. Bacteria, 
yeasts and insect cells are three major host cells used for the production of chimeric 
VLPs. The commercial HPV vaccines based on L1 capsid protein are produced by 
eukaryotic systems such as yeasts (Gardasil) and insect cells (Cervarix) [165]. The 
commercial Hepatitis Β vaccines, Recombivax and Engerix-Β, are also produced in 
yeast, and are composed of HΒsAg [166]. Different expression systems possess their 
own advantages and disadvantages. For the expression for VLPs, the structural 
complexity and immunogenicity of the desired VLPs are key determinants for the 
choice of expression system for VLP production. Table 2.7 demonstrates the 
advantages and disadvantages of different expression host cells, and the details are in 
following sections. 
2.7.3.1 Bacteria  
Bacteria is regarded as a popular prokaryotic system to express non-enveloped chimeric 
VLPs composed of one or two capsid proteins. The advantages of bacteria expression 
system are 1) high yield of target proteins, 2) ability to be scaled up and 3) low cost. 
For example, Lactobacillus casei has been successfully applied in the production of 
HPV Type 16 L1 VLPs. The presentation of the antigen in the produced VLP protein 
was detected using immunofluorescence [167]. Escherichia coli (E. coli) was another 
popular type of the bacteria used for the expression of VLPs. It has been successfully 




[168], recombinant HBc VLP [78, 125, 128], and recombinant HPV VLP [169, 170]. 
However, lack of post-translational modification (PTM) and the endotoxins from host 
cells potentially influence the immunogenicity performance of produced VLP vaccines 
[171]. In addition, some chimeric VLP proteins are reported to be expressed in the 
inclusion bodies (inactive proteins aggregates) by E. coli expression system [78, 172, 
173]. It is more complicated for the downstream processing to deal with inclusion 
bodies as VLP proteins need to be refolded to the correct conformation and assemble 
to VLP structure in vitro. In this case, efforts are made to express the VLP proteins in 
the soluble form. Some fermentation conditions have been investigated to improve the 
expression of soluble VLPs. For example, low temperature fermentation has been 
employed in the production of infectious hypodermal and hematopoietic necrosis virus 
(IHHNV) [174] and potyvirus, Potato virus Y (PVY) [175]. In addition, the 
concentration of inducer [176], composition of culture medium [177] and fusion of tag 
like small ubiquitin-like modifier (SUMO) [178, 179] have been explored to improve 
the expression of soluble VLPs. Bacteria expression system is recognized as a 
promising expression system for the production chimeric VLP vaccines. However, 
optimization of the fermentation conditions to express the chimeric VLP proteins as 
soluble VLP proteins are essential. 
2.7.3.2 Yeast 
As described above, two of the commercial VLP vaccines are produced using 
eukaryotic system such as yeast. Similar to bacteria expression system, yeast expression 




addition, yeast can also perform post-translational modifications which makes it 
capable to produce more complicated molecules. For example, P. pastoris strain was 
reported to produce the Chikungunya VLPs and the produced VLP vaccine had good 
murine immunisation performance [180]. RNA bacteriophage VLPs were also reported 
to be successfully expressed in Pichia pastoris. However, the expression level was only 
30% compared with the bacteriophage VLPs expressed in bacteria expression system 
[181]. Besides, when applying yeast expression system for enveloped VLP production, 
Morikawa et al. (2007) reported that yeast expression system missed some necessary 
host factors such as endosomal sorting molecules TSG101, Nedd4, AIP-1/ 
ALIX, and AP-3 to support the formation of enveloped VLPs [182]. Moreover, VLP 
proteins expressed by yeast expression system do not always present as assembled VLP 
structure in the cultivation. Lünsdorf et al. (2011) indicated that HBsAg expressed by 
Pichia pastoris cannot form assembled VLP in vivo, and the in vitro assembly was 
conducted during the purification downstream process [183]. It brings extra steps in 
downstream process. 
2.7.3.3 Baculovirus/insect cell (B/IC) 
B/IC expression system are composed of two steps, infection step and production step. 
The designed plasmid is transduced to the Baculovirus in the first step and then selected 
insect cells are infected by Baculovirus for the production of chimeric VLPs. The 
advantages of B/IC expression system are 1) rapid growth rate in animal product-free 
media, 2) ability for large-scale production, and 3) good ability of post-translationally 




produce more complicated or enveloped chimeric VLP compared with bacteria and 
yeast expression system due to its ability of better post-translationally modification 
[171]. Sf9 (Spodoptera frugiperda) and High Five cells (Trichoplusia ni) are two 
popular insect cells that are applied in the production of VLP proteins. Chikungunya, 
HIV or porcine parvovirus VLPs have been successfully expressed in B/IC expression 
system. The major challenge for B/IC expression system is the baculoviruses are 
produced with the production of VLP proteins. It increases the cost and hardness to 
separate baculovirus from VLP mixture. Replacing baculovirus with other transfection 
reagent can be one option to overcome this challenge. Shen et al. (2014) reported that 
they successfully used polyethyleneimine (PEI) to replace the baculovirus as the 
transfection reagent to transfer a plasmid carrying the homologous region 5 enhancer 
(hr5) and the immediate early 1 (ie1) promoter from Autographa californica 
multicapsid nucleopolyhedrovirus (AcMNPV) to Sf9 cells for the production of tumour 
necrosis factor receptor (ectodomain) fused to an Fc domain (TNFR-Fc) [185]. This 
can potentially solve the issue of baculovirus impurities in the purification. 
2.7.3.4 Mammalian cells 
It has been demonstrated that the production level of VLP proteins of mammalian cell 
expression system is lower compared with other expression systems. However, 
mammalian cells have more advantages to produce complex and accurate post-
translational modification of VLP proteins [186]. In this case, researchers employed 
mammalian cell expression system to produce complicated enveloped VLPs with 




Embryonic Kidney 293 (HEK293) cell lines [188] are two popular mammalian cell 
expression systems. CHO cell line, as it is not human derived cell line, has a lower risk 
of contamination by human virus compared with HEK293 cell line [189]. Li et al. (2010) 
successfully produced Hantaan VLP (HTN-VLPs) using CHO cells and obtained 
specific immune response in mice [190]. The HEK293 cell line are reported to 
successfully produce VLPs against rabies [191], HIV [192], and influenza [193]. 
However, the growth rate and expression level of mammalian cells are lower compared 
with other expression systems such as bacteria and yeast, which makes it not suitable 
for the production in large-scale. 
2.7.3.5 Plants 
Only 9 % of the VLPs are produced in plant system. Agrobacterium tumefaciens is one 
of bacteria used for infection and transformation of the plant cells [194]. These bacteria 
are used to introduce the designed gene of VLP protein to the host genome of plant 
cells. For example, HPV type 16 or influenza are reported to be produced using plant 
expression system. Several VLP proteins have been expressed using plants, such as 
HPV VLPs and influenza VLPs [195, 196]. Nicotiana tabacum and Arabidopsis 
thaliana [197] are two popular plant expression systems. However, due to the 
disadvantages including failure of VLP assembly after expression, low expression 
levels and antigen degradation, plant expression system is not the first option to produce 
new chimeric VLP [164]. 
2.7.4 Purification and characterization of chimeric VLPs 




need to be purified for the immunogenicity application. Downstream purification 
process is essential for the quality of chimeric VLP vaccines as impure samples can 
cause severe side effects and safety concerns. Purified chimeric VLP vaccines need to 
meet the requirements including 1) absence of contaminant proteins and DNA (host or 
viral), 2) absence of incorrectly assembled macrostructures and 3) endotoxin levels 
below those specified by regulatory agencies (Food and Drug Administration (FDA) 
and European Medicines Agency (EMEA). However, in the process of purification, 
similar protein features of impure host cell proteins to target VLP proteins such as size 
and molecular weight make the process challenging. Purification approaches are 
designed according to the nature of chimeric VLP proteins such as surface charge, 
thermostability and tolerance of ion strength and unique characteristics that strongly 
impact the design of the downstream strategy [198-201]. 
The stability and the risk of structure mutation of chimeric VLPs during the purification 
process also need to be taken into consideration [163, 164, 202]. In addition, chimeric 
VLP proteins produced by different expression systems would contain different 
impurities and the strategies for the purification vary accordingly. For small scale 
purification approach, researchers applied ultracentrifugation by sucrose or cesium 
chloride gradients to obtain small amount of VLP proteins including HBc derived VLPs 
[126, 203], dengue virus (DENV) VLP [204] and norovirus VLP [205]. Even though 
the purity of VLP proteins after ultracentrifugation is high, the yield is low compared 
with other purification process. In addition, the scale-up of ultracentrifugation is 




its high specificity. To perform affinity chromatography, an affinity tag needs to be 
fused to the VLP sequence [206, 207]. However, reports indicate that these fusion tags 
can potentially affect virion maturation and protein expression, indirectly [208, 209]. 
The purification process can vary according to the design of different chimeric VLPs 
as the impact of the insertion of foreign antigens to VLP carrier is different. The main 
challenge for the purification of chimeric VLP is to maintain its stable VLP structure 
and avoid the aggregation and disassembly as chimeric VLPs are macromolecules and 
their structure is essential for their immunogenicity. Different approaches need to be 
tested to find the optimal purification strategy for new chimeric VLP vaccines. To 
improve the yield and maintain the purity of VLP proteins, techniques including salting-
out, tangential flow filtration, gel permeation chromatography, liquid chromatography, 
ion exchange chromatography, affinity chromatography, size-exclusion 
chromatography and disposable membrane technology were developed for the 
purification of chimeric VLP proteins [210-215].  
2.7.5 Polishing and formulation 
The final step to produce chimeric VLP vaccines is polishing and formulation. Before 
injecting chimeric VLP proteins, polishing usually includes 1) removal of final 
impurities using size-exclusion chromatography, 2) addition of active compounds and 
3) exchanging buffer to the final formulation buffer [216]. In the application of vaccines, 
the addition of adjuvant is regarded as a popular approach to improve the 
immunogenicity of vaccine candidates [217]. However, one commonly used adjuvant, 




neurotoxicity [218]. How to safely apply different adjuvants in the formulation of 
vaccines could be a complicated process. Researchers have found that VLPs obtain the 
self-adjuvant property as it was assembled by the viral capsid proteins and therefore 
can induce strong immune response. For example, VLPs with the pathogen associated 
molecular pattern (PAMP) of viruses can be recognized by Toll like receptors on the 
surface of cells to induce strong immune response [219, 220]. This self-adjuvant 
property of chimeric VLPs enables it to be formulated as vaccines without additional 
adjuvant.  
2.8 Characterisation methods for VLPs 
During a desired purification processing of VLP-based vaccines, impurities were 
removed to a level meeting the regulation while maintaining target VLP proteins. 
However, the structures of VLPs are often important for their biological activities that 
are vulnerable to environmental stresses in downstream processing. Denaturation or 
disassembly of VLPs are frequently observed [221, 222]. Such changes of the structure 
of VLPs not only makes the purification process inefficient but also raise the concerns 
for their further immunogenicity problems. To avoid denaturation and disassembly of 
VLPs during downstream processing, characterization techniques have been developed 
to monitor and evaluate the condition of VLPs. Table 2.8 listed some common 







Table 2.8 Common characterization techniques for VLPs. 
No. Technique Function 
1 
High performance size exclusion 
chromatography (HPSEC)- multi‐angle 
laser light scattering (MALLS) 
Separate proteins and 
measure the molecular 
weight and size 
2 Dynamic Light Scattering (DLS) Measure particle size 
3 Circular dichroism (CD) 
Determine secondary 
structure 
4 Intrinsic fluorescence (IF) 
Determine tertiary 
structure 
5 Differential scanning calorimetry (DSC) Measure thermal stability 
6 Transmission electron microscopy (TEM) Visualize the structure 
7 Differential scanning fluorescence (DSF) Measure thermal stability 
8 Mass spectrometry (MS) 
Identify and quantify 
protein molecules 
9 Nuclear magnetic resonance (NMR) 
Determine the overall 
structure 
10 Isothermal titration calorimetry (ITC) 
Provide a complete 
thermodynamic profile 
2.8.1 High performance size exclusion chromatography (HPSEC)- 
multi‐angle laser light scattering (MALLS) 
HPSEC is a non-destructive approach to separate proteins based on their molecular 
weight. It has been applied in the study of various protein-based biomaterials such as 
antibody and vaccines. For analysis of VLPs, the major challenge is due to the pore size 
and resolution of HPSEC resins. VLPs are normally in large particle size and is difficult 
to discriminate between structural diversities of particles [223]. However, this issue was 




(more than 100nm) are now commercially available such as TSKgel G5000PWxl and 
TSKgel G4000PWxl [224]. HPSEC technique has now been applied in the separation 
of several protein-based molecules such as inactivated foot and mouth disease virus 
(FMDV) vaccine [225]. The intact FMDV, also called as 146S, can be disassembled 
into smaller 12S particle leading to lower immunogenicity issue [226]. Therefore, the 
detection of 146S during the production of FMDV vaccine is essential. HPSEC showed 
significant convenience and short time consumption in the detection compared with 
other methods such as conventional ultracentrifugation and ELISA [227]. Similar 
application of HPSEC can be applied to the production of VLPs. By developing 
appropriate procedure, different status of VLPs such as aggregation, assembly and 
disassembly can be quantitatively measured rapidly [228]. Coupling HPSEC with a 
MALLS detector further expands the application of HPSEC. MALLS detectors 
determine the weight‐average molar mass, average size by detecting the scattered light 
at multiple angles and extrapolating to 0° [229]. Therefore, HPSEC-MALLS can detect 
VLPs and aggregates based on the molecular weight and particle size. 
2.8.2 Dynamic Light Scattering (DLS) 
DLS, also known as photon correlation spectroscopy or quasi-elastic light scattering, is 
able to determine the virus-like particle size quickly and accurately. DLS has emerged 
as the simplest and most executable table-top detection method to perform, because it 
only needs an ordinary lab environment. DLS has developed into popular tools within 
pharmacy community, according to techniques that were exclusively available to 




friendly digital interfaces, which is along with possibility for the comprehensive data 
analysis. Furthermore, these techniques are non-invasive, and require minimal sample 
preparation without pre-experimental calibration. Creative Biostructure has equipped 
the modern DLS instruments which can not only guide our experienced scientists on 
the quality of the generated data with possibility for time-dependent measurements but 
also export the data traces as files compatible with various plotting software to provide 
you the best research figures. 
DLS has a lot of advantages over traditional microscopy such as TEM and AFM 
because DLS offers the hydrodynamic size of virus-like particles in solution. For 
example, TEM images often do not substantiate well with the data obtained from DLS. 
DLS is capable of measuring bigger number of particles (in millions) compared to TEM 
(few hundreds). Thus, DLS provides more robust data on size distribution and PDI. As 
a result, DLS is a promising method to measure the size of VLPs and has the potential 
to be used to process development with upstream and downstream samples. 
2.8.3 Circular dichroism (CD) 
CD is a method based on the differential absorption of left circularly polarized (LCP) 
and right circularly polarized (RCP) light by optically active chiral molecules [230]. 
The difference between the absorbance of LCP and RCP light are recorded and plotted 
against wavelength. CD spectroscopy has a wide range of applications in many different 
fields, particularly for evaluating the structure of biomolecules like proteins and 
polypeptides: CD effects in the far UV ((below 250 nm) range, caused by the protein’s 




characteristic CD bands with positive and/or negative ellipticities at defined 
wavelengths for each secondary structure element. CD effects in the near UV range (~ 
320-250 nm) are due to the presence of aromatic side chains or/and disulphide bridges 
and reflects the protein tertiary structure. Its spectral profile depends on the type and 
number of aromatic amino acids and their environment (e.g., degree of hydrogen 
bonding), therefore it differs substantially between individual proteins, and thus can be 
considered as a fingerprint region of a protein. 
2.8.4 Intrinsic fluorescence (IF) 
Tyrosine (Tyr) and Tryptophan (Trp) residues in proteins have unique intrinsic 
fluorescence. By measuring the intrinsic fluorescence, the tertiary structure of proteins 
can be revealed [231]. It is reported that differences in intrinsic fluorescence were 
associated with the transfer of tryptophan residues from a largely aqueous to a largely 
protein environment [232]. Intrinsic fluorescence has also been applied in the study of 
VLP structures including Norwalk virus [233] and hepatitis B virus [234]. The 
advantage of intrinsic fluorescence is that real time data can be obtained for assembly 
and maturation without chemically modification. However, by only measuring IF, it is 
hard to differentiate between assembly and maturation of VLPs. More techniques such 
as DLS, Western blot and transmission electron microscopy (TEM) are needed. In 
addition, IF is less sensitive to interference by small air bubbles or aggregates that can 
make sensitive for MALLS analysis [231]. 
2.8.5 Differential scanning calorimetry (DSC) 




molecular interactions of proteins directly [235]. Therefore, DSC has been employed 
in the investigation of thermal stability of protein samples. DSC enables to measure the 
temperature of protein unfolding (Tm), the molar enthalpy change (ΔH), the molar 
entropy change (ΔS), and the change in the molar heat capacity (ΔCp) accompanying a 
protein transition. Any change in the conformation of VLP proteins would be revealed 
by the change of position, sharpness, and shape of transitions in DSC scans [213]. 
Thermal stability of VLPs can be associated with the design of the purification process. 
For example, Li et al. developed a purification process of hepatitis B core antigen (HBc) 
VLP by heated VLP samples at 60°C for 30 min after they found that the Tm value of 
HBc VLP is around 96.25°C [236, 237]. Around 85.8% particle recovery and 74.7% 
purity were achieved. 
2.8.6 Transmission electron microscopy (TEM) 
VLPs, EM has been used as a popular technique to evaluate size, polydispersity, purity 
and even nanoparticle composition of proteins [238]. Transmission electron 
microscopy (TEM), scanning electron microscopy (SEM) and cryogenic electron 
microscopy (cryo-TEM) are three major types for EM. Among them, TEM is reported 
to be the best technique for the characterization of VLP structure [239]. VLP samples 
are negatively stained normally using uranyl acetate [240]. Differential electron 
scattering between the biological material and the surrounding staining layer enables 
the visualization of the specimen. TEM gives a direct detection of the structure of VLP 
proteins directly. Aggregation, assembly and disassembly of VLPs can be visually 




buffer condition as well as the selection of electron microscope can influence the quality 
of final TEM image. 
2.8.7 Other characterization techniques 
In addition to the techniques discussed above, Differential scanning fluorescence (DSF), 
Mass spectrometry (MS), Nuclear magnetic resonance (NMR), Isothermal titration 
calorimetry (ITC) have contributed to our understanding of the structure of VLPs. 
Besides various physicochemical techniques, immunochemical methods including 
ELISA, biosensor analysis and non-labelled immunoassays are also important for 
characterization of VLPs. These methods are valuable since the integrity of structures 
is often important for in vivo bio‐activities [241]. 
2.9 Summary 
Immunotherapy is a promising technology to treat cancers caused by viruses in the 
modern society. Cancer vaccines are regarded as an approach for cancer treatment with 
lower side effects compared with traditional cancer treatments. In the development of 
preventive cancer vaccines, oncoviruses that are related to various cancers globally 
have been targeted to produce cancer vaccines. Different types of vaccines including 
traditional and advanced vaccine candidates have been developed. Among these 
candidates, VLPs, is reported to be one of the most effective and safest candidates for 
the development of cancer vaccine platform. To apply VLP platform to the treatment 
of different oncoviruses, recombinant technique has been employed to construct 
chimeric VLP vaccines by fusing foreign antigens to the selected VLP carriers. In 




vaccines for the treatment of oncoviruses leading to cancers includes: 1) design of the 
sequence of chimeric VLP to expose the antigen on the surface, 2) efficient expression 
and purification of chimeric VLP proteins using suitable expression system and 
purification approach, 3) acknowledgment of the factors and mechanisms that influence 
on the stability and assembly of chimeric VLP proteins and 4) strong antigen specific 
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Chapter 3 Optimization of expression and 
purification of chimeric Hepatitis B core 
(HBc) VLPs 
Abstract 
Chimeric virus-like particle (VLP)-based vaccines were developed for the treatment of 
oncoviruses. In this chapter, two epitopes, Hepatitis C virus core (HCV core) and 
Epstein-Barr nuclear antigen 1 (EBNA1), targeting Hepatitis C virus (HCV) and 
Epstein–Barr Virus (EBV), were respectively fused into or Hepatitis B core (HBc) VLP 
protein at the N-terminus. The designed chimeric EBNA1-HBc VLP and HCV core-
HBc proteins were expressed using Escherichia coli (E. coli) expression system. The 
expression conditions including cell density of E. coli for induction, expression 
temperature and concentration of inducer for HCV core-HBc VLP and EBNA1-HBc 
VLP were optimised to improve the yields of soluble expression and reduce the 
formation of inclusion body. The soluble expressed chimeric VLP proteins were 
precipitated using Ammonium Sulphate (AS) and acid precipitation to be separated 
from the majority of protein impurities. Different concentrations of AS and different 
pH values were used to find the optimal condition for the precipitation process. It was 
found that HCV core-HBc proteins were not stable after treating with acid and they 
were sensitive to the ion strength in the precipitation process. The yield after 




removing impure proteins. Results indicate that 0.1 M AS was the optimal 
concentration for HCV core-HBc VLP precipitation and 1 M AS was optimal 
concentration for EBNA1-HBc VLP precipitation. Both HCV core-HBc VLP and 
EBNA1-HBc VLP achieved high production yields after optimization with 40.4 mg/g 
of wet cell weight for HCV core-HBc and 62.1 mg/g of wet cell weight for EBNA1-
HBc. In addition, HCV core-HBc was chosen for the study of removal of nucleic acid 
impurities forming chimeric HBc VLP proteins. Results demonstrate that the nucleic 
acid impurities of HCV core-HBc VLP could be successfully removed using Poros HQ 
chromatography with flowthrough strategy. However, after the removal of nucleic acid 
impurities, HCV core-HBc VLP was found to be unstable in the storage condition. The 
study on structure and stability of chimeric HBc VLP proteins is necessary and is 





Chimeric virus-like particle (VLP) based vaccine is a novel technology that generates 
vaccine candidates against oncoviruses which potentially lead to cancers[1]. To expand 
the application of VLP-based vaccines, chimeric VLPs, which were constructed by 
fusing foreign epitopes or antigens to well-studied VLPs, have been developed for the 
treatment of several viral infection diseases such as influenza[2, 3] and cancers[4-6]. 
Hepatitis B core (HBc) VLP is reported to be one of the most powerful VLP candidates 
to 1) display foreign epitopes for specific immunogenicity[7, 8], 2) expose cell-
targeting signals[9, 10] and 3) package poly- and oligonucleotides[11]. Comparing with 
chemical coupling, antigens added through genetic modification is more controllable 
on, particularly, the antigen density and the insertion position. These modifications 
significantly influence the immunogenicity of chimeric VLPs. However, challenges of 
removal of host cell proteins (HCPs) and host cell DNA remain for the fused VLP 
proteins in their purification process. Therefore, rapid, efficient and cost-effective 
production process of chimeric HBc VLPs is needed for large scale production and 
future commercialization. 
Previous works have proven that HBc VLP is able to display various foreign epitopes 
including HCC epitopes: MAGE-1, MAGE-3, AFP1 and AFP2[12], B cell epitopes of 
foot-and-mouth disease virus (FMDV)[13] and SP55 and SP70 epitope from EV71[14]. 
However, challenges remained, such as performing effective expression of chimeric 




purification. In addition, easily formation of mis-folding and aggregation was found 
after insertion of epitope to HBc VLP[15, 16]. These challenges can lead to failure to 
induce epitope specific immune response[17]. 
Different eukaryotic and prokaryotic expression systems were employed to produce 
chimeric VLP vaccines. Eukaryotic expression systems such as insect cells and 
mammalian cells obtain better post-translation modification systems and can be 
employed to express some structurally complicated and enveloped VLPs[18]. However, 
eukaryotic expression system is often regarded as high cost production because it 
requires long culture period and the expensive media[19]. In addition, reports also 
indicate that the glycosylation in eukaryotic expression system may cause improper 
modification of epitopes on the expressed proteins[20]. Prokaryotic expression system 
such as bacteria expression system, on the other hand, is regarded as low-cost approach 
with high expression yield in the production of recombinant proteins. In the production 
of VLPs, due to the lack of post-translation modification, bacteria expression system is 
commonly employed for the expression of non-enveloped and structurally simple VLPs 
such as HBc VLPs[21, 22]. The production yield of VLPs in bacteria expression system 
is higher and production time of bacteria expression system is less compared with 
eukaryotic expression system[23]. However, reports have indicated that VLPs 
expressed by bacteria expression system may be expressed as insoluble form such as 
inclusion bodies. This increases the difficulty in the downstream purification as the 




VLP proteins in bacteria expression system, several approaches have been adopted 
including 1) control of expression conditions during the expression including 
temperature, inducer concentration and density of bacteria for expression[25], 2) 
selection of an appropriate expression plasmid with a suitable resistance marker[26], 3) 
fusion of a tagged protein such as glutathione-S-transferase (GST)[27] and small 
ubiquitin-like modifier protein (SUMO)[28]. 
To match the regulation for commercial VLP vaccines, effective downstream 
purification process is needed to remove the impurities including proteins and nucleic 
acids from host cells. Different from other recombinant proteins, purification of VLP 
proteins has the challenges to maintain stable VLP structure which is directly related to 
its immunogenicity after the purification process[29, 30]. Various purification methods 
have been developed according to the property of VLPs. For example, 
ultracentrifugation was applied to obtain pure VLP proteins rapidly. However, the yield 
of this approach is relatively low, and the cost is high. AS precipitation has been 
reported to obtain good purification results in HBc VLP[31] and HPV VLP[32] as it 
has a minor impact on the VLP structure. However, the optimal condition for AS 
precipitation may vary according to different cases to avoid the co-precipitation with 
impure proteins from host cells[33]. Acid precipitation is another promising approach 
to remove impure proteins[34]. It relies on the different stability of target VLP and 
impurities in lower pH values. In addition, chromatography is one popular method for 




that changes in microenvironments due to different buffer condition, the interactions 
between VLPs and resin and harsh operating conditions such as extreme pH and high 
salt concentration can lead to the aggregation or disassembly of target VLPs[37]. In this 
case, different approaches for purification of new chimeric VLP proteins need to be 
examined.  
In our study, two epitopes, two different epitopes, Epstein-Barr nuclear antigens 1 
(EBNA1), and Hepatitis C virus (HCV) core, were selected to fuse to the N-terminus 
of HBc VLP to form chimeric EBNA1-HBc VLP and HCV core-HBc VLP. EBNA1 
and HCV core were reported as two epitopes targeting to Epstein-Barr virus (EBV) and 
Hepatitis C virus (HCV) infection respectively leading to cancers. EBNA1 epitope was 
chosen as the representative of short and non-structural epitope while HCV core was 
chosen as long and structural epitope for the study of impact of insertion of different 
epitopes on the purification of chimeric HBC VLPs. The recombinant HCV core-HBc 
and EBNA1-HBc proteins were expressed in E. coli expression system and the 
optimization of expression was conducted. After expression, different concentrations 
of AS were used to find the optimal one for the purification of HCV core-HBc and 
EBNA1-HBc proteins. Ion exchange chromatography was employed to remove the 




3.2. Materials and methods 
3.2.1 Plasmids construction for recombinant HCV core-HBc and 
EBNA1-HBc 
Figure 3.1 demonstrates the construction of the plasmids of the chimeric VLPs used in 
this study. The hepatitis B core antigen (HBc) gene within pET 21a(+)-HBc (State Key 
Laboratory of Biochemical Engineering of Institute of Process Engineering (IPE) of 
Chinese Academy of Sciences (CAS), China) was digested by XhoI/NdeI and then 
ligated into pET 30a plasmid (IPE of CAS, China) to generate an intermediate plasmid 
pET 30a-HBc. To make the HCV core (aa 10-53: 
KTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTS) fused HBc 
protein, two steps of polymerase chain reactions (PCRs) were performed. Briefly, in 
the first step, two complementary oligonucleotides HCV core-F, 
GGAATTCCATATGAAAACCAAAAGAAACACA and HCV core-R, 
ACCGAACTCTTTGTATGGGTCGATGTCCATAC T were designed and used to 
amplify the HCV core sequence from the template supplied from Beijing Genomics 
Institute, China. Then another two complementary oligonucleotides HBc-F, 
ATGGACATCGACCCATACAAAGAGTTCGGT and HBc-R, CCGCTCGAGTTAA 
CACTGAGATTCACG were applied to amplify the HBc sequence from pET 30a-HBc 
template. In the second step, HCV core-F, GGAATTCCATATGAAAACCAAA 
AGAAACACA and HBc-R, CCGCTCGAGTTAACACTGAGATTCACG were used 




core-HBc gene sequence was then ligated into pET 30a plasmid to yield pET 30a-HCV 
core-HBc plasmid. Plasmid pET 30a- EBNA1 (aa 407-417: HPVGEADYFEY)-HBc 
was supplied by Beijing Genomics Institute, China. The obtained plasmid sequence was 
confirmed by gene sequencing by Beijing Genomics Institute, China. 
 
Figure 3.1 Schematic representation of the expression cassettes of the pET 30a-HBc, pET 30a-
HCV core-HBc and pET 30a-EBNA1-HBc. 
3.2.2 Expression of chimeric VLPs in E. coli expression system 
After confirming the plasmid sequences of chimeric HBc VLPs, the plasmids were 
transferred to E. coli BL21 (DE3) strain (Thermo Fisher Scientific, USA) for the 
expression in Erlenmeyer flask in the shaker. pET 30a-HCV core-HBc and pET 
EBNA1-HBc were transferred to E. coli competent cells and grow on Luria-Bertani 
(LB) agarose plate overnight at 37 °C. Then, a single colony of HCV core-HBc and 
EBNA1 was cultured in 5 ml of LB medium (Thermo Fisher Scientific, USA) 
supplemented with 100 μg/ml kanamycin (Thermo Fisher Scientific, USA) at 37 °C 




in 50 ml LB medium supplemented with 100 μg/ml kanamycin at 37 °C overnight. E. 
coli BL21 cells containing HCV core-HBc and EBNA1-HBc plasmid were stored in 
25 % glycerol at -70 ℃ for future use after preculture. Target HCV core-HBc and 
EBNA1-HBc proteins were expected to be expressed in soluble form. Initially (No. 1 
in Table 3.1), the expression conditions of HCV core-HBc and EBNA1-HBc followed 
the previous work of wt HBc VLP in IPE-CAS[38]. Briefly, the precultured chimeric 
HBc E. coli cells were transferred to 2 L LB medium with 100 μg/ml kanamycin in the 
ratio of 1:1000 and cultured at 37.5 °C for 4 h at 220 rpm. 1 mM of isopropyl b-
thiogalactoside (IPTG) (Thermo Fisher Scientific, USA) was added for the expression 
of HCV core-HBc and EBNA1-HBc proteins. The culture was then incubated for 4 h 
at 37 °C with 180 rpm.  
Then the expression condition was optimized using control variable approach according 
to Table 3.1. Three factors including 1) induction cell density of bacteria, 2) expression 
temperature and 3) the concentration of IPTG were examined orderly, and the better 
condition was applied in the next expression. 
Table 3.1 Optimization of expression conditions of HCV core-HBc including concentration of 
IPTG, expression temperature and cell density of E. coli when adding IPTG. 
No Concentration of IPTG Temperature Cell density (OD600) 
1 1 mM 37 ℃ 1.2 
2 1 mM 37 ℃ 0.8 
3 1 mM 30 ℃ 0.8 




The cells were then harvested by centrifugation at 4,000 rpm for 20 min at 4 °C. The 
pellets were resuspended with 100 ml lysate buffer (20 mM Tris-HCl, 3 mM EDTA, 1 
mM Phenylmethanesulfonylfluoride (PMSF), 0.1 % Triton X100, pH 8.0). Ultrasonic 
homogenizer (Scientz-IID, Ningbo Scientz Bio-Tech Co, Ltd, China) with a 4-s on and 
6-s off pulse was used for the disruption of E. coli cells for 10 min at 360W. The crude 
lysate was then centrifuged at 10,000 rpm for 30 min. The supernatant and pellets after 
centrifugation together with the crude lysate before centrifugation were loaded to 12 % 
reducing Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
as described in section 3.2.6 for evaluation later. The concentrations of protein samples 
were examined using Bradford assay[39]. The supernatant of bacteria lysate of 
EBNA1-HBc and HCV core-HBc was observed using Transmission Electron 
Microscopy (TEM) as described in section 3.2.7 to examine the structure of expressed 
chimeric HBc VLPs. 
3.2.3 AS precipitation of chimeric VLPs 
Ammonium Sulphate (AS) precipitation was applied to purify HCV core-HBc and 
EBNA1-HBc proteins to avoid influences such as the disassembly and damage on their 
VLP structure, and high purity and recovery yield were expected. In the first trial, AS 
precipitation condition for wt HBc VLP in previous work in IPE-CAS[38] was applied 
for purification of HCV core-HBc and EBNA1-HBc proteins. Briefly, 1 M AS was 
added to the crude lysate of HCV core-HBc and EBNA1-HBc samples. Then the 




at room temperature. The pellet was resuspended using 4 M urea buffer (50 mM 
Glycine-NaOH with 4 M urea , pH 9). Resuspended samples were centrifuged at 10,000 
rpm for 30 min. Supernatants and pellets in the precipitation step and resuspension step 
were loaded to 12 % reducing SDS-PAGE as described in section 3.2.6 for examination. 
After reviewing the result of first trial of the AS precipitation of HCV core-HBc and 
EBNA1-HBc proteins, optimization of resuspension buffer and concentration of AS for 
HCV core-HBc was conducted. 
3.2.3.1 Optimization of resuspension buffer for HCV core-HBc 
To optimize the resuspension buffer for HCV core-HBc, two factors including pH value 
of buffer and concentration of urea were evaluated using control variable method. 
Briefly, 4 M urea buffers in different pH values including pH 10, pH 9, pH 8 and pH 7 
were firstly applied to resuspend HCV core-HBc proteins after precipitation with 1 M 
AS. The resuspended samples were then centrifuged at 10,000 rpm for 30 min. 
After choosing the optimal pH value, different concentrations of urea were applied. 4 
M urea buffer, 6 M urea and 8 M urea buffer (50 mM Glycine-NaOH with 6 M urea , 
pH 9 and 50 mM Glycine-NaOH with 8 M urea ) were used to resuspend HCV core-
HBc proteins after 1 M AS precipitation. The resuspended samples were then 
centrifuged at 10,000 rpm for 30 min. The concentrations of supernatants of 
resuspended samples were measured using Bradford assay and recovery yields were 
calculated using equation 3.1 for analysis. In addition, Transmission Electron 




high concentration of urea would impact on the structure of HCV core-HBc. After 
analysis, the optimal resuspension buffer for AS precipitation was employed in the 
following optimization of AS concentration.  
3.2.3.2 Optimization of AS concentration for HCV core-HBc 
To optimize the AS concentration for HCV core-HBc AS precipitation process, 
different concentrations of AS including 1 M, 0.5 M, 0.1 M, 0.05 M and 0.01 M were 
tested. The pellets of each condition were then collected and resuspended using 4 M 
urea buffer (50 mM Glycine-NaOH with 4 M urea , pH 9) which was the optimal 
resuspension buffer in previous test. Resuspended samples were centrifuged at 10,000 
rpm for 30 min. The concentrations of supernatants of resuspended samples were 
measured using Bradford assay and recovery yields were calculated using equation 3.1 
for analysis. Supernatants and pellets in the precipitation step and resuspension step 
were loaded to SDS-PAGE as described in section 3.2.6 for examination. Supernatant 
samples in resuspension step were imaged using TEM as described in section 3.2.7.  
3.2.4 Acid precipitation for chimeric HCV core-HBc 
In the first trial of AS precipitation for HCV core-HBc protein, low recovery yield was 
achieved. In this case, another purification process for tag-free HBc VLP, acid 
precipitation was applied. Briefly, the supernatant of HCV core-HBc crude lysate was 
collected. Then pH value was adjusted using buffers including 100 mM Phosphate 
buffer (PB), pH7.0, pH 6.5 and pH 6.0 and 100 mM Acetic acid/Sodium acetate buffer 




The precipitated samples were then centrifuged at 6000 rpm for 10 min. 4 M urea buffer 
was used to resuspend the pellets. The resuspended sample was then centrifuged at 
10,000 rpm for 30 min. The concentrations of supernatants of resuspended samples 
were measured using Bradford assay and recovery yield was calculated using equation 
3.1 for analysis. The supernatant after acid precipitation and supernatant after 
resuspension were loaded to 12 % reducing SDS-PAGE as described in section 3.2.6 
for evaluation. The resuspension samples precipitated at pH 6.5 and pH 6.0 were 
imaged using TEM as described in section 3.2.7. 
3.2.5 Removal of nucleic acids in chimeric HBc VLPs using 
chromatography 
After optimization of AS and acid precipitation, the impure proteins from host cells 
were removed. However, nucleic acid impurities from host cells still existed. In this 
chapter, ion exchange chromatography was applied to remove these impurities. HCV 
core-HBc proteins was used for the preliminary study of the optimal conditions for 
removal of nucleic acid impurities. 
3.2.5.1 Binding strategy for cationic exchange chromatography 
Initially, binding strategy of ion exchange chromatography was designed. The 
theoretical isoelectric point (pI) of HCV core-HBc is 11.03 according to its amino acid 
sequence and the buffer pH after AS precipitation process was pH 9. In theory, HCV 
core-HBc should obtain positive charge. Based on this, two cationic exchange 




(Cytiva, USA) chromatography were employed using AKTA pure system (Cytiva, 
USA). 50 mM Tris-HCl, 4 M urea , pH 9 was used as equilibration buffer since 
precipitation of HCV core-HBc was observed when using other buffering system such 
as PB. 50 mM Tris-HCl, 4 M urea , 1 M NaCl, pH 9 was used as elution buffer.  
3.2.5.2 Flowthrough strategy for anionic exchange chromatography 
After analysis of the result in previous binding strategy for removal of nucleic acids, 
the acquired results were not desirable, and HCV core-HBc failed to bind with the 
cationic exchange column in all tested conditions. Therefore, a flowthrough strategy 
using anionic exchange chromatography to separate HCV core-HBc proteins from 
nucleic acid impurities was designed. Briefly, three anionic exchange chromatography 
(AEC), Capto™ Q chromatography, HiTrap® Q chromatography and POROS™ 50 
HQ chromatography (Cytiva, USA) were applied using AKTA pure system (Cytiva, 
USA). For Capto™ Q chromatography and HiTrap® Q Fast Flow (FF) chromatography, 
protein samples after resuspension were loaded to Capto™ Q, HiTrap® Q FF and 
POROS™ 50 HQ chromatography using 20 mM Tris-HCl, 4 M urea , pH 9 as 
equilibration buffer and 20 mM Tris-HCl, 4 M urea , 1 M NaCl, pH 9 as elution buffer. 
Isocratic elution was performed as HCV core-HBc VLPs should obtain positive charge 
and nucleic acids should obtain negative charge when pH is 9, in theory. Flowthrough 
(FT) fraction and elution fraction were collected. All samples in different fractions were 
analysed by 12 % reducing SDS-PAGE as described in section 3.2.6 and agarose gel 




3.2.6 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE)  
SDS-PAGE was used to separate the protein samples according to their molecular 
weights and to evaluate the purity of target protein in samples [32]. In SDS-PAGE 
analysis, 12 % SDS polyacrylamide gel was employed. HCV core-HBc and EBNA1-
HBc protein samples (5 μg per lane) were mixed with SDS-gel electrophoresis sample 
buffer containing 5 % SDS and 5 % 2-mercaptoethanol. Samples were heated at 100 ºC 
for 10 min before being loaded to the SDS-PAGE gel. 90 V of power was used for the 
stacking gel and 120 V of power was used for the separating gel. The proteins samples 
were separated on 12 % SDS polyacrylamide gel in vertical chambers (Bio-Rad, USA). 
3.2.7 Transmission Electron Microscopy (TEM) 
Expressed crude lysates and purified samples of HCV core-HBc and EBNA1-HBc were 
visualized with TEM. Briefly, 5 μl sample at concentration of 0.5 mg/ml was dipped 
and incubated the carbon-Formvar coated copper grids (Zhongjingkeyi Technology, 
China) on the surface for 10 min and touched dry on blotting paper. Then the grid was 
dipped and negatively stained with 1% uranyl acetate aqueous solution. The grids were 
examined according to the instructions of the TEM microscope (Hitachi JEM-1400, 
Japan), following the local guidelines. 
3.2.8 Measurement of protein concentration and purity and 
purification yield determination 




to the manufacturer’s instruction. The purity of target protein was estimated according 
to the intensity calculation using SDS-PAGE image using ImageJ[40] and recovery 
yield was calculated using the following equation: 
𝑅𝑒𝑣𝑜𝑣𝑒𝑟𝑦 𝑦𝑖𝑒𝑙𝑑 =
𝑐𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 𝑎𝑓𝑡𝑒𝑟 𝑟𝑒𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛×𝑃𝑢𝑟𝑖𝑡𝑦 𝑎𝑓𝑡𝑒𝑟 𝑝𝑢𝑟𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 (%)
𝑐𝑡𝑜𝑡𝑎𝑙 𝑠𝑜𝑙𝑢𝑏𝑙𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛𝑠×𝑃𝑢𝑟𝑖𝑡𝑦 𝑏𝑒𝑓𝑜𝑟𝑒 𝑝𝑢𝑟𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 (%)
× 100%        (Eq. 3.1) 
The production yields of chimeric HBc VLPs were calculated using the following 
equation: 
𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑦𝑖𝑒𝑙𝑑 =
𝑐𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑡𝑎𝑛𝑡 𝑎𝑓𝑡𝑒𝑟 𝑑𝑖𝑎𝑙𝑦𝑠𝑖𝑠×𝑃𝑢𝑟𝑖𝑡𝑦 𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (%)
𝑚𝑎𝑠𝑠 (𝑔)𝑤𝑒𝑡 𝑏𝑖𝑜𝑚𝑎𝑠𝑠 𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒(𝐿)𝑏𝑖𝑜𝑚𝑎𝑠𝑠
× 100%   (Eq. 3.2) 
3.3 Results 
3.3.1 Plasmid construction and optimization of expression of chimeric 
VLP in E. coli expression system 
The N-terminal of HBc was exposed on the surface of VLP structure and can be inserted 
with large epitopes without any impact on the VLP assembly[41]. Therefore, structural 
long epitope, HCV core epitope (aa 10-53: KTKRNTNRRPQDVKFPGGGQ 
IVGGVYLLPRRGPRLGVRATRKTS) and relatively short EBNA1 (aa 407-417: 
HPVGEADYFEY) were designed to be fused at N-terminal of HBc to form the 
chimeric HCV core-HBc VLP and EBNA1-HBc VLP (as shown in Figure 3.1). pET 
30a HCV core-HBc plasmid was generated using Overlap Extension PCR[42]. 
Constructed gene sequence of HCV core-HBc was confirmed by gene sequencing(data 
not shown). Confirmed pET 30a-HCV core-HBc plasmid was transformed into E. coli 
BL21 (DE) strain for expression of HCV core-HBc proteins. Constructed pET 30a-




EBNA1-HBc plasmid was also transformed to E. coli BL21 (DE) strain for expression. 
 
Figure 3.2 SDS-PAGE of expression of EBNA1-HBc (Lane 2-4) and HCV core-HBc (Lane 5-
7) using expression condition of wt HBc VLP. Lane 1: molecular weight marker; Lane 2 and 
5: crude lysate; Lane 3 and 6: supernatant of crude lysate of EBNA1-HBc; Lane 4 and 7: pellets 
of crude lysate. (red arrow: HCV core-HBc, blue arrow: EBNA1-HBc) 
For the first trial for the expression of HCV core-HBc and EBNA1-HBc, expression 
conditions followed the expression of wt HBc VLP. As shown in Figure 3.2, around 
97 % target EBNA1-HBc proteins (according to the intensity calculation using SDS-
PAGE image) were expressed in the soluble part of E. coli while around 80 % of HCV 
core-HBc proteins were expressed in the inclusion bodies of E. coli. Therefore, 
optimization for expression of HCV core-HBc was conducted. Following the plan as 
described in section 3.2.2, three runs of expression was performed orderly. The 
harvested bacteria cells were then disrupted using ultrasonic homogenizer and 
centrifuged. The crude lysate together with supernatant and pellet after centrifugation 





Figure 3.3 SDS-PAGE of optimization of expression of HCV core-HBc following Table 3.1, 
No.1: Lane 2-4, No.2: Lane 5-7, No.3: Lane 8-10, No.4: Lane 11-13. Lane 1: molecular weight 
marker; Lane 2,5,8 and 11: crude lysate of HCV core-HBc; Lane 3,6,9 and 12: supernatant of 
crude lysate of HCV core-HBc; Lane 4,7,10 and 13: pellets of crude lysate of HCV core-HBc. 
(red arrow: HCV core-HBc) 
As shown in Figure 3.3, all SDS-PAGE results for these four runs were merged for 
analysis. For induction cell density, the expressed soluble form of HCV core-HBc 
proteins reached to 54 % with lower induction cell density of OD600 at 0.8, therefore, 
OD600 at 0.8 was chosen for next expression. For expression temperature evaluation, 
there is no significant difference of the percentage of soluble HCV core-HBc proteins 
between two expression temperature and 37 ℃ was chosen for the next expression as 
E. coli had a lower growth rate at 30 ℃, leading to less amount of biomass when the 
same expression time was applied. For concentration of IPTG, more than 95 % of 
expressed HCV core-HBc proteins were in the soluble form with the addition of 0.5 
mM IPTG. With these results, the optimal soluble expression of HCV core-HBc 
proteins is to be expressed with induction of 0.5 mM IPTG when OD600 is 0.8 and 
expression temperature is 37 ℃. TEM images of soluble part of E. coli of HCV core-




clear VLP structure (shown in Figure 3.4). The expressed HCV core-HBc and EBNA1-
HBc proteins were then purified with AS precipitation. 
 
Figure 3.4 TEM image of HCV core-HBc protein (a) and EBNA1-HBc protein (b) in the 
soluble part of bacteria lysate 
3.3.2 Purification of chimeric HBc VLPs 
According to the purification process of HBc VLP described by the research group in 
IPE[43], ammonium sulphate (AS) precipitation was applied. 1 M AS was used for 
precipitation step and 4 M urea buffer, pH 9 was employed as the resuspension buffer. 
In the trial of AS precipitation for HCV core-HBc and EBNA1-HBc was found that 
EBNA1-HBc achieved a good recovery yield using the same AS concentration and 
resuspension buffer as wt HBc VLP. After 1 M AS precipitation and 4 M urea buffer 
resuspension, the purity of EBNA1-HBc reached 95 % and the recovery yield for AS 
precipitation process was more than 39.1% (target protein/total protein including 
impurities) while the recovery yield of HCV core-HBc was only 5 % (shown in Figure 




of EBNA1-HBc protein was determined, which was around 62.1 mg/g wet cell weight 
or 248.4 mg/L. Therefore, the study focused on the optimization of HCV core-HBc 
proteins as the recovery yield of HCV core-HBc in the trial was only around 5 %. Most 
of the target HCV core-HBc remained in the pellet after resuspension. 
 
Figure 3.5 SDS-PAGE results of first trial of AS precipitation of EBNA1-HBc (Lane 2-4) and 
HCV core-HBc (Lane 5-7). Lane 1: molecular weight marker; Lane 2 and 5: supernatant after 
AS precipitation; Lane 3 and 6: supernatant after resuspension using urea buffer; Lane 4 and 7: 
pellet after resuspension using urea buffer. (red arrow: HCV core-HBc, blue arrow: EBNA1-
HBc) 
3.3.2.1 Optimization of acid precipitation of HCV core-HBc 
As HCV core-HBc proteins failed to be purified with AS precipitation with a desirable 
recovery yield, another popular precipitation process used for the purification of 
recombinant proteins, acid precipitation, was applied. To optimize the acid 
precipitation condition, six different pH values including pH 7.0, pH 6.5, pH 6.0, pH 




using 4 M urea buffer. The SDS-PAGE result of acid precipitation process for HCV 
core-HBc is illustrated in Figure 3.6a. 
 
Figure 3.6 Results of acid precipitation of HCV core-HBc. SDS-PAGE images (a), purity (b) 
and recovery yield (c). SDS-PAGE: Lane 1: molecular weight marker; Lane 2 HCV core-HBc 
sample before acid precipitation; Lane 3-8: supernatant after precipitation at pH 7.0, 6.5, 6.0, 
5.5, 5.0, 4.5; Lane 9-14: supernatant of resuspension after precipitation at pH 7.0, 6.5, 6.0, 5.5, 
5.0, 4.5. (red arrow: HCV core-HBc) 
In Figure 3.6b, HCV core-HBc samples precipitated with pH 7.0 and pH 6.5 achieved 
high purity of 92 % and 88 % while the purities achieved by other conditions were 
lower than 80 %. However, the recovery yield of HCV core-HBc sample precipitated 
at pH 7.0 was only 4.1 % and SDS-PAGE result indicates that there were still HCV 
core-HBc proteins left in the supernatant of precipitation step. As shown in Figure 3.6c, 




The achieved recovery yield was found increased with the decrease of pH value (from 
21.3 % to 53.5 %), however, the purity of target HCV core-HBc dropped (from 76 % 
to 7%) (shown in Figure 3.6b and c). Therefore, pH 6.5 was considered as the optimal 
condition for acid precipitation with a high recovery yield and high purity. Even though 
acid precipitation of HCV core-HBc achieved high purity and good recovery yield, after 
24 h storage, the purified HCV core-HBc samples were all aggregated and precipitated. 
3.3.2.2 Optimization of AS precipitation of HCV core-HBc 
Because of the stability issue observed in the acid precipitation process of HCV core-
HBc, optimization of AS precipitation was performed. In the process of AS 
precipitation of chimeric HBc VLP proteins, there are two major factors, 1) 
concentration of AS and 2) composition of resuspension buffer that have a great impact 
on the yield [59]. The optimization of resuspension buffer was firstly performed. Two 
factors, the pH value for resuspension buffer and concentration of urea , were examined 
using control variable method. The concentrations of resuspended protein samples were 
measured, and the recovery yields were calculated for analysis. As shown in Table 3.2, 
comparing different pH value of resuspension buffer, pH 9 buffer obtained the highest 
recovery yield of 5 % and pH 10 buffer achieved a slightly lower recovery yield of 
4.3%. The recovery yields achieved by the other two pH conditions were 2.1 % and 
1.1 %. Therefore, pH 9 was chosen as the optimal pH value for the resuspension buffer. 
Then different urea concentrations were examined. As shown in Table 3.2, the recovery 




8 M urea buffers were 5 %, 11.25 % and 26 %, respectively. 8 M urea buffer achieved 
the highest recovery yield. However, when detecting the resuspended samples with 
TEM (as shown in Figure 3.7), HCV core-HBc sample resuspended with 8 M urea 
buffer was found to be disassembled. For 6 M urea buffer, HCV core-HBc samples 
were disassembled partially, while the sample resuspended with 4 M urea buffer 
remained the fully assembled structure. Therefore, 4 M urea was used as the optimal 
urea concentration for the resuspension buffer. 
Table 3.2 Recovery yields of HCV core-HBc resuspended with different urea buffer. 
No. Concentration of urea  pH HCV core-HBc yield 
1 4 M 10 4.3 % 
2 4 M 9 5 % 
3 4 M 8 2.1 % 
4 4 M 7 1.1 % 
5 6 M 9 11.25 % 
6 8 M 9 26 % 
 
Figure 3.7TEM images of HCV core-HBc sample resuspended using 4 M urea buffer (a), 6 M 





Figure 3.8 SDS-PAGE results of AS precipitation of HCV core-HBc proteins. Lane 1: 
supernatant after precipitation using 1 M AS; Lane 2: supernatant of resuspension using 4 M 
urea after precipitation using 1 M AS; Lane 3: pellet of resuspension using 4 M urea buffer 
after precipitation using 1 M AS; Lane 4: supernatant after precipitation using 0.5 M AS; Lane 
5: supernatant of resuspension using 4 M urea after precipitation using 0.5 M AS; Lane 6: pellet 
of resuspension using 4 M urea buffer after precipitation using 0.5 M AS; Lane 7: supernatant 
after precipitation using 0.1 M AS; Lane 8: supernatant of resuspension using 4 M urea after 
precipitation using 0.1 M AS; Lane 9: pellet of resuspension using 4 M urea buffer after 
precipitation using 0.1 M AS; Lane 10: supernatant after precipitation using 0..05 M AS; Lane 
11: supernatant of resuspension using 4 M urea after precipitation using 0.05 M AS; Lane 12: 
pellet of resuspension using 4 M urea buffer after precipitation using 0.05 M AS ; Lane 13: 
supernatant after precipitation using 0.01 M AS; Lane 14: supernatant of resuspension using 4 
M urea after precipitation using 0.01 M AS; Lane 15: pellet of resuspension using 4 M urea 
buffer after precipitation using 0.01 M AS.(red arrow: HCV core-HBc) 
 
Table 3.3 Recovery yields of HCV core-HBc precipitated with different concentrations of AS 
No. Concentration of AS Recovery yield of HCV core-HBc 
1 1 M 5 % 
2 0.5 M 13.5 % 
3 0.1 M 22.55 % 
4 0.05 M 17.35 % 
5 0.01 M 11.2 % 
 




concentration was performed. Different concentrations including 0.01 M, 0.05 M, 0.1 
M, 0.5 M to 1 M of AS were examined to precipitate the target HCV core-HBc protein 
from the soluble part of E. coli lysate. Then precipitated pellets were resuspended using 
4 M urea buffer, pH 9. As shown in Figure 3.8, HCV core-HBc protein samples were 
fully precipitated with 0.1 M AS from the lysate buffer (Lane7-9) and purity of target 
HCV core-HBc proteins was around 96 % (according to the intensity calculation using 
SDS-PAGE image). Table 3.3 demonstrates the recovery yield when using different 
concentration of AS. Same as the results in SDS-PAGE, 0.1 M AS achieved the best 
recovery yield with 22.55 %. A slightly lower recovery yield of 17.35 % was obtained 
when precipitating with 0.05 M AS, while the recovery yield achieved by other 
concentrations were relatively low. In addition, it was found that with higher 
concentrations of AS (1 M and 0.5 M) target HCV core-HBc proteins were able to fully 
precipitate. However, these precipitated protein samples cannot be resuspended with 4 
M urea buffer with high yield (Lane 1-6). In contrast, lower concentration of AS had a 
greater loss of target proteins in the precipitation step, but the resuspension of target 
proteins was efficient (Lane 10-15). After optimization, the resuspended HCV core-
HBc proteins was examined together with EBNA1-HBc proteins using TEM. Figure 
3.9 proves that the purified HCV core-HBc and EBNA1-HBc proteins were in fully 





Figure 3.9 TEM images of supernatant of HCV core-HBc after 0.1 M AS precipitation (a) and 
EBNA1-HBc (b) after 1 M AS precipitation.  
3.3.3 Nucleic acid impurities removal by ion exchange 
chromatography 
To further remove nucleic acid impurities from produced chimeric HBc VLP proteins, 
HCV core-HBc was chosen as the target. As theoretical pI for HCV core-HBc is 11.03, 
binding strategy using two cationic exchange chromatgraphy, HiTrap CM Sepharose 
FF and HiTrap SP Sepharose FF chromatography, were applied after resuspension of 
HCV core-HBc proteins with 4 M urea buffer, pH 9. As shown in Figure 3.10, HCV 
core-HBc samples failed to bind with both of two cationic exchange columns. All HCV 
core-HBc samples were in the flowthrough (FT) fraction. The protein concentrations in 






Figure 3.10 Chromatograms of HCV core-HBc protein using HiTrap CM Sepharose FF (a) and 
HiTrap SP Sepharose FF (b) chromatography. 
 
Table 3.4 Concentration of protein in different fractions. 
No. Fraction Concentration of protein (mg/ml) 
1 Before loading to chromatography 2.08 
2 FT fraction of CM chromatography 1.91 
3 FT fraction of SP chromatography 1.87 
Then, a flowthrough strategy was applied using three anion exchange chromatography 
(AEC) resins including Capto™ Q chromatography, HiTrap® Q FF chromatography 
and POROS™ 50 HQ chromatography. Figure 3.11 illustrates the chromatography 
results of HCV core-HBc VLP purified with Capto™ Q chromatography, HiTrap® Q 
FF chromatography and POROS™ 50 HQ chromatography. Two fractions, FT fraction 
and elution fraction, were clearly observed. Figure 3.12a and b demonstrates the SDS-
PAGE and DNA gel electrophoresis results of different fractions in the chromatography. 
More than 95 % of HCV core-HBc proteins remained in the FT fraction of all three 




40 % of nucleic acids remained in the FT fraction of Capto™ Q and HiTrap® Q FF 
chromatography, respectively. In contrast, POROS™ 50 HQ chromatography obtained 
a good ability to remove nucleic acids from HCV core-HBc proteins. Less than 10 % 
of nucleic acids left in the FT fraction of POROS™ 50 HQ chromatography, and 90 % 
of nucleic acids were in the elution fraction. Therefore, POROS™ 50 HQ 
chromatography is potentially more suitable to remove nucleic acid impurities for HCV 
core-HBc proteins. Afterwards, HCV core-HBc sample was dialysed against 20 mM 
PB, pH 7.4 to eliminate urea to be prepared for the following in vivo immunogenicity 
experiments. TEM image of dialysed HCV core-HBc proteins was taken and VLP 
structures of HCV core-HBc were clearly observed (shown in Figure 3.12c). However, 
after being stored for a short period, irrevesible precipitation of all purified HCV core-






Figure 3.11 Purification of HCV core-HBc by Capto™ Q chromatography (a), HiTrap® Q FF 
chromatography (b) and POROS™ 50 HQ chromatography (c) using 4 M urea buffer, pH 9 as 





Figure 3.12 SDS-PAGE (a) and DNA gel electrophoresis (b) of HCV core-HBc samples in 
Capto™ Q, HiTrap® Q FF and POROS™ 50 HQ chromatography and TEM image (c) of FT 
fraction from POROS™ 50 HQ chromatography. SDS-PAGE: Lane 1: molecular weight 
marker; Lane 2: HCV core-HBc sample before loading to chromatography; Lane 3: FT fraction 
of Capto™ Q chromatography; Lane 4: Elution fraction of Capto™ Q chromatography; Lane 
5: FT fraction of HiTrap® Q FF chromatography; Lane 6: Elution fraction of HiTrap® Q FF 
chromatography, Lane 7: FT fraction of POROS™ 50 HQ chromatography; Lane 8: Elution 
fraction of POROS™ 50 HQ chromatography. DNA gel: Lane 1: HCV core-HBc sample before 
loading to chromatography; Lane 2: FT fraction of Capto™ Q chromatography; Lane 3: Elution 
fraction of Capto™ Q chromatography; Lane 4: FT fraction of HiTrap® Q FF chromatography; 
Lane 5: Elution fraction of HiTrap® Q FF chromatography, Lane 6: FT fraction of POROS™ 
50 HQ chromatography; Lane 7: Elution fraction of POROS™ 50 HQ chromatography. (red 






In the development of vaccines for oncoviruses, virus like particles (VLPs) have shown 
great potentials to induce strong and long-term immune responses due to their unique 
structure[44]. To target different infection origins, recombinant protein technique has 
been applied by fusing target antigens to selected VLP carriers[45]. Hepatitis B core 
VLP, one of the broadly studied VLP candidates, demonstrates a good ability to display 
foreign epitopes on the surface of its VLP structure and have been reported to elicit 
strong in vivo epitope specific immunogenicity[44]. However, in the production of 
chimeric HBc VLP vaccines targeting different infection origins, challenges in 
expression and purification remain[20, 46]. 
The primary objectives of this chapter are 1) expression of the chimeric HBc VLP 
proteins presenting HCV core epitope and EBNA1 epitope in soluble form using E. coli 
expression system, 2) optimization of the purification process of these two chimeric 
VLP proteins to achieve high production yields and 3) removal of nuclear acid 
impurities from chimeric HBc VLP proteins. 
Both HCV core epitope and EBNA1 epitope were fused to the N-terminal of HBc VLP 
by gene engineering to expose them on the surface of HBc VLPs. HCV core-HBc 
plasmid was successfully constructed using overlapped PCR and EBNA1-HBc VLP 
was supplied by Beijing Genomics Institute, China. In the production of chimeric VLP-
based vaccines, E. coli has been chosen as an efficient host cell to express VLP proteins 




proteins were followed the conditions for the expression of wild type (wt) HBc as 
described in previous work in IPE[38]. Around 97 % of EBNA1-HBc was successfully 
expressed in the soluble form with the expression condition for wt HBc while only 
around 20 % HCV core-HBc proteins were expressed in soluble form. This could be 
because of the insertion of different epitopes as EBNA1 is a 11-mer and non-structural 
epitope while HCV core is a 44-mer epitope (4 times larger than EBNA1) with α-helix 
which potentially increases the difficulty for E. coli to fold the proteins into the correct 
structure. Therefore, a control variable of the expression conditions including cell 
density for induction, expression temperature and concentration of IPTG was 
conducted. After optimization, 95 % of target HCV core-HBc proteins were 
successfully expressed in soluble form in E. coli with cell density for induction at OD600 
0.8, expression temperature at 37 ℃ and 0.5 mM IPTG. In addition, it was found that 
expression temperature could have a minor impact on the improvement of soluble 
expression for chimeric HBc proteins while the other two factors which could directly 
influence the expression rate of chimeric HBc proteins have larger influence of soluble 
expression of chimeric HBc proteins. 
After successfully expression of HCV core-HBc and EBNA1-HBc in soluble form 
using E. coli, both chimeric HBc proteins were purified using Ammonium Sulphate 
(AS) precipitation following the process described in previous work in IPE[38]. In the 
process, 1 M AS was applied for the precipitation and 4 M urea buffer, pH 9 was used 




with recovery yield of 39.1 % and the purity reached 95 % while the recovery yield of 
HCV core-HBc was only 5 %. Most of the target HCV core-HBc proteins remained in 
the pellets after resuspension. Chen et al. (2015) found a similar issue and they claimed 
that high concentration of AS potentially caused the change in interaction between 
subunits in the VLPs and form strong aggregation[48]. Therefore, two plans were 
formed. For the first plan. acid precipitation, one popular purification approach for 
recombinant proteins, was applied and optimized to replace the AS precipitation. The 
acid precipitation result indicates that pH 6.5 was the optimal condition to obtain the 
high recovery yield of 19.4 % and high purity of 88 % for target HCV core-HBc 
proteins. The achieved recovery yield and purity are lower compared with EBNA1-
HBc sample purified using AS precipitation. In addition, HCV core-HBc sample 
purified with acid precipitation at pH 6.5 was found instable and the sample aggregated 
and precipitated after storage for 24 hours. This suggests that acid precipitation is 
potentially not suitable for the purification of HCV core-HBc proteins. 
For the second plan, AS precipitation process for HCV core-HBc proteins was 
optimized. Two factors including resuspension buffer and concentration of AS in AS 
precipitation process was optimized to achieve high recovery yield of HCV core-HBc 
with high purity. As a result, 4 M urea buffer, pH 9 and 0.1 M AS were determined as 
the optimal conditions for AS precipitation for HCV core-HBc. With the optimized 
condition, the recovery yield of HCV core-HBc reached 22.5 % with a purity of 96 %. 




PB, pH 7.4 for the evaluation of production yield. The production yields of chimeric 
HCV core-HBc VLP and EBNA1-HBc VLP were 161.6 mg/L or 40.4 mg/g of wet cell 
weight (HCV core-HBc) and 248.4 mg/L or 62.1 mg/g of wet cell weight (EBNA1-
HBc), respectively. The achieved yields of our chimeric HBc VLPs are significantly 
higher than other reported HBc VLPs of 6.4 mg/L produced using Cell-free protein 
synthesis (CFPS) system[49] and 3.21  mg/L produced using E. coli expression system 
in inclusion bodies[50]. In addition, our achieved yields are also higher than the 
reportedly high production yield in P. pastoris of 3 mg/g of wet cell weight[51]. In 
addition to high production yield, TEM images prove that purified HCV core-HBc and 
EBNA1-HBc proteins were in assembled VLP structure. 
After being purified with AS precipitation, chimeric HCV core-HBc proteins were 
loaded to ion exchange chromatography for the preliminary study to eliminate the 
nucleic acid impurities from chimeric VLP samples. Binding strategy with cationic 
exchange chromatography, HiTrap CM Sepharose FF and HiTrap SP Sepharose FF 
chromatography was designed to have HCV core-HBc proteins bind with column while 
remain nuclear acid in the FT fraction according to the pI information of HCV core-
HBc. However, it was found that HCV core-HBc proteins failed to bind with column 
and all samples were in the FT fraction together with nucleic acid impurities. Therefore, 
a flowthrough strategy was designed and three types of anionic exchange 
chromatography including Capto™ Q[52, 53], HiTrap® Q FF[54, 55] and POROS™ 




nucleic acids from chimeric VLP proteins were employed. DNA gel electrophoresis 
results indicate that both Capto™ Q and HiTrap® Q FF resins are not suitable for the 
removal of nucleic acid impurities for HCV core-HBc VLP as 80 % and 40 % of nucleic 
acids remained in the FT fractions of two chromatography, respectively. For POROS™ 
50 HQ chromatography, 90 % of nucleic acid impurities were bound with the column 
and observed in the elution fraction, and 95 % of target HCV core-HBc VLP samples 
remained in the flowthrough fraction. TEM image also confirms the assembled VLP 
structure of HCV core-HBc after removal of nucleic acid impurities. However, all HCV 
core-HBc proteins after removal of nucleic acids were found to aggregate and 
precipitate after a short period storage. This could result from the instability of HCV 
core-HBc subunit caused by the absence of nucleic acids, because HBc protein has the 
arginine-rich domain (ARD) at the C terminal. Le Pogam’ group and Chua’s group 
have made hypothesis that missing the nucleic acids can lead to the instability of the 
HBc VLP structure due to the charge balance and chaperone activity[59, 60]. 
3.5 Conclusion 
In this project, gene sequences of HCV core epitope and EBNA1 epitope targeting HCV 
and EBV respectively were successfully fused with HBc VLP sequence at 5’-terminal 
in pET 30a plasmid. pET 30a-HCV core-HBc and pET 30a-EBNA1-HBc were 
transferred into E. coli BL21 (DE) for expression. Both HCV core-HBc and EBNA1-
HBc proteins were successfully expressed in the soluble form with high production 




that control of expression rate is essential for expression of chimeric HBc protein in 
soluble form. Both HCV core-HBc and EBNA1-HBc protein were found to be 
expressed as VLP structures in E. coli. In addition, it was found that the nature of 
presented antigens of chimeric HBc proteins can influence the expression of chimeric 
HBc protein in soluble form as long and structural epitope (HCV core) has a larger 
impact than short and non-structured epitope (EBNA1). The optimization of AS 
precipitation process of expressed VLP protein samples were then performed. Results 
indicate that 0.1 M AS was the optimal AS concentration for HCV core-HBc. After 
optimization, the recovery yield of HCV core-HBc improved from 5 % to 22.5 % with 
a purity of 96 %. On the other hand, 1 M AS was the optimal AS concentration for 
EBNA1-HBc precipitation. The precipitated chimeric HBc VLP samples were then 
resuspended with 4 M urea buffer, pH 9. It was also found that the insertion of a longer 
and structural epitope, HCV core-HBc, can change the property of chimeric HBc VLP 
in AS precipitation and irreversible precipitation can be formed with high concentration 
of AS. Finally, POROS™ 50 HQ chromatography is proven to remove nucleic acid 
impurities from HCV core-HBc proteins effectively. However, HCV core-HBc proteins 
after removal of nucleic acids were found to be precipitated after short period storage 
due to the charge balance hypothesis and chaperone activity. Further study on the 
stability and structure of the chimeric VLP presenting different epitopes is described in 





[1] H.K. Ong, W.S. Tan, K.L. Ho, Virus like particles as a platform for cancer vaccine 
development, PeerJ 5 (2017) 4053-4053. 
[2] S. Buffin, I. Peubez, F. Barrière, M.-C. Nicolaï, T. Tapia, V. Dhir, E. Forma, N. Sève, I. 
Legastelois, Influenza A and B virus-like particles produced in mammalian cells are highly 
immunogenic and induce functional antibodies, Vaccine 37(46) (2019) 6857-6867. 
[3] A. Kazaks, I.N. Lu, S. Farinelle, A. Ramirez, V. Crescente, B. Blaha, O. Ogonah, T. 
Mukhopadhyay, M.P. de Obanos, A. Krimer, I. Akopjana, J. Bogans, V. Ose, A. Kirsteina, 
T. Kazaka, N.J. Stonehouse, D.J. Rowlands, C.P. Muller, K. Tars, W.M. Rosenberg, 
Production and purification of chimeric HBc virus-like particles carrying influenza virus 
LAH domain as vaccine candidates, BMC Biotechnol. 17(1) (2017) 79. 
[4] S. Kruger, M. Ilmer, S. Kobold, B.L. Cadilha, S. Endres, S. Ormanns, G. Schuebbe, B.W. 
Renz, J.G. D’Haese, H. Schloesser, V. Heinemann, M. Subklewe, S. Boeck, J. Werner, M. 
von Bergwelt-Baildon, Advances in cancer immunotherapy 2019 – latest trends, J. Exp. 
Clin. Cancer Res. 38(1) (2019) 268. 
[5] P.J. Farrell, Epstein–Barr Virus and Cancer, Annual Review of Pathology: Mechanisms of 
Disease 14(1) (2019) 29-53. 
[6] A.F. Sander, P.L. Lollini, Virus-like antigen display for cancer vaccine development, what 
is the potential?, Expert Rev Vaccines 17(4) (2018) 285-288. 
[7] P. Pumpens, E. Grens, HBV core particles as a carrier for B cell/T cell epitopes, 
Intervirology 44(2-3) (2001) 98-114. 
[8] K. Roose, S.D. Baets, B. Schepens, X. Saelens, Hepatitis B core–based virus–like particles 
to present heterologous epitopes, Expert review of vaccines 12(2) (2013) 183-198. 
[9] I.F.M. Suffian, J.T.W. Wang, F.N. Faruqu, J. Benitez, Y. Nishimura, C. Ogino, A. Kondo, 
K.T. Al-Jamal, Engineering Human Epidermal Growth Receptor 2-Targeting Hepatitis B 
Virus Core Nanoparticles for siRNA Delivery in Vitro and in Vivo, ACS Applied Nano 
Materials 1(7) (2018) 3269-3282. 
[10] I.F.B. Mohamed Suffian, J.T.-W. Wang, N.O. Hodgins, R. Klippstein, M. Garcia-Maya, 
P. Brown, Y. Nishimura, H. Heidari, S. Bals, J.K. Sosabowski, C. Ogino, A. Kondo, K.T. 
Al-Jamal, Engineering hepatitis B virus core particles for targeting HER2 receptors 
in vitro and in vivo, Biomaterials 120 (2017) 126-138. 
[11] A. Strods, V. Ose, J. Bogans, I. Cielens, G. Kalnins, I. Radovica, A. Kazaks, P. Pumpens, 
R. Renhofa, Preparation by alkaline treatment and detailed characterisation of empty 
hepatitis B virus core particles for vaccine and gene therapy applications, Sci. Rep. 5(1) 
(2015) 11639. 
[12] Y. Zhang, S. Song, C. Liu, Y. Wang, X. Xian, Y. He, J. Wang, F. Liu, S. Sun, Generation 
of chimeric HBc proteins with epitopes in E.coli: Formation of virus-like particles and a 
potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in 
vivo, Cellular Immunology 247(1) (2007) 18-27. 
[13] Y. Lei, J. Shao, F. Zhao, Y. Li, C. Lei, F. Ma, H. Chang, Y. Zhang, Artificially designed 




mouth disease virus as a bivalent vaccine candidate, J. Med. Virol. 91(12) (2019) 2142-
2152. 
[14] X. Ye, Z. Ku, Q. Liu, X. Wang, J. Shi, Y. Zhang, L. Kong, Y. Cong, Z. Huang, Chimeric 
Virus-Like Particle Vaccines Displaying Conserved Enterovirus 71 Epitopes Elicit 
Protective Neutralizing Antibodies in Mice through Divergent Mechanisms, J. Virol. 88(1) 
(2014) 72. 
[15] D.S. Peabody, B. Manifold-Wheeler, A. Medford, S.K. Jordan, J. do Carmo Caldeira, B. 
Chackerian, Immunogenic display of diverse peptides on virus-like particles of RNA 
phage MS2, J Mol Biol 380(1) (2008) 252-63. 
[16] J.C. Caldeira, D.S. Peabody, Thermal stability of RNA phage virus-like particles 
displaying foreign peptides, J Nanobiotechnology 9 (2011) 22. 
[17] J. Schumacher, T. Bacic, R. Staritzbichler, M. Daneschdar, T. Klamp, P. Arnold, S. Jagle, 
O. Tureci, J. Markl, U. Sahin, Enhanced stability of a chimeric hepatitis B core antigen 
virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide, J 
Nanobiotechnology 16(1) (2018) 39. 
[18] M.T. Arevalo, T.M. Wong, T.M. Ross, Expression and Purification of Virus-like Particles 
for Vaccination, Journal of visualized experiments : JoVE (112) (2016) 54041. 
[19] M. Merlin, E. Gecchele, S. Capaldi, M. Pezzotti, L. Avesani, Comparative Evaluation of 
Recombinant Protein Production in Different Biofactories: The Green Perspective, 
BioMed Research International 2014 (2014) 136419. 
[20] G.L. Rosano, E.A. Ceccarelli, Recombinant protein expression in Escherichia coli: 
advances and challenges, Front. Microbiol. 5(172) (2014). 
[21] X. Huang, X. Wang, J. Zhang, N. Xia, Q. Zhao, Escherichia coli-derived virus-like 
particles in vaccine development, NPJ vaccines 2 (2017) 3. 
[22] A. Zeltins, Construction and Characterization of Virus-Like Particles: A Review, Mol. 
Biotechnol. 53(1) (2013) 92-107. 
[23] C. Ladd Effio, P. Baumann, C. Weigel, P. Vormittag, A. Middelberg, J. Hubbuch, High-
throughput process development of an alternative platform for the production of virus-like 
particles in Escherichia coli, J Biotechnol 219 (2016) 7-19. 
[24] W. Dai, P. Xiong, X. Zhang, Z. Liu, J. Chen, Y. Zhou, X. Ye, C. Zhang, Recombinant 
virus-like particle presenting a newly identified coxsackievirus A10 neutralization epitope 
induces protective immunity in mice, Antiviral Res. 164 (2019) 139-146. 
[25] H.P. Sørensen, K.K. Mortensen, Soluble expression of recombinant proteins in the 
cytoplasm of Escherichia coli, Microbial Cell Factories 4(1) (2005) 1. 
[26] A.M. Al-Hejin, R.S. Bora, M.M.M. Ahmed, Plasmids for Optimizing Expression of 
Recombinant Proteins in E. coli, Plasmid, IntechOpen2019. 
[27] I. Rabhi-Essafi, A. Sadok, N. Khalaf, D.M. Fathallah, A strategy for high-level expression 
of soluble and functional human interferon α as a GST-fusion protein in E.coli, Protein 
Engineering, Design and Selection 20(5) (2007) 201-209. 
[28] J. Li, Q. Han, T. Zhang, J. Du, Q. Sun, Y. Pang, Expression of soluble native protein in 
Escherichia coli using a cold-shock SUMO tag-fused expression vector, Biotechnology 




[29] K.M. Frietze, D.S. Peabody, B. Chackerian, Engineering virus-like particles as vaccine 
platforms, Curr. Opin. Virol. 18 (2016) 44-49. 
[30] N.K.C. Linda H.L. Lua, Frank Sainsbury, Yap P. Chuan,Nani Wibowo, Anton P.J. 
Middelberg, Bioengineering Virus-Like Particles as Vaccines, Biotechnology and 
Bioengineering 111 (2014) 425-440. 
[31] J. Freivalds, A. Dislers, V. Ose, P. Pumpens, K. Tars, A. Kazaks, Highly efficient 
production of phosphorylated hepatitis B core particles in yeast Pichia pastoris, Protein 
Expr Purif 75(2) (2011) 218-24. 
[32] M. Zahin, J. Joh, S. Khanal, A. Husk, H. Mason, H. Warzecha, S.-j. Ghim, D.M. Miller, 
N. Matoba, A.B. Jenson, Scalable Production of HPV16 L1 Protein and VLPs from 
Tobacco Leaves, PLoS One 11(8) (2016) 160995. 
[33] A. Kazaks, I.N. Lu, S. Farinelle, A. Ramirez, V. Crescente, B. Blaha, O. Ogonah, T. 
Mukhopadhyay, M.P. de Obanos, A. Krimer, I. Akopjana, J. Bogans, V. Ose, A. Kirsteina, 
T. Kazaka, N.J. Stonehouse, D.J. Rowlands, C.P. Muller, K. Tars, W.M. Rosenberg, 
Production and purification of chimeric HBc virus-like particles carrying influenza virus 
LAH domain as vaccine candidates, BMC biotechnology 17(1) (2017) 79-79. 
[34] D. Rajalingam, C. Loftis, J.J. Xu, T.K.S. Kumar, Trichloroacetic acid-induced protein 
precipitation involves the reversible association of a stable partially structured 
intermediate, Protein science : a publication of the Protein Society 18(5) (2009) 980-993. 
[35] P. Pereira Aguilar, T.A. Schneider, V. Wetter, D. Maresch, W.L. Ling, A. Tover, P. 
Steppert, A. Jungbauer, Polymer-grafted chromatography media for the purification of 
enveloped virus-like particles, exemplified with HIV-1 gag VLP, Vaccine 37(47) (2019) 
7070-7080. 
[36] C. Ladd Effio, S.A. Oelmeier, J. Hubbuch, High-throughput characterization of virus-like 
particles by interlaced size-exclusion chromatography, Vaccine 34(10) (2016) 1259-67. 
[37] Y. Yang, Y. Mengran, S. Zhang, G. Ma, Z. Su, Adsorption of virus-like particles on ion 
exchange surface: Conformational changes at different pH detected by dual polarization 
interferometry, Journal of Chromatography A 1408 (2015) 161-168. 
[38] Y. Zhang, Y. Liu, B. Zhang, S. Yin, X. Li, D. Zhao, W. Wang, J. Bi, Z. Su, In vitro 
preparation of uniform and nucleic acid free hepatitis B core particles through an 
optimized disassembly-purification-reassembly process, Protein Expression and 
Purification (2020) 105747. 
[39] M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities 
of protein utilizing the principle of protein-dye binding, Analytical Biochemistry 72(1) 
(1976) 248-254. 
[40] C.A. Schneider, W.S. Rasband, K.W. Eliceiri, NIH Image to ImageJ: 25 years of image 
analysis, Nat. Methods 9(7) (2012) 671-675. 
[41] E.A. Blokhina, V.V. Kuprianov, L.A. Stepanova, L.M. Tsybalova, O.I. Kiselev, N.V. 
Ravin, K.G. Skryabin, A molecular assembly system for presentation of antigens on the 
surface of HBc virus-like particles, Virology 435(2) (2013) 293-300. 
[42] A.V. Bryksin, I. Matsumura, Overlap extension PCR cloning: a simple and reliable way 




[43] Y. Zhang, S. Yin, B. Zhang, J. Bi, Y. Liu, Z. Su, HBc-based virus-like particle assembly 
from inclusion bodies using 2-methyl-2, 4-pentanediol, Process Biochem. (2019). 
[44] K. Roose, S. De Baets, B. Schepens, X. Saelens, Hepatitis B core-based virus-like particles 
to present heterologous epitopes, Expert Rev Vaccines 12(2) (2013) 183-98. 
[45] S.L. Stephen, L. Beales, H. Peyret, A. Roe, N.J. Stonehouse, D.J. Rowlands, Recombinant 
Expression of Tandem-HBc Virus-Like Particles (VLPs), Methods Mol Biol 1776 (2018) 
97-123. 
[46] J. Fuenmayor, F. Gòdia, L. Cervera, Production of virus-like particles for vaccines, N. 
Biotechnol. 39(Pt B) (2017) 174-180. 
[47] Y. Xiao, H.Y. Chen, Y. Wang, B. Yin, C. Lv, X. Mo, H. Yan, Y. Xuan, Y. Huang, W. 
Pang, X. Li, Y.A. Yuan, K. Tian, Large-scale production of foot-and-mouth disease virus 
(serotype Asia1) VLP vaccine in Escherichia coli and protection potency evaluation in 
cattle, BMC Biotechnol. 16(1) (2016) 56. 
[48] Y. Chen, Y. Zhang, C. Quan, J. Luo, Y. Yang, M. Yu, Y. Kong, G. Ma, Z. Su, Aggregation 
and antigenicity of virus like particle in salt solution--A case study with hepatitis B surface 
antigen, Vaccine 33(35) (2015) 4300-6. 
[49] A.J. Spice, R. Aw, D.G. Bracewell, K.M. Polizzi, Synthesis and Assembly of Hepatitis B 
Virus-Like Particles in a Pichia pastoris Cell-Free System, Frontiers in Bioengineering 
and Biotechnology 8(72) (2020). 
[50] I.F. Bin Mohamed Suffian, M. Garcia-Maya, P. Brown, T. Bui, Y. Nishimura, A.R.B.M.J. 
Palermo, C. Ogino, A. Kondo, K.T. Al-Jamal, Yield Optimisation of Hepatitis B Virus 
Core Particles in E. coli Expression System for Drug Delivery Applications, Sci. Rep. 7(1) 
(2017) 43160. 
[51] J. Freivalds, A. Dislers, V. Ose, P. Pumpens, K. Tars, A. Kazaks, Highly efficient 
production of phosphorylated hepatitis B core particles in yeast Pichia pastoris, Protein 
Expression and Purification 75(2) (2011) 218-224. 
[52] T. Weigel, T. Solomaier, A. Peuker, T. Pathapati, M.W. Wolff, U. Reichl, A flow-through 
chromatography process for influenza A and B virus purification, J. Virol. Methods 207 
(2014) 45-53. 
[53] S. Chandramouli, A. Medina-Selby, D. Coit, M. Schaefer, T. Spencer, L.A. Brito, P. Zhang, 
G. Otten, C.W. Mandl, P.W. Mason, Generation of a parvovirus B19 vaccine candidate, 
Vaccine 31(37) (2013) 3872-3878. 
[54] T.A.d.C. Lamounier, L.M.d. Oliveira, B.R.d. Camargo, K.B. Rodrigues, E.F. Noronha, 
B.M. Ribeiro, T. Nagata, Production of Brazilian human norovirus VLPs and comparison 
of purification methods, Brazilian Journal of Microbiology 46(4) (2015) 1265-1268. 
[55] H.W. Ng, M.F.X. Lee, G.K. Chua, B.K. Gan, W.S. Tan, C.W. Ooi, S.Y. Tang, E.S. Chan, 
B.T. Tey, Size‐selective purification of hepatitis B virus‐like particle in flow‐through 
chromatography: Types of ion exchange adsorbent and grafted polymer architecture, J. 
Sep. Sci. 41(10) (2018) 2119-2129. 
[56] K. Stubenrauch, A. Bachmann, R. Rudolph, H. Lilie, Purification of a viral coat protein by 
an engineered polyionic sequence, Journal of Chromatography B: Biomedical Sciences 




[57] N. Landry, B.J. Ward, S. Trépanier, E. Montomoli, M. Dargis, G. Lapini, L.-P. Vézina, 
Preclinical and clinical development of plant-made virus-like particle vaccine against 
avian H5N1 influenza, PLoS One 5(12) (2010) e15559. 
[58] N. Landry, S. Pillet, D. Favre, J.-F. Poulin, S. Trépanier, B. Yassine-Diab, B.J. Ward, 
Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-
functional and cross-reactive T cell responses to influenza HA antigens, Clin. Immunol. 
154(2) (2014) 164-177. 
[59] S. Le Pogam, P.K. Chua, M. Newman, C. Shih, Exposure of RNA templates and 
encapsidation of spliced viral RNA are influenced by the arginine-rich domain of human 
hepatitis B virus core antigen (HBcAg 165-173), J. Virol. 79(3) (2005) 1871-1887. 
[60] P.K. Chua, F.-M. Tang, J.-Y. Huang, C.-S. Suen, C. Shih, Testing the Balanced 
Electrostatic Interaction Hypothesis of Hepatitis B Virus DNA Synthesis by Using an 





Chapter 4 Characterization and stability 
evaluation of chimeric HBc VLPs presenting 




In the development of chimeric virus like particle (VLP) based cancer vaccines, the 
stability of produced vaccines is essential to ensure its potency to induce strong antigen 
specific immune response. In this chapter, the study aims to investigate and evaluate 
the influences of insertion of foreign epitopes on the stability of chimeric HBc VLPs 
after insertion of foreign epitopes assisted with computational protein modelling. Two 
different epitopes, short and non-structural Epstein-Barr nuclear antigen 1 (EBNA1) 
(aa: 407-417) and long and structural Hepatitis C virus core (HCV core) (aa: 10-53) 
were fused with HBc VLP to form chimeric HBc VLPs. Chimeric EBNA1-HBc and 
HCV core-HBc were expressed and purified using Escherichia coli (E. coli) under 
optimized conditions achieved in Chapter 3. Produced chimeric HBc proteins showed 
similar morphology and correctly assembled VLP structure of chimeric HBc proteins 
were observed after purification. The evaluation of the stability of chimeric HBc VLPs 
under different physical (freeze/thaw cycles and temperature) and chemical stresses 




(wt) HBc VLP. HCV core-HBc VLP was found to form irreversible precipitates during 
the evaluation and was sensitive to the applied stresses. In contrast, EBNA1-HBc VLP 
showed similar stabilities to wt HBc VLP under all tested physical stresses, however, 
its stability was found to be lower when treating with 0.06 % SDS or in the environment 
at pH 5 compared with wt HBc VLP. To investigate the mechanism behind these 
findings, 3D protein structures of both chimeric HCV core-HBc and EBNA1-HBc 
monomer were investigated using computational protein modelling compared with wt 
HBc monomer. It is considered that the hydrophobicity of chimeric HBc monomer 
could be related to the stability of chimeric HBc VLP. The hydrophobicity of HCV 
core-HBc monomer was determined to decrease significantly compared with wt HBc 
monomer after inserting HCV core-epitope. The huge change of the hydrophobicity 
potentially leads to its instability as the hydrophobic interaction between HCV core 
monomers would be significantly influenced. In contrast, the hydrophobicity of 
EBNA1-HBc monomer only decreased slightly, and this can explain the similar 
stability achieved by EBNA1-HBc VLP compared with wt HBc VLP. In addition, 
molecular dynamic (MD) simulation confirms that HCV core-HBc monomer obtained 
less stability compared with EBA1-HBc monomer and wt HBc monomer. 
Key words: Epstein-Barr virus; Hepatitis C virus; Virus-like particles; Hepatitis B 





In Chapter 3, two different type of foreign epitopes, Hepatitis C virus core (HCV core) 
and Epstein-Barr nuclear antigen 1 (EBNA1), were designed and fused into the N-
terminus of HBc VLP to form chimeric HCV core-HBc VLP and chimeric EBNA1-
HBc VLP. HCV core epitope (aa: 10-53) is composed with 44 amino acids including 
18 hydrophilic amino acids and it contains the structure of α-helix, while EBNA1 
epitope (aa: 407-417) is composed with 11 amino acid including 3 hydrophilic amino 
acids and it has no special structure. The expression and purification of two chimeric 
HBc VLPs were optimized in Chapter 3. However, different stability and resistance of 
the conditions such as pH, buffer composition and temperature were observed during 
expression, purification and storage of these two chimeric HBc VLPs, especially for 
HCV core-HBc proteins. HCV core-HBc proteins was found to form irreversible 
precipitation under some conditions during the optimization of Ammonium Sulphate 
(AS) and acid precipitation process. It is reported that insertion of different foreign 
epitopes can have different influence on the stability and assembly of chimeric HBc 
VLPs by affect the hydrophobic interaction between monomers [1-3]. 
To further understand the mechanism that cause the change of the stability of chimeric 
HBc VLPs after insertion of foreign epitopes, computational protein modelling has 
been developed for the analysis and understand the factors that affect the stability of 
VLPs. Computational protein modelling is an advanced technique developed to assist 
the study of the nature of proteins [4]. To effectively applied this technique in the 




needs to be constructed [5]. Several structure determination methods such as X-ray 
crystallography [6], cryoEM [7] and NMR [8] have been developed to form the 
structure files of target proteins. For example, truncated HBc VLP structure was 
determined using X-ray crystallography to 3.3Å resolution in 1999 [118]. The formed 
structure files of different proteins can be found in Protein Data Bank (PDB, 
https://www.rcsb.org/) now. New structure of chimeric VLP proteins either constructed 
through structure determination methods or by using bioinformatics combined with 
software such as BIOVIA Discovery Studio [9] and UCSF Chimera [10]. In addition to 
construct protein structures, Discovery Studio and Chimera can be applied in the study 
and design of chimeric HBc VLP vaccines. With the software, surface property and 
bioinformation of the amino acids constituting the VLPs can be achieved. Furthermore, 
the interaction and stability of VLPs can be analysed using molecular dynamic (MD) 
simulation technique s [11], and several software such as GROMACS [12], AMBER 
[13] and NAMD [14] have been employed.  
 
Therefore, in this chapter, two physical stresses, freeze/thaw cycles and temperature, 
and two chemical stresses, different pH and different concentrations of Sodium 
Dodecyl Sulphate-Polyacrylamide (SDS), were designed for the stability evaluation of 
HCV core-HBc VLP and EBNA1-HBc VLP compared with wild type (wt) HBc VLP. 
Freeze/thaw cycles and temperature were selected to examine the resistance of chimeric 
HBc VLPs against the change of temperatures. SDS as an ionic detergent containing a 




chimeric HBc VLPs against the electrostatic interaction and hydrophobic interaction. 
Different pH values were used to examine the pH sensitivity of chimeric HBc VLPs. 
The wt HBc VLP was used as comparison and evaluate the influence of insertion 
foreign epitopes on the stability of chimeric HBc VLPs. HPSEC-MALLS was 
employed to examine the morphology, molecular weight and hydrodynamic radius of 
chimeric HBc VLPs. In addition, computational protein modelling of the monomers of 
two chimeric HBc VLPs and wt HBc VLP was performed. The hydrophobicity of 
monomers of two chimeric HBc VLPs were calculated and compared with the 
monomer of wt HBc VLP to analyse the influence on the hydrophobic interaction 
between monomers caused by insertion of foreign epitopes. Finally, to study the impact 
of insertion of foreign epitopes to HBc sequence on the conformation and the stability 
of chimeric HBc VLPs, root-mean-square deviation (RMSD) and radius of gyration 
(Rg) have been applied in the study of the stability of proteins [12, 15]. It is regarded 
that the smaller the value of RMSD and lower fluctuation level of Rg are the more 
stable target protein is. This can guide the design of the purification process of chimeric 
HBc VLPs and save massive experimental time. 
4.2. Materials and Methods 
4.2.1 Production of chimeric HBc VLP vaccines displaying EBNA1 
and HCV core epitope 
Chimeric EBNA1-HBc and HCV core-HBc VLPs were expressed and purified with the 




4.2.2 Characterization of chimeric EBNA1-HBc VLP 
Characterization of purified HCV core-HBc and EBNA1-HBc VLP samples were 
evaluated with, Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE), High-Performance Size-Exclusion Chromatography (HPSEC) - Multi-Angle 
Static Laser Light Scattering (MALLS), Intrinsic Fluorescence (IF) and Transmission 
electron microscopy (TEM). 
4.2.2.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE)  
12 % SDS-PAGE was prepared for the evaluation of HCV core-HBc and EBNA1-HBc 
proteins according to the process described in section 3.2.6. 
4.2.2.2 High-Performance Size-Exclusion Chromatography (HPSEC) - Multi-
Angle Static Laser Light Scattering (MALLS) 
To further detect the molecular weight of the protein samples, MALLS was applied as 
it measures the light scattered by a sample into a plurality of angles. In our study, the 
purity and molecular weight of purified HCV core-HBc and EBNA1-HBc VLP were 
evaluated by HPSEC-MALLS. HPSEC analysis was performed in Shimadzu UHPLC 
XR system (Shimadzu, Japan), equipped with TSKgel G4000SWXL column (TOSOH 
Bioscience, Japan). 50 μl of sample was loaded and eluted at 0.8 ml/min with 50 mM 
Phosphate buffer (PB) with 100 mM sodium sulphate, pH 7.4. Elution buffer was 
degassed and filtered by 0.22 μm Millipore membrane (Pall Corporation, USA). The 
retention time and absorbance at 280 nm were recorded. The HPSEC system was 




and Optilab T-rEx (Wyatt Technology, USA) for the detection of the molecular weight. 
The data were processed with ASTRA software (v. 6.1). 
4.2.2.3 Circular Dichroism (CD) Spectroscopy 
Circular Dichroism (CD) is an absorption spectroscopy method based on the 
differential absorption of left and right circularly polarized light and is commonly 
employed in the evaluation of the secondary structure of protein samples [17]. In our 
study, difference of secondary structures between HCV core-HBc, EBNA1-HBc VLP 
and HBc VLP was detected by a Jasco- 810 spectropolarimeter (Jasco, Japan), using a 
quartz cuvette with 0.1 cm pathlength. All the protein samples were prepared at the 
concentration of 0.4 mg/ml in 20 mM PB (pH 7.4). The baseline of buffer was 
subtracted from the experimental spectra for corrections. The reported CD spectra are 
the average of three scans. 
4.2.2.4 Intrinsic Fluorescence (IF) 
Intrinsic fluorescence is a type of electromagnetic spectroscopy using ultraviolet light 
(UV light) to excite the electrons in molecules of proteins [18]. IF spectroscopy can be 
applied to evaluate the conformational state of protein samples leading to the 
tryptophan fluorescence shifts [19]. HCV core-HBc, EBNA1-HBc and HBc VLPs were 
analysed using Hitachi F-4500 fluorescence spectrofluorometer (Hitachi, Japan) using 
a quartz cell of 1.0 cm path length. The emission spectra were excited at 280 nm with 
a slit width of 5.0 nm and recorded between 300 and 400 nm. The measurement was 




4.2.2.5 Transmission electron microscopy (TEM). 
TEM of EBNA1-HBc and HCV core-HBc was taken as described in section 3.2.7. 
4.2.3 Stability evaluation of chimeric HBc VLPs 
The stability of chimeric EBNA1-HBc and HCV core-HBc VLP was examined and 
compared with wt HBc VLP under different stresses including temperatures, 
freeze/thaw cycles, sodium dodecyl sulphate (SDS) and pH. The molecular weight and 
hydrodynamic radius (Rh) of dialyzed samples were examined using HPSEC-MALLS 
analysis. Chimeric HBc VLP samples after treating with different stresses were 
centrifuged at 10,000 rpm for 30 min and the concentration of the supernatant of each 
sample was examined using Bradford assay [21]. The concentration of dialyzed 
samples was adjusted to 1 mg/ml using 20 mM PB, pH 7.4 before the stability 
evaluation under different stresses. The wt HBc VLP at 1mg/ml was used as reference.  
For temperature assay, chimeric HBc VLP samples were placed in the water bath for 
30 min at the designed temperature (25 ºC, 50 ºC, 70 ºC, 80 ºC and 90 ºC). After 
treatment, samples were stored at 4 °C and analysis was conducted within 4 h. For 
freeze/thaw cycle assay, chimeric HBc VLP samples were stored in -20 °C overnight 
and thaw at 25 °C in a water bath for 4 different cycles. For SDS resistance assay, 
chimeric HBc VLP samples were incubated for 30 min in SDS-Tris-HCl buffer, pH 7.4 
at the given concentrations (w/v) including 0.05 %, 0.06 %, 0.07 % and 0.08 % before 
analysis. For pH stability assay, chimeric HBc VLP samples were incubated with 
different buffers at designed pH values including pH 11.0, pH 9.0, pH7.5, pH 5.0 and 





4.2.4 Computational simulation of chimeric HBc VLPs 
To understand and investigate the possible causes for the differences of chimeric HBc 
VLPs after insertion of foreign epitopes, atomic structure of HBc (PDB ID: 3J2V) was 
employed. EBNA1 epitope (HPVGEADYFEY) form EBNA1 protein (PDB ID: 5WMF) 
and HCV core epitope (KTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGP 
RLGVRATRKTS) from HCV core protein (PDB ID: 1NLB) were added to the N-
terminus of HBc to form the atomic structure of chimeric EBNA1-HBc and HCV core-
HBc using BIOVIA Discovery Studio. Due to the limitation of the calculation power 
of the computer, bioinformation of EBNA1-HBc monomer, HCV core-HBc monomer 
and HBc monomer were investigated. Hydrophobicity of whole monomer and 5-
residue running average hydrophobicity representing the hydrophobicity of an area was 
calculated with the data from BIOVIA Discovery Studio. MD simulations were 
performed using GROMACS 2018.5 using GROMOS96 43a1 force field. SPC/E water 
model in a cubic box with a distance of 1.0 nm was applied for simulation and system 
was neutralized with Na and Cl ions. Energy minimization was performed using the 
steepest descent algorithm with a maximum force constraint of 1000.0 kJ/mol/nm. 
Particle mesh Ewald (PME) method and Linear Constraint Solver (LINCS) algorithm 
was employed to calculate and constrain bonds. Temperature equilibration was 
performed at 300 K for 100 ps with the V-rescale method. Then, the pressure was 
equilibrated with the pressure coupling of Parrinello–Rahman for 100 ps. Finally, MD 




simulations were analysed for root-mean-square deviation (RMSD) and the RMSD data 
was visualized with Origin 9. 
4.3 Results and discussion 
4.3.1 Conformation characterization of chimeric HBc VLPs after 
purification 
 
Figure 4.1 HPSEC (A) -MALLS (B) of the purified EBNA1-HBc and HCV core-HBc on TSK 
G4000 SWXL column. (pink line: molecular weight) Characterization of chimeric HBc VLP 
including CD spectra(C), IF spectra (D) and TEM analyses (E). 
Reports have indicated that the insertion of foreign epitopes to HBc VLP proteins can 
potentially decrease the stability of VLP structure or inhibit the assembly of HBc into 




the developed purification process is suitable to produce chimeric HBc VLPs in 
correctly assembled VLP structure, the purified EBNA1-HBc VLP and HCV core-HBc 
VLP were characterized using HPSEC, CD, IF and TEM, the conformation of VLPs 
was compared with HBc VLP. 
As is shown in Figure 4.1A and B, purified chimeric EBNA1-HBc VLP showed similar 
morphology compared with HBc VLP. HPSEC-MALLS is often used for the separation 
and analysis of protein sample according to their molecular weights [25, 26]. The 
molecular weight of chimeric EBNA1-HBc VLP was around 4.58 × 106 Da, which is 
close to the theoretical molecular weight of 3.97 × 106 Da (T=3) and 5.29 × 106 Da 
(T=4). The detected molecular weight of expressed HCV core-HBc VLP was around 
5.58 × 106 Da which is within the theoretical molecular weight for HCV core-HBc VLP 
(4.67 × 106 Da (T=3) or 6.23 × 106 Da (T=4)). This suggested that chimeric HBc VLPs 
were expressed in a mixture of T=3 and T=4 particles. Small amount of aggregation 
(around 15 %) of both chimeric EBNA1-HBc VLP and HBc VLP were observed in 
HPSEC-MALLS results. However, in the HPSEC result, only one fraction peak was 
detected. This phenomenon could be explained by limitation of TSKgel G4000SWXL 
column which cannot separate between the aggregation peak and the VLP peak of HCV 
core-HBc. The small amount of aggregation of chimeric HBc VLP could result from 
the aggregation behaviour from HBc VLP due to the solution environment such pH and 
the buffering agent [27]. For example, Schumacher et.al. (2018) claimed that self-
aggregation of HBc VLP was formed over time in Tris-buffer [1]. 




core-HBc VLP were examined by (CD) spectroscopy analysis. As is shown in Figure 
4.1C, in comparison to HBc VLP, the peak at 222 nm which represented the α-helix 
structure of chimeric EBNA1-HBc VLP was negligible impacted after insertion of 
EBNA1 epitope. The increase of the ellipticity value at 222nm of chimeric EBNA1-
HBc VLP suggests a structurally increase in α-helix content after the insertion of 
foreign EBNA1 epitope to HBc VLP. On the other hand, HCV core-HBc VLP had a 
large decrease of ellipticity value at peak of 222 nm in CD measurement, corresponding 
to the change of α-helix structure. This suggests that the α-helix structure on HCV core 
epitope could influence the formation of α-helix in chimeric HCV core-HBc, leading 
to the reduce of the ratio of α-helix. In the fluorescent measurement of EBNA1-HBc 
VLP, HCV core-HBc VLP and HBc VLP shown in Figure 4.1D, same fluorescence 
maximum emission wavelengths were observed. This suggests that there is no 
significant impact of the EBNA1 epitope and HCV core epitope on the tertiary structure 
of VLPs. The integrity of chimeric EBNA1-HBc VLP and HCV core-HBc VLP were 
characterized by TEM. TEM image in Figure 4.1E demonstrates that the produced 
EBNA1-HBc and HCV core-HBc proteins obtained the same VLP structure as HBc 
VLP. 
4.3.2 Stability evaluation of chimeric HBc VLPs 
Stable VLP structure of chimeric VLP-based vaccine is essential to ensure its 
immunogenicity in vivo. The stability of expressed chimeric EBNA1-HBc VLP and 
HCV core-HBc VLP was evaluated under different stresses including temperature, 




same conditions as reference. In the evaluation, HCV core-HBc VLP was found to be 
sensitive to the stresses and formed irreversible precipitation. Table 4.1 illustrates the 
concentrations of supernatants of HCV core-HBc protein samples after being treated 
with different stresses. HCV core-HBc VLP was found to be sensitive to pH value and 
SDS. All HCV core-HBc VLP formed irreversible precipitation with 0.05 % or higher 
concentration of SDS, while it was only stable at around pH 7.5. When treating with 
physical stresses, HCV core-HBc showed good stability for freeze/thaw cycles assay as 
it remained concentration of 0.87 mg/ml, and 0.56 mg/ml HCV core-HBc VLP proteins 
left when testing with temperature of 50 ºC. However, the stability of HCV core-HBc 
VLP is much lower than EBN1-HBc and wt HBc VLP, in general. 
 
 
Table 4.1 Concentrations of supernatant of chimeric HBc VLP samples after being treated with 
different stresses 
Stress Conditions CHCV core-HBc (mg/ml) CEBNA1-HBc (mg/ml) Cwt HBc (mg/ml) 
Temperature 25 ºC 1 1 1 
 50 ºC 0.56 0.84 0.91 
 70 ºC 0 0.86 0.87 
 80 ºC 0 0.53 0.62 
 90 ºC 0 0 0 
Freeze/thaw cycles 0 1 1 1 
 1 0.96 1 1 
 2 0.91 0.96 0.97 
 3 0.92 0.97 0.97 
 4 0.87 0.85 0.96 
SDS 0.00 % 1 1 1 




 0.06 % 0 0 0.42 
 0.07 % 0 0 0 
 0.08 % 0 0 0 
pH value 11 0 0.55 0.31 
 9 0.36 0.84 0.91 
 7.5 1 1 1 
 5 0 0 0.74 
 2 0 0.35 0.21 
Since HCV core-HBc showed poor stability and formed irreversible precipitation in 
most cases. HPSEC-MALLS results for detection of morphology, molecular weight 
and Rh of EBNA1-HBc wt and wt HBc VLP samples were presented. As shown in 
Figure 4.2, chimeric EBNA1-HBc VLP was not able to maintain the VLP structure 
when it was heated at 80 °C or higher temperatures. Compared with HBc VLP, chimeric 
EBNA1-HBc VLP showed a similar thermal stability. Also, the molecular weight and 
Rh measurement of EBNA1-HBc VLP under different temperatures were similar to wt 
HBc VLP. In addition, when temperature reached to 80 °C, the VLP and aggregation 
peaks in HPSEC of both EBNA1-HBc VLP and wt HBc VLP were disappear while the 
protein concentration, molecular weight and Rh can all be detected with large error bar. 
It suggests that EBNA1-HBc VLP and wt HBc VLP can form large soluble 





Figure 4.2 Effects of temperature on VLPs stability. HPLC of EBNA1-HBc VLPs (A) and 
HBc 183 (B). Molecular weight (C) and Rh (D) of EBNA1-HBc VLPs and HBc 183 (★). 
To test the stability of chimeric EBNA1-HBc VLP in the freezing storage condition, 
various numbers of repeated freeze/thaw cycles on EBNA1-HBc VLP were conducted. 
As shown in Figure 4.3, EBNA1-HBc VLP showed similar morphology, molecular 
weight and Rh in freeze/thaw cycles assay compared with wt HBc VLP. However, in 
the fourth cycle, an increased particle size of EBNA1-HBc VLP (Rh of 29.5 nm) was 
detected and a slightly lower protein concentration was detected for 0.85 mg/ml (shown 
in Table 4.1) compared with HBc VLP. The achieved results indicate that the insertion 
of EBNA1-HBc VLP showed minor impact on the structure of chimeric EBNA1-HBc 





Figure 4.3 Effects of freeze/thaw cycles on VLPs stability. HPLC of EBNA1-HBc VLPs (A) 
and HBc 183 (B). Molecular weight (C) and Rh (D) of EBNA1-HBc VLPs and HBc 183 (★). 
For further evaluation of the stability of EBNA1-HBc VLP, two chemical stresses 
including treating with different concentration of SDS and pH values were examined. 
As shown in Figure 4.4, the influence of an ionic surfactant agent (SDS) at 
concentrations between 0.01 and 0.08 % on the stability of chimeric EBNA1-HBc VLP 
and wt HBc VLP was analysed. Molecular weight and Rh results indicate that EBNA1-
HBc VLP was able to maintain the VLP structure with lower than 0.05 % of SDS while 
HBc VLP can still keep VLP structure at 0.06 % of SDS. This matches with the results 
measured with HPSEC-MALLS that all peaks disappeared in chimeric EBNA1-HBc 
VLP when concentration of SDS was higher than 0.06 %. In addition, a broad pH range 




VLP. As shown in Figure 4.5, HBc VLP showed a better resistance at lower pH value 
(pH=5) than EBNA1-HBc VLP and EBNA1-HBc VLP was stable between pH 7.5 to 
pH 11. In addition, the protein concentration of wt HBc VLP at pH 11 (0.31 mg/ml) 
was slightly lower than that of EBNA1-HBc VLP (0.5 mg/ml). After insertion of 
EBNA1 epitope, stronger influence on the stability of chimeric VLP under chemical 
stress than that on physical stress was detected in the evaluation. 
 
Figure 4.4 Effects of SDS on VLPs stability. HPLC of EBNA1-HBc VLPs (A) and HBc 183 





Figure 4.5 Effects of pH on VLPs stability. HPLC of EBNA1-HBc VLPs (A) and HBc 183 




4.3.3 Molecular Dynamic (MD) simulation to predict protein stability 
after insertion of different epitopes 
 
Figure 4.6 3D image of chimeric HBc VLP monomers with water shell after MD simulation 
(A). Plot of RMSD (B) and radius of gyration (C) of HBc, EBNA1-HBc and HCV core-HBc 
monomer running with GROMACS in CHARMM force field in water environment. HBc in 
blue, EBNA1 in green and HCV core in yellow.  
Insertion of foreign antigens to HBc VLP could have impacts on their stability which 
would then influence the purification process. To predict the stability of chimeric HBc 
VLP after insertion of foreign epitopes and assist the design for purification process for 
removal of HCPs, Molecular Dynamic simulation (MD simulation) was applied to 




(Figure 4.6A). Data of RMSD and Rg of EBNA1-HBc, HCV core-HBc and HBc was 
processed and plot into graphics. As is shown in Figure 4.6A, EBNA1-HBc showed 
similar backbone RMSD compared with HBc while HCV core-HBc had a higher 
RMSD, it indicates that HCV core-HBc had a lower stability in water environment 
compared with EBNA1-HBc and HBc. In Figure 4.6B, the radius of gyration of HCV 
core-HBc fluctuates about 0.2 nm higher than the fluctuation level of EBNA1-HBc and 
HBc (less than 0.1 nm). The RMSD and Rg results indicated that HCV core-HBc is less 
stable than other two samples in the water environment, which indicating that HCV 
core-HBc VLP potentially had weaker interaction with water molecules in the 
environment. This finding potentially suggested that HCV core-HBc was more 
hydrophobic, comparing with EBNA1-HBc in theory.  
The value of hydrophobicity (Figure 4.7) and 5-residue running average 
hydrophobicity (Figure 4.8) of the monomers of HCV core-HBc, EBNA1-HBc and 
HBc were calculated using Discovery Studio. As shown in Figure 4.9, the total value 
of hydrophobicity of monomer of HCV core-HBc turned to negative (-7.3) which 
indicates that after insertion HCV core epitope, its surface turns to a hydrophilic 
potential, while the hydrophobicity of EBNA1-HBc monomer (5.6) decreased but 





Figure 4.7 hydrophobicity of amino acids in HBc, EBNA1-HBc and HCV core-HBc monomer. 
 






Figure 4.9 Hydrophobicity and 5-Residue Running Average Hydrophobicity of HBc, EBNA1-
HBc and HCV core-HBc monomer. 
On the other hand, the value of hydrophobicity and 5-residue running average 
hydrophobicity of EBNA1-HBc reduced compared with HBc but EBNA1-HBc 
monomer remained hydrophobic. This could be the reason why it has a minor influence 
on the stability of chimeric EBNA1-HBc under the physical stress, but when treating 
with SDS, whose mechanism is to disturb the hydrophobic bond in the proteins, reduced 
resistance of EBNA1-HBc VLP was detected compared with wt HBc VLP. 
4.4 Discussion 
In our project, two different types of epitopes, short and non-structural EBNA1 epitope 
and long and structural HCV core epitope were fused with HBc VLP to form 
recombinant chimeric HBc VLPs. HCV core and EBNA epitopes were designed to 




strong immune response. The soluble expression yields in E. coli expression system of 
these two chimeric HBc VLPs were optimized, and the purification process was also 
optimized. However, during the optimization process, irreversible aggregation and 
precipitation of HCV core-HBc VLP proteins was detected. In addition, these 
precipitation and aggregation could be related to several conditions such as pH value, 
buffer composition and temperature. Since stable VLP structure of chimeric HBc VLP 
is essential to ensure its in vivo immunogenicity, stabilities of produced HCV core-HBc 
VLP and EBNA1-HBc VLP were evaluated in this project. 
One apparent influence caused by the insertion of foreign epitope reported by Karpenko 
et al., (2000) is that it can affect the appropriate conformation of chimeric HBc VLP 
and prevent the formation of correctly assembled VLP structure [22]. The 
characterization results indicate that the insertion of long and structural foreign epitopes, 
HCV core, has a major impact on the secondary structure, but a minor impact on the 
tertiary structure and conformation. By contrast, EBNA1 made negligible impact on all 
levels of HBc VLP structure. The change on the secondary structure of HCV core-HBc 
VLP, compared with EBNA1-HBc VLP and HBc VLP, could potentially cause the 
difference in the stability of EBNA1-HBc VLP and HCV core-HBc VLP. Aside this, 
the tertiary structure and TEM image results of HCV core-HBc and EBNA1-HBc 
proves that the developed downstream process has negligible impact on the assembly 
structure of both chimeric HBC VLPs which could keep the antigenicity of both 




Then different physical and chemical stresses were applied to examine the ability of 
chimeric HBc VLP to maintain the assembly of VLP structure. In the stability 
evaluation, HCV core-HBc VLP shows lower stability to resist the stresses compared 
with EBNA1-HBc VLP and wt HBc VLP. This could come from the nature and 
property of HCV core epitope as it is a long and structural epitope. In addition, for 
EBNA1-HBc, it obtains similar stability under physical stress compared with wt HBc 
VLP, while when applying chemical stresses, it shows lower stability compared with 
wt HBc VLP. Its resistance limit for SDS is 0.05 % while the resistance limit of wt HBc 
VLP for SDS is 0.06. SDS is an ionic detergent containing a long aliphatic chain and a 
sulphate group. Its hydrophobic tail can interact with hydrophobic groups in the 
proteins, which can influence the assembly of chimeric HBc VLPs, as the formation of 
VLP structure is an entropy-driven process relying on hydrophobic interaction [28]. 
The decreased tolerance of EBNA1-HBc VLP to SDS suggests that the insertion of 
EBNA1 epitope to HBc VLP affect the hydrophobic conformation and makes it easier 
to be interacted by SDS. In addition, the stability of EBNA1-HBc VLP in low pH 
environment (pH 5) was also lower than wt HBc VLP. 
To understand the mechanism behind the decreased stability of chimeric HBc VLPs 
compared with wt HBc VLP, computational protein modelling was applied. To perform 
the protein modelling, several stages are included such as 1) construction of protein 
structures, 2) analysis of the properties of constructed protein molecules including 




using Molecular Dynamic (MD) simulation [5]. In our project, the protein structures of 
HCV core-HBc monomer, EBNA1-HBc monomer and wt HBc monomer were 
generated from the protein structures from PDB. The constructed chimeric HBc 
monomers were evaluated using BIOVIA Discovery Studio. Results indicate that after 
the insertion of EBNA1 and HCV core, the hydrophobicity of chimeric HBc monomers 
decreased. Since hydrophobic interaction is vital for the assembly of HBc VLP structure, 
the decreased hydrophobicity of the monomers can largely influence the hydrophobic 
interaction between monomers and further impact on the stability and assembly of 
chimeric HBc VLPs. For HCV core-HBc VLP, the calculated hydrophobicity of HCV 
core-HBc monomer turns to be negative which can explain its sensitivity to the minor 
changes of the environment as it can be in a fragile condition. The different 
hydrophobicity of HCV core-HBc and EBNA1-HBc monomers confirms that the 
impact of the insertion of foreign antigens comes from the nature of antigens, and the 
hydrophobicity of chimeric HBc monomer can be used to reflect the stability of 
chimeric HBc VLP. In addition, RMSD and Rg results confirms our findings that HCV 
core-HBc was less stable in the water environment compared with EBNA1-HBc and 
HBc. These findings in computational protein modelling can be used to guide the design 
of chimeric HBc VLP and optimize the purification and storage conditions to maintain 
its assembled VLP structure. 
4.5 Conclusion 




to HBc VLP on the stability, short and non-structured EBNA1 epitope and long and 
structured HCV core epitopes were employed in our study and two chimeric EBN1-
HBc VLP and HCV core-HBc VLP were expressed and purified for the evaluation. It 
is found that insertion of HCV core epitope had impact on the secondary structure of 
HCV core-HBc which potentially is the reason for the less stability of HCV core-HBc, 
compared with EBNA1-HBc and HBc. Aside this, the tertiary structure and TEM image 
results confirm that the produced chimeric HBc VLPs are in correctly assembled VLP 
structure. In the stability evaluation, HCV core-HBc VLP is found to be sensitive and 
less stable than EBNA1-HBc VLP as minor changes such as temperature and buffer 
condition can lead to irreversible precipitation. EBNA1-HBc VLP shows good stability 
under physical stresses while the stability dropped when applying chemical stresses like 
low pH and high concentration of SDS. According to the protein modelling results, a 
possible explanation for this phenomenon is that after the insertion of HCV core epitope 
to HBc VLP, the hydrophobicity of HCV core-HBc monomer significantly drops as 
well as the hydrophobic interaction between monomers, leading to a relatively fragile 
HCV core-HBc VLP assembly. In contrast, after insertion of EBNA1 epitope, only a 
minor change of hydrophobicity of EBNA1-HBc monomer was found compared with 
wt HBc monomer. The slightly changed surface property can explain the minor 
influence on the morphology of chimeric EBNA1-HBc VLP compared with HBc VLP. 
However, the reduced hydrophobicity could cause the lower resistance against protein 




addition, RMSD and Rg results indicate that after insertion of long and structural HCV 
core epitope, HCV core-HBc was less stable in the water environment compared with 
EBNA1-HBc and HBc without insertion of foreign epitopes. These findings could be 
beneficial to the design and production of chimeric HBc VLP-based vaccines. However, 
further computational protein simulation evaluations such as the binding energy and 
interaction between the monomers and VLP structures of chimeric HBc VLP-based 
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Chapter 5 Immunogenicity evaluation of 
adjuvant-free chimeric Hepatitis B core 
(HBc) virus like particle (VLP) presenting 
Epstein-Barr nuclear antigens 1 (EBNA1) 
epitope 
Abstract 
Epstein-Barr virus (EBV) is regarded as the leading factor of infectious mononucleosis 
and is linked closely with several epithelial and lymphoid cancers. Since no licensed 
vaccine against EBV is developed, there is an urgent need for the development of an 
effective vaccine candidate for treatment of EBV related diseases and cancers. Epstein-
Barr nuclear antigens 1 (EBNA1) is found to be crucial for the maintenance of EBV 
viral genome and its protein expression for survival. Here, virus-like particle (VLP) 
was applied to display EBNA1 epitope (aa: 407-417) for the potential vaccine 
development for protection of EBV infection. Hepatitis B virus core antigen (HBc) VLP 
was selected to carry and display short and non-structural EBNA1 epitope at the N-
terminus. Chimeric EBNA1-HBc VLP was expressed in Escherichia coli (E. coli) 
expression system and purified by ammonium sulphate (AS) precipitation as described 
in Chapter 3. Immunogenicity evaluation results by animal test indicate that adjuvant 




immune response compared with the groups with aluminium hydroxide adjuvant. The 
achieved immune response level is significantly higher than that achieved with only 
EBNA1 peptide. In addition, adjuvant free EBNA1-HBc VLP is proven to have long-
term immunogenicity because of the evidence that vaccinated mice have produced 
epitope specific memory T cells in spleen. It suggests that HBc VLP platform is a 
promising candidate to present EBNA1 epitope and chimeric EBNA1-HBc is 
potentially an effective vaccine candidate for the protection of EBV infection with long-
term protection. 
Key words: Epstein-Barr virus; Virus-like particles; Hepatitis B virus core antigen 






Epstein-Barr virus (EBV) is one of the γ-herpesvirus that is endemic in the world 
population and primarily infects B cells and epithelial cells[1]. Burkitt's lymphoma, 
Hodgkin lymphoma,[2], nasopharyngeal carcinoma, gastric and sporadic carcinoma 
tend to develop in EBV infected individuals[3, 4]. In addition, EBV has been proven to 
be related with the development of cancers such as lymphoid cancers[5], epithelial 
cancers[6] and pediatric leiomyosarcoma[7] by various factors[3]. Investigations have 
been conducted on the study of EBV, and it was found that EBV was able to transform 
cells due to the transactivating feature of Epstein-Barr nuclear antigens (EBNA)[8]. 
Therefore, EBNA have been studied as the antigens for the development of EBV 
vaccines[9-11]. 
In the absence of any commercial vaccines for the treatment of EBV, various vaccine 
candidates based on the capsid proteins of EBV were developed in the last decade 
against EBV infection[1, 9, 10, 12, 13]. However, the effectiveness, safety and long-
term immunogenicity protection against EBV limited the application of these vaccine 
candidates. Epstein-Barr virus nuclear antigen-1 (EBNA1) protein was found in all 
tumours relating to EBV and it was regarded as a marker to identify the cancer cells 
caused by EBV. EBNA1 protein is crucial for the maintenance of EBV genome and 
viral DNA replication by binding with sequence-specific DNA[9]. EBNA1 has been 
reported to be related to cell transformation of EBV, however, the mechanism remains 




for the development of EBV vaccine. 
Virus-like particles (VLPs) are promising candidates for the development of cancer 
vaccine delivery platform in the last decade[15]. Various VLPs from different viruses 
have been studied and evaluated, and now been adopted for the application for carrying 
foreign epitopes[16-18]. VLP-based vaccine platform possesses several benefits to 
develop safe and efficient cancer vaccines[19, 20]. Firstly, its repetitive antigenic 
structure ensures its good ability to present the foreign epitope in a high density and 
trigger high immune response[21, 22]. Secondly, it is a safer vaccine candidate 
compared with the traditional viral based vaccines because of its absence of the viral 
genome, which makes VLP-based vaccines non-infectious[23, 24]. Finally, VLP-based 
vaccines can be expressed and purified efficiently in the bacteria expression system 
with a relatively low cost[25, 26]. 
Taking advantages of the recent success of chimeric virus-like particle (VLP) vaccine 
strategies targeting hepatitis B virus (HBV) and human papillomavirus (HPV) and their 
associated tumours[27, 28], similar chimeric VLP-based vaccines for EBV related 
diseases and cancers could be developed. Among all VLP candidates, Hepatitis B virus 
core antigen (HBc) is the most widely used icosahedral VLPs carrier. These core 
particles are icosahedral nucleocapsids with primarily triangulation number T = 3 or 
T = 4 symmetry, each containing 180 and 240 units of 21 kDa core monomers[29]. In 
many ways, HBc VLPs attracts the researchers’ attention because of its flexibility in 




assembly ability in all known expression systems[30]. Several chimeric HBc VLP-
based vaccines displaying foreign epitopes have been developed against viruses such 
as HCV[31], influenza virus[32] and foot‐and‐mouth disease virus (FMDV)[33]. 
To produce safe and effective vaccines is the ultimate goal to perform successful 
immunotherapy. To improve the immunogenicity, adjuvants are commonly used 
together with Active Pharmaceutical Ingredients (API) to form the vaccines. 
Aluminium adjuvant is one of the popular adjuvants and has been added in the 
commercial HBc VLP vaccines. However, reports have argued about the safety for the 
application of aluminium adjuvant as it may potentially cause post-immunization 
headache, arthralgia and myalgia[34]. In addition, reports have also indicated that 
aluminium adjuvant can improve the Th2 cells derived immune response with increased 
eosinophil and immunoglobulin (Ig) E production leading to the increase of the risk of 
allergy and anaphylaxis[35, 36]. 
In this study, the aim is to construct and evaluate the immunogenicity of a chimeric 
HBc VLP by presenting a short and non-structural antigen, EBNA1 epitope, by HBc 
VLP platform. Short EBNA1 peptide was designed to be fused to the N-terminus of 
HBc VLP to form the recombinant chimeric EBNA1-HBc VLP protein. Optimized 
expression and purification were conducted as described in Chapter 3. In vivo immune 
response of adjuvant free EBNA1-HBc VLP was evaluated compared with EBNA1-
HBc VLP with aluminium adjuvant, HBc VLP and EBNA1 peptide in mice. Long-term 




memory T cells produced in the immunized mice. 
5.2 Materials and Methods 
5.2.1 Expression and purification of EBNA1-HBc VLP 
Chimeric EBNA1-HBc VLP was expressed and purified with the optimized condition 
as described in Chapter 3.  
5.2.2 Immunization schemes 
Female BALB/c mice aged at 6–8 weeks (body weight about 18–20 g) were purchased 
from SPF Biotechnology Co., Ltd. (Beijing, China) and maintained with pathogen-free 
water and food. The animals were randomly divided into 6 groups with 8 animals per 
group. The six groups were 1) control groups: PBS (negative control), Ovalbumin 
(OVA, positive control), EBNA1 peptide group, wt HBc VLP, 2) sample groups: 
EBNA1-HBc VLP without adjuvant, and EBNA1-HBc with aluminium hydroxide 
adjuvant (SERVA Electrophoresis GmbH, Germany) groups. For sample groups, the 
mice were immunized intraperitoneally with 100 μg of samples in 200 μl of sterile PBS 
on days 0, 14, and 28. For EBNA1 peptide group, 5.7 μg of EBNA1 peptide in 200 μl 
of sterile PBS was injected on days 0, 14, and 28. For HBc VLP group, 94 μg of HBc 
VLP in 200 μl of sterile PBS was injected on days 0, 14, and 28. For evaluation of the 
humoral immune response, immune serum was collected 10 days after first and second 
boost. For T-cell proliferation measurement and lymphocytes experiments, mice were 




isolated and stored at -70 ℃. 
5.2.3 ELISA for antibody titer 
Enzyme-linked immunosorbent assay (ELISA) was performed for the detection of 
epitope specific antibody titer. Briefly, 100 μl of HBc VLP and EBNA1 peptide (aa 
407-417) were coated overnight at 4 °C to 96-well plate at 10 μg/ml in 50 mM sodium 
carbonate buffer, pH 9.6. After being blocked with 200 μl of PBS containing 1 % bovine 
serum albumin (BSA) (Sigma-Aldrich, USA) for 2 h at 37°C, 100 μl of serial dilutions 
of sera samples from mice after immunized with EBNA1-HBc VLP with and without 
aluminium adjuvant for 24 and 38 days were added to the plate and incubated for an 
additional 2 h at 37°C. Same volume of serial diluted sera samples from mice after 
immunized with HBc VLP group and EBNA1 peptide group were used as references. 
After being washed three times with PBS containing 0.1 % Tween-20, 100 μl of anti-
mouse IgG conjugated with horseradish peroxidase (Solarbio Life Sciences, China) was 
added at a 1:5,000 dilution. Following 2 h of incubation at 37°C, the plate was washed, 
and 100 μl of 3,3′,5,5′-Tetramethylbenzidine (TMB) single-component substrate 
solution (Sigma-Aldrich, USA) was added for colour development. The colour 
development was stopped by adding 100 μl of 1 M H2SO4. The results were recorded 
in a microplate reader (Perlong, China) at wavelength of 450 nm. The endpoint titers 
were defined as the highest serum dilution that resulted in an absorbance value two 
times more than that of negative-control sera derived from nonimmunized mice. 




evaluate the Th1/Th2 tendency of immune response triggered by produced chimeric 
EBNA1-HBc VLP. Briefly, 100 μl of EBNA1 peptide (aa 407-417) was coated 
overnight at 4°C to 96-well plate at 10 μg/ml in 50 mM sodium carbonate buffer, pH 
9.6 and the plate was divided into two parts. The plate was then blocked with 200 μl of 
PBS containing 1 % bovine serum albumin (BSA) (Sigma-Aldrich, USA) for 2 h at 
37°C. Sera samples after immunized with EBNA1-HBc VLP with and without 
aluminium adjuvant for 38 days were diluted with same ratio at the endpoint. 100 μl of 
diluted sera samples from both groups were added to. After being washed three times 
with PBS containing 0.1 % Tween-20, 100 μl of goat anti-mouse IgG1 and goat anti-
mouse IgG2a (Sigma-Aldrich, USA) were added to the two parts of the plate, 
respectively at a dilution rate of 1:1,000. The plate was washed three times with PBS 
containing 0.1 % Tween-20. After washing, 100 μl of rabbit anti-goat IgG conjugated 
with horseradish peroxidase (Beijing Biosynthesis Biotechnology Co., Ltd., China) was 
added at a 1:1,000 dilution. Following 2 h of incubation at 37°C, the plate was washed, 
and 100 μl of TMB single-component substrate solution (Sigma-Aldrich, USA) was 
added for colour development. The colour development was stopped by adding 100 μl 
of 1 M H2SO4. The results were checked in a microplate reader (Perlong, China) at 
wavelength of 450 nm. 
5.2.4 T-cell proliferation assay 
Murine splenocytes were harvested using red blood cell lysing buffer (Sigma-Aldrich, 




1640 (Gibco, Germany) with the appropriate HBc VLP and EBNA1 peptide at 20 μg/ml. 
Concanavalin A (Sigma-Aldrich, USA) was used as a positive control at 2 μg/ml. The 
plate was then incubated for 48 h before the addition of 10 μl of Cell Counting Kit – 8 
(CCK-8) (Sigma-Aldrich, USA) per well. The absorbance at wavelength of 450 nm was 
recorded by microplate reader (Perlong, China) after 4 h incubation at 37°C. The more 
and faster the cells proliferate, the higher the detected absorbance would be. The results 





A(sample): A450 nm of the sample group with CCK-8 and stimulated with EBNA1 
peptide 





5.2.5 Cytokine test 
For detection of gamma interferon (IFN-γ), interleukin 2 (IL-2), interleukin 4 (IL-4), 
and interleukin 10 (IL-10) cytokines in cell cultures, the spleen cells from the mice 
immunized with EBNA1-HBc VLP with and without aluminium adjuvant were seeded 
in the 24 well plate at 4 x 106 cells/ml. After culturing for 24 and 48 hours, cells and 
culture media were collected and centrifuged at 1000 rpm for 10 min. The supernatants 
were used for cytokine assay. Analysis for the presence of cytokines in cell supernatants 
was performed using the commercial tests OptEIA Mouse IFN-γ, IL-2, IL-4 and IL-10 




Briefly, 96 well plate was coated with 100 µL/well of capture antibody in PBS buffer 
(supplied in the kit). The plate was sealed and incubated overnight at 4°C. Plate was 
washed 3 times with PBS buffer with 0.05 % Tween-20. Wells were blocked with 200 
µL of ELISA/ELISPOT Diluent (1X) and incubated at room temperature for 1 hour. 
After washing with PBS buffer with 0.05 % Tween-20, 2-fold serial dilutions of the 
standards (provided in the kit) to make the standard curve for a total of 8 points. 100 
µL/well of supernatant samples of lymphocyte culture were then added to the 
appropriate wells. 100 µL of ELISA/ELISPOT Diluent (1X) was added to the blank 
well and the plate was sealed and incubated at room temperature for 2 hours. After 
washing for five times with PBS buffer with 0.05 % Tween-20, 100 µL/well diluted 
Detection Antibody (provided in the kit) was added to all wells. The plate was then 
sealed and incubated at room temperature for another 1 hour. 100 µL/well of diluted 
Streptavidin-HRP (provided in the kit) was added after washing plate for five times 
with PBS buffer with 0.05 % Tween-20 and incubate at room temperature for 30 min. 
100 µL/well of 1X TMB Solution was added after five times washing with PBS buffer 
with 0.05 % Tween-20 and incubate at room temperature for 15 minutes for 
colourisation. Finally, 100 µL/well of 1 M H2SO4 was added to each well stop the 
reaction. The absorbance at wavelength of 450 nm was recorded in a microplate reader 
(Perlong, China). 
5.2.6 Lymphocyte activation 




60 h at 37°C in 24 well plate with cell density of 4 × 106 cells/ml before mixing with 
FITC CD4 Monoclonal antibody, PerCP-Cy 5.5 CD8a Monoclonal antibody, APC-
eFluor 780 CD19 Monoclonal antibody and APC CD25 Monoclonal antibody (Thermo 
fisher, USA) at 4 °C. After washing with PBS, fluorescence patterns were analysed 
using a FACSCanto II (BD Biosciences, USA). The percentage of CD25+/CD4+ T cells, 
CD25+/CD8+ T cells and CD25+/CD19+ B cells were recorded and analysed using 
FACSCanto II software. 
5.2.7 Memory T cells activation assay 
Similar to lymphocyte activation assay, splenocytes from immunized mice with and 
without EBNA1 peptide were cultured for 60 h at 37°C in 24 well plate with cell density 
of 4 x 106 cells/ml before mixing with FITC CD4 Monoclonal antibody, PerCP-Cy 5.5 
CD8a Monoclonal antibody, PE CD62L (L-Selectin) Monoclonal Antibody and PE-
Cyanine7 CD44 Monoclonal Antibody, (Thermo fisher, USA) at 4 °C. After washing 
with PBS, fluorescence patterns were analysed using a FACSCanto II (BD Biosciences, 
USA). The percentage of CD44hiCD62Lhi/CD4+ T cells, CD44hiCD62Llow/CD4+, 
CD44hiCD62Lhi /CD8+ T cells and CD44hiCD62Llow/CD8+ T cells were recorded and 
analysed using FACSCanto II software. 
5.2.8 Statistical analysis 
Statistical results were analysed using GraphPad-Prism 6 software (GraphPad Software, 
USA). The values of P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) were considered 




5.2.9 Ethical statement 
This study was approved by the Animal Ethics Committee of Shanxi University of 
Chinese Medicine (Shanxi, China Approval number: 2019LL137). 
5.3 Results 
5.3.1 Humoral response of EBNA1-HBc VLP 
Serum of mice was collected on day 24 and 38 after initial vaccination. The 2nd boost 
resulted in a substantial improvement of EBNA1 specific antibody response (Figure 
5.1). Mice immunized with wt HBc VLP and EBN1 peptide were applied as reference 
groups. As shown in Figure 5.1, anti-EBNA1 specific antibody titers achieved after 
2nd boost vaccinated with chimeric EBNA1-HBc VLP with and without adjuvant were 
significantly higher than that after 1st boost. The anti-EBNA1 specific antibody titer of 
EBNA1-HBc VLPs with and without adjuvant reached 2.7 × 105 and 3.1 × 105 after 
2nd boost, respectively. The EBNA1 specific humoral immune response vaccinated 
with chimeric EBNA1-HBc VLP group improved significantly compared with the 
group vaccinated with only EBNA1 peptide where the anti-EBNA1 antibody titer was 
8.9 × 103 after 2nd boost. The anti-EBNA1 specific antibody titer of EBNA1-HBc VLP 
group with adjuvant showed only a slight improvement compared with that of adjuvant 
free group. In addition, the insertion of the EBNA1 epitope to the HBc VLP caused a 
dramatic reduction of HBc VLP specific response where the antibody titer was around 
4 × 105. The reduced carrier specific immune response could be one merit for the 




immune response is not the effective response. However, the total antibody titer value 
achieved by chimeric EBNA1-HBc VLP groups was found to be lower compared with 
total antibody titer of wt HBc VLP group. This could be resulted from the carrier 
induced epitopic suppression (CIES) effect[37].  
 
Figure 5.1 Induction of antibodies (Ab) in mice by chimeric HBc-derived VLPs. Shown are 
antibody titers in pools of sera from mice at day 24 (1st boost) and at day 38 (2nd boost) after 
the first immunization. Titers in specimens were determined on plate coated with HBc VLP 
and EBNA1 peptide. Antibody titers of mice treated with EBNA1 peptide and HBc VLP were 
used as references. Data are expressed as mean ± SD (n=8) (*p<0.05; **p<0.01; ***p<0.001). 
5.3.2 Cellular immune response and cytokine assay 
The proliferations of T-cells of mice vaccinated with chimeric EBNA1-HBc VLP with 
and without adjuvant were examined to demonstrate the cellular immune response level 
after stimulated with EBNA1 peptide and HBc VLP in vitro at day 38 after the first 
immunization. As shown in Figure 5.2, T-cell proliferations of both chimeric EBNA1-
HBc VLP groups with and without adjuvant were detected against EBNA1 peptide. 




without adjuvant groups both improved more than three folds compared with the group 
vaccinated with EBNA1 peptide. However, the total proliferation index of these two 
groups were significantly lower compared with HBc VLP groups because of the CIES 
effect[37]. With the addition of adjuvant, the proliferation index of EBNA1-HBc VLP 
with adjuvant group was slightly higher than that of adjuvant free group. Figure 5.3 
illustrates the direct evaluation of the Th1 cell-derived cytokines IFN-γ, IL-2, and IL-
10 after stimulation with EBNA1 peptide and HBc VLP with 24 h and 48 h. Culture of 
48 h showed significantly higher levels of all cytokines and it is possible because more 
lymphocytes were proliferated and activated. Among Th1 cell derived cytokines, 
production of IL-2 was relatively reduced compared with production of IFN-γ and IL-
10. Produced IFN-γ by adjuvant free EBNA1-HBc VLP and EBNA1-HBc VLP with 
adjuvant reached 63.6 pg/ml and 73.1 pg/ml, respectively, after being stimulated by 
EBNA1 peptide for 48 h and produced IL-10 reached 570 pg/ml and 515 pg/ml, 
respectively while produced IL-2 only reached 17.3 pg/ml and 26 pg.ml, respectively. 
Th2 cell-derived cytokine, IL-4 was also examined. The production of IL-4 was still 
detectable; however, the production of IL-4 was lower than all Th1 cell derived 
cytokines. The produced IL-4 by adjuvant free EBNA1-HBc VLP and EBNA1-HBc 
VLP with adjuvant were 19.1 pg/ml and 21.3 pg/ml, respectively, after being stimulated 
by EBNA1 peptide for 48 h. In addition, only slightly difference was detected between 
the produced cytokines by adjuvant free EBNA1-HBc VLP and the group with 





Figure 5.2 T-cell proliferation after immunization of mice by EBNA1-HBc VLPs, wt HBc 
VLP and EBNA1 peptide. PI were measured in response to stimulation of T cells with HBc 
VLP and EBNA1 peptide. The error bars indicate standard deviations. Proliferation results for 
T-cells of mice treated with EBNA1 peptide and HBc VLP were used as references. Data are 





Figure 5.3 Cytokines produced by T cells after immunization of mice with EBNA1-HBc VLPs. 
Cell supernatants were removed and analysed at 24 h and 48 h for IFN-γ(a), IL-2 (b), IL 4 (c) 
and IL-10 (d) production after stimulation with HBc VLP and EBNA1 peptide. Data are 
expressed as mean ± SD (n=8) (*p<0.05; **p<0.01; ***p<0.001). 
5.3.3 IgG isotype of chimeric EBNA1-HBc VLP 
Specific isotypes of antibodies of mice vaccinated with EBNA1-HBc VLP with and 
without aluminium adjuvant were analysed and shown in Figure 5.4. Both groups of 
EBNA1-HBc VLP with and without adjuvant showed a predominantly EBNA1 specific 
IgG1 antibody response, indicating that EBNA1-HBc VLP has the tendency of Th2 
cells derived immune response. In addition, a slightly improved tendency of Th2 cells 






Figure 5.4 IgG isotype distribution in serum collected 10 days after 2nd boost vaccination of 
mice by chimeric EBNA1-HBc VLP with and without adjuvant. EBNA1 peptide and wt HBc 
VLP groups were used as references. The red line depicts the equivalent distribution of IgG2a 
and IgG1 isotypes. 
5.3.4 Lymphocyte activation 
CD25 marker is the activation marker for T cells and B cells, indicating the activation 
level of lymphocytes after being stimulated with specific antigens. To further review 
the immune response of chimeric EBNA1-HBc VLP, the percentage of activated 
lymphocytes was evaluated in CD4+ T cells, CD8+ T cells and CD19+ B cells using the 
flow cytometry (Figure 5.6). As shown in Figure 5.5, both chimeric EBNA1-HBc VLP 
with and without adjuvant groups showed a significant increase in the percentage of 
activated CD4+ T cells and CD19+ B cells. The percentage of CD4+ T cells and CD19+ 




and 3.7 %, respectively. However, the increase of the activated CD8+ T cells was minor, 
suggesting that the cellular immune response triggered by the adjuvant free EBNA1-
HBc VLP is potentially lower than the humoral immune response. After adding the 
adjuvant, the cellular immune response level improved slightly compared with the one 
without adjuvant. The results suggest that when displaying EBNA1 epitope on the HBc 
VLP platform, a stronger humoral immune response than the cellular immune response 
would be achieved, and this explained high level of EBNA1-specific antibody titer. 
 
Figure 5.5 Activation of CD19+ B cells (a), CD4+ T cells (b) and CD8+ T cells (c) of 
lymphocytes after immunization of mice with EBNA1-HBc VLPs stimulated by EBNA1 





Figure 5.6 Flow cytometry of CD25 marker in CD19+ B cells, CD4+ T cells and CD8+ T cells 
of lymphocytes after immunization of mice with EBNA1-HBc VLPs stimulated by EBNA1 
peptide. 
5.3.5 Memory T cells  
Long-term protection is the primary feature for a successful vaccine development. To 
evaluate the long-term protection property of constructed vaccine samples, the 
percentage of memory CD4+ and CD8+ T cells were evaluated. CD44 and CD62L are 
two markers on the surface of memory T cells. On the surface of central memory T 
cells (TCM cells), CD44 and CD62L makers are highly expressed, while on the surface 




expressed in low level. The surface markers of CD4+ and CD8+ T cells of the mice 
vaccinated with chimeric EBNA1-HBc VLP were evaluated with flowcytometry 
(Figure 5.8). As shown in Figure 5.7, a significant decrease in the percentage of CD4+ 
and CD8+ TCM cells was detected after vaccinated with EBNA1-HBc VLP with and 
without adjuvant. The percentage of CD4+ and CD8+ TEM cells were increased after 
being stimulated with specific epitope. The percentage of CD4+ and CD8+ TCM cells 
induced by adjuvant free EBNA1-HBc VLP decreased from 2 % and 3.5 % to 0.9 % 
and 1.1 %, respectively, and the percentage of CD4+ and CD8+ TEM cells increased from 
12.8 % and 15.8 % to 26.5 % and 22 %, respectively. This demonstrates the successful 
production of the central memory T cells targeting to specific epitope after immunized 






Figure 5.7 Measurement of central (CD44hiCD62Lhi)/effector (CD44hiCD62Llow) memory 
CD4+ and CD8+ T cells. Splenocytes were harvested on day 38 after the first immunization 
and stimulated in vitro by EBNA1 peptide for 60 h. The frequency of CD44hiCD62Lhi/CD4+ T 
cells, CD44hiCD62Llow/CD4+ T cells, CD44hiCD62Lhi/CD8+ T cells, and 
CD44hiCD62Llow/CD8+ T cells were measured by flow cytometry. Data are expressed as mean 
± SD (n=3) (*p<0.05; **p<0.01; ***p<0.001). 
 





In vivo immunogenicity of EBNA1-HBc VLP with and without addition of aluminium 
adjuvant were evaluated through various experiments. Both EBNA1-HBc groups with 
and without adjuvant elicit significantly higher EBNA1 specific humoral immune 
response compared with the group immunized with only EBNA1 peptide. In addition, 
the epitope specific antibody titer level achieved by adjuvant free EBNA1-HBc VLP 
reached 105 and this is higher or similar to other reported EBV vaccine candidates such 
as chimeric EBVgp350/220 VLP produced by Ogembo’s research group with the 
antibody titer level of 102 without adjuvant and chimeric gp350-HBc VLP produced by 
Zhang’s group with the antibody titer level of 105 with addition of aluminium 
adjuvant[38, 39]. When analysing the influence of adjuvant on the immune response, 
adjuvant free EBNA1-HBc VLP induced a similar immune response in mice compared 
with the group with aluminium adjuvant. This may be because of the self-adjuvant 
property of HBc VLP[40]. The cellular immune response results also indicate that 
adjuvant free EBNA1-HBc VLP induced three times higher cellular immune response 
compared with EBNA1 peptide and no significant difference was found between 
adjuvant free group and the group with aluminium adjuvant. In addition to examination 
of the immune response level of adjuvant free EBNA1-HBc VLP, predominant immune 
response type was also examined by evaluating the IgG isotype ratio. As a result, both 
EBNA1-HBc VLP with and without aluminium adjuvant elicited predominant humoral 




for humoral immune response because of the propensity of aluminium adjuvant to 
induce IL-1[41]. These results prove that adjuvant free EBNA1-HBc VLP is able to be 
applied as an effective vaccine candidate to trigger strong epitope specific humoral and 
cellular immune response. 
To further evaluate the immune response after being stimulated with EBNA1 peptide, 
the activation of T cells and B cells was examined for EBNA1-HBc VLP with and 
without adjuvant groups. CD25 maker was used to prove the successful activation of T 
cells and B cells. CD 25 is the alpha chain of the trimeric IL-2 receptor and is commonly 
used as the marker to detect the activation of T cells and B cells[42, 43]. Both EBNA1-
HBc VLP groups with and without aluminium adjuvant demonstrate a significant 
increase of the percentage of activated CD4+ cells and CD19+ B cells after stimulation 
with EBNA1 peptide where the percentage of CD4+ cells and CD19+ B cells increased 
by 1.7 % and 2.7 %, respectively, while the percentage of activated CD8+ T cells 
increased slightly. This is for the reason that EBNA1-HBc predominately induces Th2 
derived humoral immune response as discussed previously.  
In addition to the evaluation of immunogenicity and activation of lymphocytes, EBNA1 
specific long-term immunogenicity was detected by measuring the central memory T 
cells. Long term protection is regarded as the ultimate goal for a successful 
vaccination[44]. There are two types of memory T cell that are responsible for long-
term immunogenicity, central memory T cells (TCM cells) and effective memory T cells 




have a shorter lifetime but perform rapid respond[45]. It is also reported that after 
stimulation with antigen, TCM cells could differentiate into TEM cells[46]. On the surface 
of TCM cells, CD44 and CD62L makers are highly expressed, while on the surface of 
TEM cells, CD44 maker is highly expressed and CD62L is expressed in low level. In 
this case, CD44 and CD62L marker were detected in our study to evaluate the density 
of memory T cells among lymphocytes in the spleen of immunized mice. EBNA1 
peptide was used as the stimulator to examine the specific response of memory T cells 
against EBNA1 peptide. Results indicate that mice immunized with both adjuvant free 
EBNA1-HBc VLP group and EBNA1-HBc VLP with aluminium adjuvant group are 
able to produce CD4+ TCM cells, CD4
+ TEM cells, CD8
+ TCM cells and CD8
+ TEM cells. 
After being stimulated with EBNA1 peptide, the percentage of CD4+ TCM cells and 
CD8+ TCM cells of both adjuvant free EBNA1-HBc VLP and EBNA1-HBc with 
aluminium adjuvant group decreased significantly. This confirms that the produced TCM 
cells have a specific response against EBNA1 peptide and also potentially demonstrates 
the long-term protection ability of EBNA1-HBc VLP. No significant difference was 
found between adjuvant free EBNA1-HBc VLP group and EBNA1-HBc VLP with 
aluminium adjuvant group. In addition, after stimulation with EBNA1 peptide, the 
percentage of CD4+ TEM cells increased more than the increase of the percentage of 
CD8+ TEM cells. This matches with our previous finding that EBNA1-HBc VLP elicits 





In our study, EBNA1 epitope is successfully presented using HBc VLP platform for the 
first time. The chimeric EBNA1-HBc was expressed and purified according to previous 
work in Chapter 3. In vivo immunogenicity evaluation demonstrates that adjuvant free 
EBNA1-HBc VLP is able to elicit strong EBNA1 specific humoral and cellular immune 
response due to its self-adjuvant property with the antibody titer level of 105 and three 
folds of T-cell proliferation compared with EBNA1 peptide group. This property 
potentially ensures that adjuvant free EBNA1-HBc VLP is able to be applied as an 
effective vaccine candidate for the protection of EBV infection. In addition, adjuvant 
free EBNA1-HBc VLP also shows long-term protection property as the mice 
vaccinated with EBNA1-HBc VLP can successfully produce epitope specific memory 
T cells and the activation of these memory T cells after stimulation with EBNA1 
peptide is confirmed. These findings demonstrate that HBc VLP platform is promising 
to present short and non-structural antigen like EBNA1 epitope as an adjuvant free 
vaccine candidate to elicit epitope specific strong and long-lasting immune response. 
However, further EBV neutralization assay is needed to confirm that adjuvant free 
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Chapter 6 Immunogenicity evaluation of 
chimeric hepatitis B core (HBc) virus-like 
particle (VLP) displaying Hepatitis C virus 
core (HCV core) epitope 
Abstract 
Hepatitis C virus (HCV) is regarded as the cause for the chronic liver diseases leading 
to a high risk of liver cancer, however, there is no commercial HCV vaccines in the 
market yet. Production of effective and long-term protective HCV vaccine is necessary. 
HCV core is the most highly conserved region of the translated HCV genome, making 
it a promising epitope candidate in the HCV vaccine development. In this project, long 
and α-helix structured HCV core epitope (aa: 10-53) was inserted at the N-terminus of 
HBc VLP to form chimeric HCV core-HBc VLP. Designed HCV core-HBc was 
expressed and purified in the Escherichia coli (E. coli) expression system under 
optimized conditions as described in Chapter 3. For in vivo immunogenicity evaluation, 
adjuvant free HCV core-HBc VLP is proven to elicit strong epitope specific immune 
response by animal test. A tendency of Th1 cell derived cellular immune response was 
detected in the mice immunized with adjuvant free chimeric HCV core-HBc VLP, 
while another chimeric HBc VLP, EBNA1-HBc, elicits predominant humoral immune 




the immune response type for HCV core-HBc VLP by improving the epitope specific 
humoral immune response and suppress the cellular immune response. Finally, similar 
to EBNA1-HBc VLP, specific memory T cells were detected in the mice after being 
immunized with HCV core-HBc VLP. This proves that HCV core-HBc VLP obtain the 
ability to induce long-term immunogenicity in vivo. In conclusion, HBc VLP platform 
is proven to be able to present long and structural antigen and HCV core-HBc VLP is 
potentially a promising candidate for the treatment of HCV infection. 
Key words: Hepatitis C virus; Virus-like particles; Hepatitis B virus core antigen 





Liver cancer is a malignant tumour that grows in the liver in three different types 
including hepatocellular carcinoma (HCC), cholangiocarcinoma, and angiosarcoma[1]. 
It has been reported that chronic infection with hepatitis C virus and hepatitis B virus 
could lead to the development of HCC[2, 3]. Recently, vaccines based on HBV was 
developed and among them, Engerix-B (ENG) and Recombivax HB (REC) are the two 
FDA-approved vaccines that prevent the infection of HBV. However, there is no 
reported HCV vaccines for liver cancer treatment yet. 
Based on the process for the successful development of hepatitis B virus and human 
papillomavirus vaccines[4, 5], recombinant chimeric virus-like particle (VLP) based 
vaccines for HCV related diseases and cancers could be a promising approach to 
develop effective vaccines against HCV. Virus-like particles (VLPs) have been proven 
to be one of the candidates for the development of cancer vaccine delivery platform in 
last decade[6]. Various VLPs from different viruses have been studied and evaluated to 
be adopted for presenting foreign epitopes[7-9].  
Hepatitis B virus core antigen (HBc) is one of the most popular VLP carriers that have 
been developed and has been regarded as the most flexible model for foreign peptides 
presentation in the last decade[10]. HBc VLP has been developed as the promising 
vaccine platform for presenting foreign epitopes due to its high-level synthesis and 
efficient self-assembly in all expression system[11]. In the application of HBc VLP 




chosen as they are considered to have less impact on the structure and stability of 
chimeric HBc VLPs[12]. Several chimeric HBc VLPs have been developed by using 
HBc VLP to present short epitopes such as SP55 (PDSRESLAWQTATNP) and SP70 
(YPTFGEHKQEKDLEY) epitope of EV71[13] and HCC epitopes MAGE-1(278-
286aa), MAGE-3(271-279aa), AFP1 (158-166aa) or AFP2 (542-550aa)[14]. However, 
challenges for soluble expression of these designed chimeric HBc VLPs remained. In 
Chapter 5, Hepatitis B core virus like particle (HBc VLP) is able to present short and 
non-structural antigen with stable assembled VLP structure and elicit strong and long-
term immune response against the specific antigen. Recently, several strategies have 
been developed to improve the ability of HBc VLP to present large foreign antigen 
sequence and these strategies includes the SplitCore[15], the use of a non-covalent 
“binding-tag” peptide[16], and the tandem core technology[17]. However, all these 
strategies focus on the insertion of foreign epitopes in the major immunodominant 
region (MIR) of HBc and there is no report about the study for insertion of large foreign 
antigens at N-terminal of HBc VLP yet. 
In this chapter, HCV core epitope (aa 10-53) was designed to fused at the N-terminus 
of HBc VLP for the evaluation. HCV core was reported to be involved in the activation 
of several cellular signalling pathways of HCV. Moreover, HCV core plays a crucial 
role in the regulation of the gene expression of HCV leading to HCC[18]. This makes 
HCV core antigen to be a promising target for the treatment of HCV related diseases 




acids including 12 positively charged amino acids and it also contains the structure of 
α-helix. The designed recombinant chimeric HCV core-HBc VLP was expressed using 
optimized E. coli expression system and purified with optimized ammonium sulphate 
precipitation process as described in Chapter 3. In vivo immunogenicity of chimeric 
HCV core-HBc VLP with and without adjuvant was evaluated to investigate the 
performance of chimeric HBc VLP when presenting long and structural antigen on the 
surface. In addition, long-term immunogenicity of chimeric HCV core-HBc VLP was 
examined by the measurement of memory T cells. 
6.2 Materials and Methods 
6.2.1 Expression and purification of HCV core-HBc VLP 
Chimeric HCV core-HBc VLPs were expressed and purified with the optimized 
condition as described in Chapter 3.  
6.2.2 Immunization scheme and immunogenicity evaluation 
Similar to the scheme in Chapter 5, female BALB/c mice aged at 6–8 weeks (body 
weight about 18–20 g) were purchased from SPF Biotechnology Co., Ltd, (Beijing, 
China) and maintained with pathogen-free water and food. The animals were randomly 
divided into 6 groups for 8 animals per group. The six groups were 1) control groups: 
PBS (negative control), OVA (positive control), HCV core peptide group, wt HBc VLP 
and 2) sample groups: HCV core-HBc VLP without adjuvant, and HCV core-HBc with 




sample group, the mice were immunized intraperitoneally with 100 μg of samples in 
200 μl of sterile PBS on days 0, 14, and 28. For HCV core peptide group, 19.4 μg of 
HCV core peptide in 200 μl of sterile PBS was injected on days 0, 14, and 28. For HBc 
VLP group, 80.6 μg of HBc VLP in 200 μl of sterile PBS was injected on days 0, 14, 
and 28. For evaluation of the humoral immune response, immune serum was collected 
10 days after first and second boost. For T-cell proliferation measurement and 
lymphocytes experiments, mice were sacrificed, and spleens were obtained at day 38 
after the first immunization. Sera were isolated and stored at -70 ℃ until use. The 
design and progress of immunogenicity evaluation of HCV core-HBc VLP including 
ELISA for antibody titer, T-cell proliferation assay, Cytokine test, Lymphocyte 
activation evaluation, and Memory T cells activation assay were the same as described 
in Chapter 5. 
6.2.3 Statistical analysis 
Statistical results were analysed using GraphPad-Prism 6 software (Graph- Pad 
Software, USA). The values of P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) were 
considered statistically significant between the experimental groups, respectively. 
6.2.4 Ethical statement 
This study was approved by the Animal Ethics Committee of Shanxi University of 





6.3.1 Humoral response in mice 
Serum of mice vaccinated with HCV core-HBc VLP was collected on day 24 and 38 
after initial immunization for immunogenicity evaluation. Reference groups were 
immunized with wt HBc VLP and HCV core peptide. As shown in Figure 6.1, the 2nd 
boost of vaccination resulted in a significant improved HCV core specific antibody titer 
of HCV core-HBc VLP groups with and without adjuvant compared with HCV core 
peptide group. The epitope specific antibody titer achieved by adjuvant free HCV core-
HBc was 9.1 × 104 after 2nd boost while the antibody titer achieved by the group with 
aluminium adjuvant achieved by 2.9 × 105. This suggested that aluminium adjuvant 
potentially have large improvement for the humoral immune response of HCV core-
HBc VLP. However, HBc VLP specific antibody titers were detected in both HCV 
core-HBc VLP groups with and without adjuvant. This indicated that when presenting 





Figure 6.1 Induction of antibodies in mice by chimeric HBc-derived VLPs. Shown are antibody 
titers in pools of sera from eight animals at day 24 (1st boost) and at day 38 (2nd boost) after 
the first immunization. Titers in specimens were determined on plate coated with HBc VLP 
and HCV core peptide. Antibody titers of mice treated with HCV core peptide and HBc VLP 
were used as references. Data are expressed as mean ± SD (n=8) (*p<0.05; **p<0.01; 
***p<0.001). 
6.3.2 Cellular immune response and cytokine assay 
There are specific antigen receptors on the surface of B cells and T cells. With this 
property, lymphocytes proliferated by the stimulation of specific antigens, and the 
proliferation of lymphocytes was used to evaluate the cellular immune response of the 
vaccines[19]. Lymphocytes of mice immunized with chimeric HCV core-HBc VLP 
with and without adjuvant demonstrated detectable proliferation after being stimulated 
with HCV core peptide and HBc VLP in vitro at day 38 after the first immunization 
(Figure 6.2). Both chimeric HCV core-HBc VLPs with and without adjuvant groups 




compared with the group immunized with HCV core peptide, where adjuvant free HCV 
core-HBc group achieved around 6 times of the T-cell proliferation and the group with 
adjuvant achieved around three times of T-cell proliferation compared with HCV core 
peptide group. 
 
Figure 6.2 Lymphocyte proliferation after immunization of mice by HCV core-HBc VLPs, wt 
HBc VLP and HCV core peptide. PI were measured in response to stimulation of T cells with 
HBc VLP and HCV core peptide. The error bars indicate standard deviations. Proliferation 
results for T-cells of mice treated with HCV core peptide and HBc VLP were used as references. 





Figure 6.3 Cytokines produced by T cells after immunization of mice with HCV core-HBc 
VLPs. Cell supernatants were removed and analysed at 24 h and 48 h for IFN-γ(a), IL-2 (b), IL 
4 (c) and IL-10 (d) production after stimulation by HBc VLP and HCV core peptide. Data are 
expressed as mean ± SD (n=8) (*p<0.05; **p<0.01; ***p<0.001). 
Figure 6.3 illustrates the detected concentration of the Th1 cell-derived cytokines IFN-
γ, IL-2, and IL-10 after stimulation with HCV core peptide and HBc VLP for 24 h and 
48 h. The observed results matched with previous lymphocytes proliferation 
examination. All cytokine expression levels were increased after 48 h culture compared 
with the one with 24 h culture due to the proliferation and activation of lymphocytes 




cytokines, the detected amount of IL-2 was relatively low (23.7 pg/ml for adjuvant free 
group and 11.2 pg/ml for the group with adjuvant) compared with that of IFN-γ (119.8 
pg/ml for adjuvant free group and 73.6 pg/ml for the group with adjuvant) and IL-10 
(620 pg/ml for adjuvant free group and 674.5 pg/ml for the group with adjuvant). Th2 
cell-derived cytokine IL-4 were also measured, and the amount of IL-4 was detectable, 
but much lower than all Th1 cell-derived cytokines (10.3 pg/ml for adjuvant free group 
and 19.3 pg/ml for the group with adjuvant). After the addition of adjuvant, the detected 
Th1 cell-derived cytokines IFN-γ and IL-2 were lower than those of adjuvant free group, 
while the detected amount of Th2 cell-derived cytokine, IL-4 was slightly higher. This 
suggests that the aluminium adjuvant had the potential to regulate the immune response 
of chimeric HCV core-HBc VLP to a Th2 cell derived immune response and potentially 




6.3.3 IgG isotype of HCV core-HBc VLP 
 
Figure 6.4 IgG isotype distribution in serum collected 10 days after 2nd boost vaccination of 
mice by HCV core-HBc VLP with and without adjuvant. The red line depicts the equivalent 
distribution of IgG2a and IgG1 isotypes. 
The IgG isotype in the sera of mice immunized with HCV core-HBc VLP with and 
without adjuvant was examined using ELISA. HCV core peptide and wt HBc VLP 
groups were used as references. As shown in Figure 6.4, both reference groups showed 
a IgG2a/IgG1 ratio at around 1. Adjuvant free HCV core-HBc VLP group showed a 
predominated HCV core specific IgG2a in the immunized mice. This indicates that 
adjuvant free HCV core-HBc VLP elicited predominated Th1 cell derived immune 
response in vivo. After addition of aluminium adjuvant, it was found that the 
predominated IgG type changed to IgG1 which represents a predominated Th2 cell 
derived immune response. This finding matches with our previous finding in the 




induced immune response still existed and the carrier specific immune response 
remained as predominated Th2 cell derived immune response. 
6.3.4 Lymphocyte activation 
To further review the immune response of chimeric HCV core-HBc VLP, the 
percentage of activated lymphocytes was examined in CD4+ T cells, CD8+ T cells and 
CD19+ B cells using the flowcytometry (Figure 6.6). CD25 marker was applied as the 
active marker for the detection[20]. As shown in Figure 6.5, chimeric HCV core-HBc 
VLP with and without adjuvant groups showed a significant increase in the percentage 
of activated CD19+ B cells, CD4+ T cells and CD8+ T cells after being stimulated with 
HCV core peptide. The percentage of CD19+ B cells, CD4+ T cells and CD8+ T cells 
induced by adjuvant free HCV core-HBc increased from 0.7 %, 0.5 % and 1.2 % to 
2.5 %, 6.1 % and 5.5 %, respectively. This indicates that chimeric HCV core-HBc VLP 
potentially induced strong cellular immune response. After adding the adjuvant, the 
percentages of activated T cells were found to be lower than the adjuvant free group 
while the percentages of activated B cells was higher. 
 
Figure 6.5 Activation of CD19+ B cells (a), CD4+ T cells (b) and CD8+ T cells (d) of 
lymphocytes after immunization of mice with HCV core-HBc VLPs stimulated by HCV core 





Figure 6.6 Flow cytometry of CD25 marker in CD19+ B cells, CD4+ T cells and CD8+ T cells 
of lymphocytes after immunization of mice with HCV core-HBc VLPs stimulated by HCV core 
peptide. 
 
6.3.5 Memory T cells 
Long-term protection is the ultimate goal for successful vaccines. To evaluate the long-
term protection property of HCV core-HBc VLP, the percentage of memory CD4+ and 
CD8+ T cells were evaluated. CD44 and CD62L are two major markers on the surface 
of memory T cells and have been applied in our previous work. On the surface of central 
memory T cells (TCM cells), CD44 and CD62L makers are highly expressed, while on 




CD62L is expressed in low level. The surface markers of CD4+ and CD8+ T cells of the 
mice vaccinated with HCV core-HBc VLP were evaluated with flowcytometry (Figure 
6.8). As shown in Figure 6.7, the percentage of CD4+ and CD8+ TCM cells induced by 
adjuvant free HCV core-HBc VLP decreased from 3 % and 6.8 % to 1 % and 2.6 %, 
respectively, and the percentage of CD4+ and CD8+ TEM cells increased from 12 % and 
17.6 % to 34.5 % and 27.4 %, respectively. It is also observed that CD8+ TCM cells 
produced in adjuvant free HCV core-HBc VLP group was higher than that produced by 
the group with aluminium adjuvant. This demonstrates the successful production of the 
central memory T cells targeting against HCV core peptide after immunized with 






Figure 6.7 Measurement of central (CD44hiCD62Lhi)/effector (CD44hiCD62Llow) memory 
CD4+ and CD8+ T cells. Splenocytes were harvested on day 38 after the first immunization and 
stimulation in vitro by HCV core peptide for 60 h. The frequency of CD44hiCD62Lhi/CD4+ T 
cells, CD44hiCD62Llow/CD4+ T cells, CD44hiCD62Lhi/CD8+ T cells, and 
CD44hiCD62Llow/CD8+ T cells were measured by flow cytometry. Data are expressed as mean 
± SD (n=3) (*p<0.05; **p<0.01; ***p<0.001). 
 





Hepatitis C virus (HCV) is regarded as the cause for chronic infection leading to the 
liver cancers. To treat HCV infection, an effective preventive vaccine with long-term 
protection is required. However, up to date, there is no commercial HCV vaccine 
available yet. In our project, the aim is to construct an effective and long-lasting 
preventive HCV vaccine by presenting the long and structural HCV core epitope using 
HBc VLP platform to form chimeric HCV core-HBc VLP. HCV core-HBc VLP 
proteins were expressed and purified under optimized conditions as described in 
Chapter 3. The purified HCV core-HBc VLP proteins were dialysed against 20 mM 
PB, pH 7.4 for evaluation of in vivo immunogenicity. 
In the immunogenicity evaluation by animal test, both HCV core-HBc VLP groups with 
and without adjuvant induced significantly improved HCV core specific antibody titer 
compared with HCV core peptide group after second boost. However, the HCV core 
specific antibody titer achieved by HCV core-HBc VLP group with aluminium 
adjuvant was significantly higher than that of adjuvant free HCV core-HBc VLP group. 
However, the achieved epitope specific antibody titer level of 9.1 × 104 by adjuvant 
free group is still higher than other reported HCV vaccine candidates produced by 
Sominskaya’s group (antibody titer less than 2,000)[21] and is similar to a recent 
reported HCV VLP containing the HCV core and the E1 and E2 envelope glycoproteins 
produced by Christiansen’s group (antibody titer level at around 104)[22]. In the cellular 




higher cellular immune response compared with HCV core peptide group and twice 
higher cellular immune response compared with HCV core-HBc VLP with adjuvant 
group. The lower cellular immune response achieved by HCV core-HBc VLP with 
adjuvant group indicates that aluminium adjuvant may cause the suppression of cellular 
immune response induced by HCV core-HBc. These findings in humoral and cellular 
immune response induced by HCV core-HBc VLP groups indicate that the immune 
response type of HCV core-HBc VLP can be largely influenced by the addition of 
aluminium adjuvant while it has minor influence on the immune response type of our 
previously produced EBNA1-HBc VLP in Chapter 5. For HCV core-HBc VLP, 
aluminium adjuvant can significantly suppress the cellular immune response while also 
significantly improve the humoral immune response of chimeric HCV core-HBc VLP 
at the same time. Cytokine assay results also indicate that a higher level of cellular 
immune response related cytokines was produced in adjuvant free HCV core-HBc VLP 
group compared with the group with aluminium adjuvant. These findings match with 
IgG isotype assay where predominated Th2 cell derived HCV core specific humoral 
immune response was found for HCV core-HBc VLP group with aluminium adjuvant 
and adjuvant free HCV core-HBc VLP group induced predominated Th1 cell derived 
HCV core specific cellular immune response[23]. In addition, similar to our previous 
finding in Chapter 5, carrier induced epitopic suppression (CIES) effect[24] is also 
found in the immune response induced by both HCV core-HBc VLP groups with and 




were lower compared with that achieved by wt HBc VLP group. Report has suggested 
that higher coupling densities, repeated injections or higher doses of vaccination could 
be applied to solve this issue[24]. Chimeric HCV core-HBc VLP showed a weaker self-
adjuvant effect compared with other reported vaccines[9, 25, 26] and also our produced 
EBNA-HBc VLP. This could be caused by the impact on the structure and the property 
of VLPs after insertion of HCV core epitope. 
The activation of T cells and B cells of HCV core-HBc VLP with and without adjuvant 
groups after stimulation with HCV core peptide was examined to further evaluate the 
immune response induced by HCV core-HBc VLPs. Similar to our previous work, 
CD25 maker was used the activation marker for T cells and B cells[20, 27]. Both HCV 
core-HBc VLP groups with and without aluminium adjuvant observed a significant 
increase of the percentage of activated CD19+ B cells, CD4+ cells and CD8+ T cells 
after stimulation with HCV core peptide. High percentage of activated CD4+ T cell and 
CD8+ T cells were achieved by 6.1 % and 5.5 %, respectively. This matches with our 
previous findings that adjuvant free HCV core-HBc VLPs elicits predominated cellular 
immune response and it also proves that chimeric HCV core-HBc VLP is promising to 
induce strong epitope specific immune response. 
Finally, HCV core specific long-term immunogenicity was detected by measuring the 
central memory T cells. Similar to our previous work in Chapter 5, two types of 
memory T cells, central memory T cells (TCM cells) longer lifetime but the slower 




were measured using flowcytometry[28]. HCV core peptide was used as the stimulator 
to examine the specific response of memory T cells against HCV core peptide. Results 
indicate that mice immunized with both HCV core-HBc VLP groups with and without 
aluminium adjuvant group are able to produce CD4+ TCM cells, CD4
+ TEM cells, CD8
+ 
TCM cells and CD8
+ TEM cells. Higher percentage of CD8
+ TCM cells was observed in 
adjuvant free HCV core-HBc VLP group as it triggers predominated Th1 cell derived 
cellular immune response. After being stimulated with HCV core peptide, the 
percentage of CD4+ TCM cells and CD8
+ TCM cells of both HCV core-HBc VLP groups 
with and without aluminium adjuvant decreased. In addition, higher percentage of 
CD8+ TCM cells (6.8 %) produced with adjuvant free HCV core-HBc VLP vaccinated 
mice was detected compared with that (3.5 %) produced by adjuvant free EBNA1-HBc 
VLP vaccinated mice as described in Chapter 5. This could be explained by the 
stronger cellular immune response of HCV core-HBc VLP compared with EBNA1-
HBc VLP. Memory T cell assay result demonstrates that the produced TCM cells have 
specific response against HCV core peptide and indicates that chimeric HCV core-HBc 
VLP obtain the long-term protection ability against HCV core peptide. 
6.5 Conclusion 
In this chapter, 44-mer HCV core epitope with an α-helix was successfully fused into 
the N-terminus of HBc VLP to form chimeric HCV core-HBc VLP. The expression 
and purification process were followed by our previous work in Chapter 3. High purity 




In vivo immunogenicity evaluation demonstrates that adjuvant free HCV core-HBc 
VLP is able to elicit strong HCV core specific immune response and it has the tendency 
to induce predominated cellular immune response. However, after addition with 
aluminium adjuvant, the tendency of immune response changes to predominated 
humoral immune response. The influence of aluminium adjuvant on the immune 
response performance is critical compared with other HBc derived VLP vaccines and 
our EBNA1-HBc VLP when presenting short and non-structural antigen using HBc 
VLP platform. This finding indicates that when displaying long and complicated 
antigens on HBc VLP platform, the immunogenicity of induced by chimeric HBc VLP 
is easy to be influenced by other factors such as the property of the adjuvant and the 
nature of the presented antigen. In addition to elicit strong immune response, adjuvant 
free HCV core-HBc VLP is proven to induce high percentage of memory T cells with 
3 % for CD4+ TCM cells and 6.8 % CD8
+ TCM cells. These findings indicate that HBc 
VLP platform can be applied to present long and structural foreign antigen at N-
terminus and the produced adjuvant free HCV core-HBc VLP is promising to be applied 
as the vaccine candidate for the treatment of HCV infection. Further HCV 
neutralization assay is needed to confirm that HCV core-HBc VLP is a suitable vaccine 
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Chapter 7 Conclusions and future directions 
7.1 Conclusions 
In conclusion, two chimeric HBc VLPs, chimeric EBNA1-HBc VLP and HCV core-HBc VLP 
have been optimized to be expressed using the E. coli expression system and purified with 
ammonium sulphate precipitation with high production yields. In the property and stability 
examination of chimeric HBc VLPs presenting different epitopes, chimeric EBNA1-HBc VLP 
shows a similar stability when being treated with different temperature and freeze/thaw cycles 
compared with wt HBc VLP. Lower tolerances were detected in treatment of high concentration 
of SDS and low pH value. However, when presenting long and structured epitope, HCV core, 
with HBc VLP, chimeric HCV core-HBc shows a much worse stability compared with EBNA1-
HBc VLP and wt HBc VLP. With the help of computational protein modelling, it is found that 
the hydrophobicity of chimeric HBc monomers has great relationship with the stability of 
chimeric HBc VLPs as the hydrophobic interaction between monomers is vital for the assembly 
of chimeric HBc VLPs. More epitopes need to be examined to confirm this finding. 
In the immunogenicity evaluation, both adjuvant free chimeric EBNA1-HBc VLP and HCV 
core-HBc VLP elicit strong epitope specific immune response compared with other reported 
vaccines against EBV and HCV. A predominated humoral immune response is detected in the 
mice vaccinated with chimeric EBNA1-HBc VLP while mice immunized with chimeric HCV 
core-HBc VLP shows a predominated cellular immune response. The different immune 
response performance and tendency is potentially caused by the nature of epitopes presented 
by HBc VLP. In addition, aluminium adjuvant is able to improve the humoral immune response 
of both chimeric HBc VLP vaccines due to the propensity of aluminium adjuvant to induce IL-




HBc VLP is observed compared with chimeric HCV core-HBc VLP. In addition, mice 
immunized with both adjuvant free EBNA1-HBc and HCV core-HBc VLPs obtain long-term 
immunogenicity by producing epitope specific memory T cells. 
In conclusion, HBc VLP platform is able to present either short and non-structural antigen or 
long and structural antigen to form chimeric HBc VLPs and can be effectively expressed and 
purified in bacteria expression system with high production yields. The produced chimeric HBc 
VLPs show great potentials to possess strong and long-term antigen specific immunogenicity 
in vivo without addition of adjuvant. The produced adjuvant free chimeric EBNA1-HBc VLP 
and HCV core-HBc VLP are promising vaccine candidates against EBV and HCV infection. In 
addition, the type of antigens presented by HBc VLP platform is found to influence the stability 
and structure of chimeric HBc VLP vaccines because of the nature and properties of the 
antigens. It is found that the hydrophobicity of chimeric HBc monomers is related to the 
stability to maintain its assembled VLP structure. Further studies of the impact of different 
types of epitopes on the HBc VLP assembly are still needed for the development of promising 
chimeric HBc VLP vaccines. 
7.2 Future directions 
Based on the conclusions in this thesis, chimeric HBc VLP vaccine presenting foreign epitopes 
targeting to oncoviruses is a promising strategy for the development of effective and safe cancer 
vaccines. However, the insertion of foreign epitopes to HBc VLP is found to influence the 
stability of chimeric HBc VLP vaccines due to the nature of the foreign epitope. To further 
apply HBc VLP platform in the development of cancer vaccines in the future, several 
investigations are needed including:  
1) To further study the impact of insertion of foreign epitopes to HBc on chimeric HBc 
VLP stability using computational protein simulation, study on the interaction mechanism and 




such as surface charge and hydrogen bond that would affect the stability of chimeric HBc VLPs 
aiding with MD simulation, 
2) Since EBNA1-HBc and HCV core-HBc has been confirmed to elicit strong in vivo 
immune response, further evaluate the virus neutralization assay for the development of 
produced adjuvant free chimeric EBNA1-HBc VLP and HCV core-HBc VLP vaccines. 
3) It has been confirmed that HBc VLP platform can present both short and long epitopes 
to form chimeric HBc VLP and obtain desired immunogenicity. Further application for 
presenting other foreign epitopes targeting oncoviruses or other diseases caused by the virus 
infections using HBc VLP platform should be investigated to broaden its application not only 
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